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ABSTRACT 
With the advent of rapid diagnostic tests (RDT) for malaria detection, parasitological confirmation 
of malaria diagnoses has become more readily accessible and increasingly more affordable. 
However, questions are being asked about how useful they are in screening programmes, 
particularly for pregnant women who very often may harbour placental malaria infections which 
may not be detected by peripheral blood smear microscopy. It is also necessary to examine how 
many malaria infections go undetected by RDTs and whether such undetected infections have any 
negative consequences for women who carry such RDT-negative infections.  
This sub-study was conducted as part of a large multi-country trial of intermittent preventive 
treatment with sulfadoxine pyrimethamine versus intermittent screening and treatment of malaria 
in pregnancy which in Burkina Faso, Gambia, Ghana and Mali. The study enrolled 5,354 primi- 
and secundigravidae who attended antenatal clinics at study sites in the four countries from May 
2010 to October 2011.  
The sensitivity of the RDT to detect peripheral malaria in pregnancy using PCR as the reference 
declined from 89.3% (95% CI 85.5-92.4) on the day of enrollment to 57.7% (95% CI 46.5-73.0) 
at delivery. However, the sensitivity of the RDT to detect placental malaria was lower when 
placental histology was used as the reference ranging from 72% (95% CI 63.3-79.7) for any 
woman who tested RDT positive at any scheduled ANC visit, to 35.4% (95% CI 26.6-45.0) at the 
delivery visit. The prevalence of sub-RDT malaria was highest at delivery (6.3%). There was no 
significant association between sub-RDT malaria infection and low birth weight. Of the women in 
a sub-sample who were seen at first ANC visit, 39.0% had malaria infections out of which 1.7% 
were non-falciparum infections presenting as mono-infections or mixed infections with P. 
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falciparum. Clinical symptoms and signs were not sensitive enough to predict a positive RDT test 
and therefore the presence of malaria parasites. 
Women whose malaria infections get missed by RDTs are not at great risk of developing adverse 
pregnancy outcomes when compared with women who had no malaria. All pregnant women 
should be screened with RDT if IST was considered to replace IPTp-SP in areas where SP 
resistance is too high or transmission intensity is very low.   
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CHAPTER ONE 
 
Introduction 
1.1 Thesis Organisation  
This thesis is organized into eight chapters.  
Chapter 1 describes how this thesis is organized and also presents a rationale for the study, 
followed by the aim and objectives of the study.  
Chapter 2 presents the background to the study and a review of relevant current literature. 
Chapter 3 presents the study design, a description of the study area, study population and the 
methods used to research into study questions, the outcomes of interest, sampling and sample size 
determination, data management and analysis and ethical issues of concern and how they were 
addressed. 
Chapter 4 reports the results of a comparison of the sensitivity and specificity of Rapid Diagnostic 
Tests and microscopy with PCR in the diagnosis of placental malaria and malaria in pregnancy 
generally. 
Chapter 5 reports the results of a comparison of the prevalence of anaemia, placental malaria and 
low birth weight among pauci-gravid women with microscopic malaria, sub-microscopic malaria 
and no malaria, attending antenatal clinics in West Africa 
Chapter 6 presents estimates of the prevalence of non-falciparum malaria infections among 
pregnant women attending ANC in four West African countries and the proportion of non-
falciparum malaria infections not detected by rapid diagnostic testing. 
.  
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Chapter 7 examines the symptomatology of malaria in pregnancy to determine if a score could be 
developed to predict the need for RDT screening to detect malaria among pregnant women 
attending ANC. 
Chapter 8 discusses the results presented in the previous chapters in the light of current literature. 
This chapter also summarises the findings emerging from the study and the conclusions, and ends 
with recommendations for policy and further research. 
 
1.2 Role of the student investigator in this PhD study 
This PhD sub-study was nested within a larger non-inferiority trial of “Intermittent Preventive 
Treatment with Sulfadoxine-Pyrimethamine (SP) versus Intermittent Screening and Treatment of 
Malaria in Pregnancy” which was conducted in Burkina Faso, the Gambia, Ghana and Mali. 
The student investigator coordinated the trial at the Ghana site which was located in the Kassena-
Nankana District in the Upper East Region of the country. This involved taking part in the 
overall design and development of the main trial protocol, submission of the trial protocol for 
ethical approvals in Ghana (including amendments to trial protocol), coordination and 
supervision of data collection, coordination of laboratory work and supervision of data 
management. 
Concerning the PhD sub-study, the student traveled to London in January 2011 to work with his 
Supervisor and other members of his Advisory Committee to develop his PhD protocol. The 
protocol which was developed was subsequently successfully presented to a panel at an 
Upgrading Seminar in January 2012. Following the seminar, the student was upgraded from the 
Master of Philosophy (MPhil) level to the Doctor of Philosophy (PhD) level. 
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The student subsequently discussed plans for the PhD with the Advisory Committee, which led 
to the decision for the student to conduct PCR assays on filter paper blood spots collected from 
study participants at the Medical Research Council (MRC) Unit Laboratories in the Gambia from 
October to November, 2012. The student took part in all the PCR assay processes with 
supervision and support from MRC staff. The student had to make a further two-week trip to the 
Gambia in March 2013 to help complete the reading of PCR assay results. 
The student was responsible for the statistical analyses that were conducted for the various 
objectives of the study, with support from Dr. Mathew Cairns, a member of the Advisory 
Committee. The write-up of this thesis was the sole responsibility of the student with reviews by 
the Supervisor and Professor Brian Greenwood, a member of the Advisory Committee. 
1.3 Publications that have resulted from this study 
Two articles have been written and published from this thesis. These publications are: 
i. Williams, J.E., Cairns, M., Quaye, S.L., Awine, T., Oduro, A., Tagbor, H., Bojang, 
K., Magnussen, P., Ter Kuile, F., Wokeu, A., Milligan, P., Chandramohan, D., and 
Greenwood, B. (2015) The performance of a rapid diagnostic test in detecting malaria 
infection in pregnant women and the impact of missed infections. Journal of Clinical 
Infectious Diseases, doi: 10.1093/cid/civ1198. 
ii. Williams, J., Cairns, M., Bojang, K., Coulibaly, S.O., Kayentao, K., Abubakar, I., 
Akor, F., Mohammed, K., Bationo, R., Dabira, E., Soulama, A., Djimde, M., Guirou, 
E., Awine, T., Quaye, S.L., Ordi, J., Doumbo, O., Hodgson, A., Oduro, A., 
Magnussen, P., ter Kuile, F.O., Woukeu, A., Milligan, P., Tagbor, H., Greenwood, B. 
and Chandramohan, D. (2016) Non-falciparum malaria infections in pregnant women 
in West Africa. Malaria Journal 15: 53 doi: 10.1186/s12936-016-1092-1 
In addition to these articles which have been published, the student plans to develop at least 
one other manuscript by conducting further analyses on the placental malaria data obtained 
from this study. 
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1.4 Rationale 
Rapid diagnostic testing for malaria has become increasingly important in the diagnosis of malaria 
in many endemic countries. This is largely as a result of WHO (World Health Organisation) 
recommendation that as much as possible the diagnosis of malaria should be based upon 
parasitological confirmation of the presence of malaria parasite in the bloodstream of a person 
suspected to be infected, as well as the increasing commercial availability of rapid diagnostic tests 
(RDTs). Some of the difficulties associated with blood smear microscopy have largely been 
overcome by the availability of cheaper RDTs with better sensitivity. However, as RDTs have 
become more accessible and consequently more utilised in many settings where malaria testing 
was previously inaccessible or unreliable, questions are being asked about how useful they are in 
screening programmes, particularly for pregnant women who very often may harbour placental 
malaria infections which may not be detected by peripheral blood smear microscopy. It is also 
necessary to examine how many malaria infections go undetected by RDTs and whether such 
undetected infections have any negative consequences for women who carry such RDT-negative 
infections. While considering the possibility of screening of pregnant women and treatment of 
those infected instead of IPTp (Intermittent Preventive Treatment in pregnancy), it is necessary to 
determine whether these RDT-negative malaria infections are of any significant consequence for 
the health of the woman and her baby. 
Even though non-falciparum infections are estimated to be of low prevalence in West African 
populations in general and among pregnant women in these populations in particular, very little is 
known about the true burden of these infections among the affected populations. While many 
RDTs have been developed to detect both falciparum and non-falciparum malaria, it is necessary 
to determine whether RDTs are able to detect these infections effectively. 
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As RDT use becomes more universal there is the need to examine ways in which their use can be 
optimised in settings where supplies cannot always be guaranteed. Furthermore, it is not known 
how feasible it is to integrate screening of pregnant women using RDTs in busy antenatal clinics 
in sub-Saharan Africa where midwives are already overstretched with many tasks.  Therefore, 
restricting the number of pregnant women who need screening with RDT at antenatal clinics using 
a clinical symptoms and signs based algorithm also needs to be examined.  
Answers to the following questions are needed to make evidence-based policies on screening and 
treatment instead of IPTp to control malaria in pregnancy in the West Africa: 
• What is the prevalence of sub-microscopic malaria infections in pregnancy? 
• Do sub-microscopic malaria infections in pregnancy have clinical consequences? 
• What is the prevalence of non-falciparum malaria in pregnancy as revealed by PCR testing?   
• Could a symptoms and signs based criterion be useful as a screening tool to detect pregnant 
women who will need further screening using RDTs 
 
1.5 Aim and Objectives 
1.5.1 Aims 
To address the knowledge gap in the understanding of the epidemiology and consequences of sub-
microscopic malaria infections in pregnancy and to contribute to the evidence base under-pinning 
polices for control of malaria in pregnancy in West Africa.  
1.5.2 Objectives 
1. To determine the accuracy of RDTs for detecting placental malaria. 
2. To determine accuracy of RDTs for detecting sub-microscopic peripheral malaria 
parasitaemia in pregnancy. 
19 
 
3. To estimate the prevalence and effects of submicroscopic malaria infections among pauci-
gravid pregnant women attending antenatal clinics in four West African countries. 
4. To determine the prevalence of non-falciparum malaria infections among pregnant women 
attending antenatal clinics in four West African countries.  
5. To assess the usefulness of symptom and signs-based scores to predict malaria in 
pregnancy which could be used as a tool to select women needing RDT screening at 
antenatal clinics. 
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CHAPTER TWO 
  
Literature Review 
2.1 Burden of malaria 
Malaria remains a major public health problem in many parts of the world. According to the World 
Health Organisation (WHO), 91 countries, mainly in tropical and some subtropical regions of the 
world are currently classified as malaria-endemic (World Malaria Report, 2016). The WHO 
estimates that the number of malaria cases rose from 233 million in 2000 to 244 million in 2005 
but has since declined to 212 million in early 2015.The number of deaths due to malaria is also 
estimated to have declined from 985,000 in 2000 to 429,000 in 2015. Most of these deaths occurred 
mainly in children aged under 5 years in Africa. Even though these statistics suggest that the 
burden of malaria is declining, it still remains a major public health issue, particularly in sub-
Saharan Africa; its effects are felt mostly among children and pregnant women, who are among 
the most vulnerable populations in society. It has been estimated that malaria mortality accounts 
for 42 million disability-adjusted life years (DALYs) globally, representing 3% of the total DALYs 
worldwide (Breman et al.  2004). In Africa however, malaria mortality is estimated to constitute 
10% of total DALYs. In malaria endemic areas, young children suffer most of the burden of 
malaria-related morbidity and mortality as most individuals acquire significant clinical protection 
during the first decade of life (Riley et al. 1994).  
2.2 Species of malaria 
Five species of the malaria parasite are capable of causing disease in humans. These are 
Plasmodium falciparum, which is responsible for the most severe disease and also the most 
common type of malaria; P. vivax, which requires the Duffy blood group antigen to be able to 
invade red blood cells and therefore is unable to cause disease in many African populations; P 
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malariae, P. ovale and finally P. knowlesi, which was previously thought to be responsible solely 
for malaria in macaque monkeys, but is now known to be an important cause of malaria infection 
in man in South East Asia.  
Of the four non-falciparum plasmodium species which cause human disease, P. vivax malaria is 
the commonest, occurring in many parts of the tropical world, from areas in the south Pacific, 
across Asia and Africa to the western coasts of South America. The parasite has even been found 
in some temperate regions in Asian countries like China and Korea (Maguire and Baird, 2010). It 
has long been known, that the inherited absence of the Duffy antigen on the red blood cells in West 
and Central African populations, where more than 95% of the populations is Duffy negative, spares 
them from getting vivax malaria. Homozygosity for the Duffy-negative blood group antigen 
confers almost complete resistance to vivax malaria (Langhi and Bordin, 2006). Lately, questions 
have been raised about whether Duffy antigen is the sole receptor/mechanism for the invasion of 
erythrocytes by P. vivax parasites. Menard et al. (2010) have shown that, in Madagascar, P. vivax 
has broken through its dependence on the Duffy antigen for invasion of human red blood cells and 
therefore disease due to this parasite is found in this part of Africa, as well as in Ethiopia and the 
horn of Africa. 
In contrast to P. vivax, P. malariae and P. ovale infections, though not as common as P. falciparum 
are well recognised among West and Central African populations. P. ovale malaria is endemic in 
western Africa and is also found in isolated pockets in South-East Asia and Oceania. P. malariae 
occurs throughout the tropics in isolated foci at relatively low frequencies (Maguire and Baird, 
2010). Several studies in West Africa have described the burden of P. malariae and P. ovale 
malaria, mainly in children.  The prevalence of P. malariae has ranged from 4-33% depending 
upon whether the survey was done in the dry season or wet season and, in some cases, upon the 
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vegetational zone in which the survey was done. For P. ovale, the prevalence ranged between 2.6 
and 15%. Greenwood et al. (1987) found the prevalence of P. malariae to range between 13% in 
the wet season to 33% in the dry season among febrile children in The Gambia. The prevalence 
among afebrile children was 4% in the wet season and 8% during the dry season in this study. In 
Burkina Faso, Boudin et al. (1991) obtained a prevalence of P. malariae ranging between 3.5-25% 
among children 0-14 years old, with the annual mean being 14.2% for the 0-4year group, 14.0% 
for the 5-9 year age-group and 10.8% for the 10-14 year age-group. 
In the Central Region of Ghana, Afari et al. (1993) obtained a prevalence for P. malariae of 20.4% 
using microscopy among children under five years old. In the Ashanti Region of Ghana, Browne 
et al. (2000) obtained a prevalence of 10.4% for P. malariae in the forest zone compared to 22.8% 
for the Savanna zone in the same country. They obtained prevalence of 15.5% for P. ovale in the 
forest area compared to 2.6% in the Savanna area. In a longitudinal study of natural malaria 
transmission in a holoendemic area in Senegal, Trape et al. (1994) found a prevalence of 21.1% 
for P. malariae and 6.0% for P. ovale among the population aged 0 - >60 years using microscopy. 
2.3 Malaria in pregnancy 
Contrary to what pertains in adults who acquire some level of immunity to malaria, pregnant 
women living in malaria endemic areas are particularly susceptible to malaria, leading to a higher 
prevalence and greater severity of disease (Brabin 1983). It is estimated that over 50 million 
women living in malaria endemic areas in the world are exposed to the risk of malaria in pregnancy 
each year. Malaria in pregnancy is known to cause substantial maternal, fetal and infant morbidity 
resulting in an estimated 75,000-200,000 infant deaths every year (Steketee et al. 2001; Desai et 
al, 2007). Studies have shown that malaria in pregnancy (MiP) occurs largely because infected 
erythrocytes accumulate in the placenta (Walter et al. 1982), with the sequestration of trophozoites 
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and schizonts, which are usually absent from the peripheral blood, in the placenta (Beeson et al. 
2002). Accumulation of parasites in the intervillous space of the placenta is the cause of maternal 
anaemia as well as low birthweight, prematurity and increased infant mortality (McGregor et al. 
1983). Research has shown that the var2csa variant of P. falciparum erythrocyte membrane protein 
1 (PfEMP1) is the main protein that mediates parasite accumulation in the placenta (Salanti et al. 
2003). Placental parasites appear to bind preferentially to chondroitin sulphate A (CSA) (Achur et 
al. 2000). In endemic areas, MiP is found mainly among primigravid women suggesting that 
protective immunity to MiP is acquired as a function of parity (Brabin, 1983). Women acquire 
immunity to MiP by producing antibodies to MiP variant surface antigens in a gravidity-dependent 
manner (Rogerson et al. 2007; Ricke et al. 2000). 
2.4 Non-falciparum malaria in pregnancy 
It is known that pregnant women can be infected by all the plasmodium species which cause human 
disease except P. knowlesi, for which data on pregnant women is unavailable. Nevertheless, given 
the known behaviour of this parasite, infections in pregnant women would be expected to occur. 
However, studies of MiP are mainly focused on susceptibility and clinical consequences of P. 
falciparum and P. vivax. The susceptibility to P. falciparum is increased in pregnancy (Diagne et 
al. 1997). Studies have also shown that pregnant women are at an increased risk of P. vivax malaria, 
though this risk is less pronounced than with P. falciparum (Desai et al, 2007) and that vivax 
malaria during pregnancy adversely affects the outcome of pregnancy. Nosten et al. (1999), 
studying P. vivax malaria among Karen women living in camps on the western border of Thailand, 
showed that vivax malaria in pregnancy is associated with maternal anaemia and low birthweight, 
even though these effects were less striking compared to those caused by P. falciparum malaria. 
They also found that P. vivax relapses were more common among pregnant women than in non-
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pregnant women.  In contrast to P. falciparum, which is known to cause most of its effects in 
pregnant women through sequestration by cyto-adhesion to the syncytiotrophoblast layer, there 
appears to be little evidence that P. vivax also produces its effects in pregnant women through this 
mechanism (Umbers et al.  2011). However, Carvalho et al. (2010) have shown P. vivax adhesion 
to placental cryo-section in-vitro. 
There is very little literature on the epidemiology of P. malariae and P. ovale in any population 
and in pregnant women in particular. Older studies which used microscopy alone tended to report 
low prevalences of both these species. There is increasing evidence from studies using PCR that 
the prevalence of these infections may have been underestimated. Studies have also shown that in 
sub-Saharan Africa, P. malariae and P. ovale are often present as co-infections with P. falciparum 
(Desai et al. 2007). Studies in Ghana (Mockenhaupt et al. 2000) and Cameroon (Walker-Abbey et 
al. 2005) found largely mixed infections of P. malariae and/or P. ovale with P. falciparum in 
pregnant women by PCR. There are no studies of the impact of mono infections of P. malariae or 
P. ovale on the outcome of pregnancy. 
2.5 Submicroscopic malaria infections in pregnancy 
While microscopy for the detection of malaria parasites in peripheral blood has remained the gold 
standard for malaria diagnosis for a long time, recent advances in diagnostics, particularly PCR 
methods, have allowed the identification of malaria parasitaemia below the threshold of detection 
by microscopy. Studies in sub-Saharan Africa have demonstrated high levels of submicroscopic 
plasmodial infections by PCR in children and non-pregnant adults (Bottius et al. 1996; Wagner et 
al. 1998). Several studies in sub-Saharan Africa have also shown that submicroscopic plasmodial 
infections are very common among pregnant women. These low density infections could have 
resulted from the gravidity or even previous antimalarial treatment the woman had taken 
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(Kyabayinze et al. 2016). A study in Ghana, conducted in 1998 among 530 pregnant women living 
in the forest zone of the country found that while 32% of the women had malaria parasitaemia by 
microscopy, this increased to 63% using PCR (Mockenhaupt et al. 2000) (Table 2.1). This study 
also found that women who had antimalarials in their blood stream were 1.8 times (95% CI 1.2-
3.0, p value=0.008) more likely to have submicroscopic infections compared to women who had 
no antimalarials present in their bloodstream. Similarly, they also found that gravidity 
independently predicted submicroscopic P. falciparum infection in pregnancy in this region. 
Women in their 3rd or 4th pregnancy were 4.6 (95% CI 2.4-8.5, p value=<0.0001) times more 
likely to have submicroscopic infections compared to primigravid women, while women who had 
been pregnant five or more times were 6.3 (95% CI 3.1-12.6, p value=<0.0001) times more likely 
than primigravid women to have submicroscopic malaria infections. These authors suggest that 
submicroscopic malaria infections in pregnant women may lead to mild anaemia and inflammation 
in seemingly aparasitaemic pregnant women. 
In a study in Cameroon among 78 pregnant women who had normal singleton vaginal delivery 
(Walker-Abbey et al. 2005) found that the prevalence of P. falciparum parasitaemia in the 
peripheral blood by microscopy was 27.5% while PCR gave a prevalence of 82.4%. This suggests 
a high prevalence of submicroscopic infections in this population. A similar pattern was obtained 
by Schleiermacher et al. (2001) in Senegal, who found that 29% of blood samples from pregnant 
Senegalese women were slide positive while 85% were positive by PCR. These studies and others 
in sub-Saharan Africa (Saute et al. 2002; Mayengue et al. 2004; Mayor et al. 2009; Rantala et al. 
2010) have demonstrated the phenomenon of submicroscopic infections where parasite DNA is 
found in the blood of pregnant women who are blood smear negative. 
 
26 
 
Table 1 Prevalence of submicroscopic malaria infections in pregnancy 
Country Microscopy (%) PCR (%) Submicroscopic (%) Reference 
Ghana 32 63 31 Mockenhaupt et al. 2000 
Cameroon 27.5 82.4 54.9 Walker-Abbey et al. 
2005 
Senegal 29 85 56 Schleiermacher et al. 
2001 
 
2.6 Diagnosis of malaria in pregnancy 
The diagnosis of malaria remains a challenge particularly in resource poor settings. The severe 
consequences of malaria among children and pregnant women makes early and accurate diagnosis 
extremely important. The WHO has consistently advocated early and accurate diagnosis of malaria 
and appropriate case management as essential to addressing the burden of malaria in pregnancy as 
one of the main interventions of the Global Malaria Control Strategy (WHO, 2000; Bell et al, 
2006). Two main approaches for the diagnosis of malaria in pregnancy are currently used. These 
are clinical diagnosis made presumptively using signs and symptoms at presentation and 
laboratory diagnosis based on the various tests which are currently available. 
2.6.1 Clinical diagnosis of malaria in pregnancy 
Most health care practitioners in sub-Saharan Africa rely on clinical features to make a diagnosis 
of malaria in pregnancy. The main clinical feature used in this process is the presence of, or a 
history of, fever (Uneke 2008). Even though this approach may not necessarily be the best, it is 
often justified in view of the fact that in endemic areas individuals may be parasitaemic most of 
the time (WHO, 2000b) and the presence of parasites in non-pregnant individuals is not always 
indicative of disease even though this may not necessarily be true in pregnant women. Clinical 
diagnosis was also largely accepted in the past when inexpensive and well-tolerated antimalarials 
were still effective (Biritwum et al. 2000; Ruebush et al. 1995). 
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According to WHO, clinical diagnosis of malaria may pose problems for the following reasons 
(WHO, 2000b): 
1. There is no clinical picture of malaria or its complications that is unequivocally diagnostic 
of the infection as all features can be mimicked by other tropical diseases. 
2. The presence of parasitaemia does not prove that malaria is the main or only cause of a 
patient’s illness. 
The role of clinical features in diagnosing malaria in pregnancy remains unclear. In areas where 
malaria transmission is low and unstable, malaria in pregnancy is usually symptomatic and acute 
and is associated with detectable peripheral parasitaemia (Brabin 1985; Shulman et al. 2001; Adam 
et al. 2005). It had previously been thought that in areas where transmission is stable and intense, 
malaria in pregnancy was nearly always asymptomatic in spite of the sequestration of infected 
erythrocytes in the placenta (Brabin1985; Shulman et al. 2001; Steketee et al. 2001). However, 
Tagbor et al. (2008) working in an area of intense and stable transmission in Ghana concluded that 
malaria in pregnancy was sometimes symptomatic. They found that the incidence of a history of 
fever, headache, vomiting, malaise, dizziness or fatigue was substantially higher in parasitaemic 
primigravid women compared to aparasitaemic primigravid women. Similarly, in a hospital-based 
descriptive study conducted in rural Mozambique between 2003 and 2005 aimed at characterizing 
the clinical presentation of malaria in African pregnant women Bardaji et al. (2008) found that 
symptoms suggestive of malaria such as headache, arthromyalgias and history of fever were very 
frequent among pregnant women. However, less than a third of them were parasitaemic. In view 
of the fact that the authors only used peripheral blood smears for malaria detection and the fact 
that placental malaria is not reflected adequately by peripheral parasitaemia, the prevalence of 
malaria among those presenting with symptoms was probably higher than they recorded.  
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2.6.2 Parasite-based diagnosis of malaria in pregnancy 
Laboratory diagnosis of malaria involves the use of tests and assays to detect the presence of 
malaria parasites or antigens in an infected individual. The three main types of tests used are blood 
smear microscopy, rapid diagnostic tests based on lateral flow immunochromatographic 
technology and the polymerase chain reaction for the detection of malaria parasite DNA. 
2.6.2.1 Blood smear microscopy 
The standard laboratory practice for the diagnosis of malaria is the preparation and microscopic 
examination of blood films stained with either Giemsa, Field’s or Wright’s stains (Warhurst and 
Williams, 1996). This has subsequently become the gold standard of malaria diagnosis 
(Wongsrichanalai et al. 2007). Two types of films can be prepared - the thick and the thin film. 
The thick film concentrates layers of red blood cells on a small surface and enhances the sensitivity 
of the blood film technique, while the thin film facilitates species identification, providing greater 
specificity than the thick film (Moody, 2002). In addition, smear microscopy is used for estimation 
of parasite density (Murray et al, 2008). It is, therefore, used as a tool to monitor the response of 
individuals to therapeutic agents. However, microscopy requires well-trained microscopists, good 
quality laboratory supplies, rigorous maintenance of equipment and well-functioning quality 
control and quality assurance systems (Wongsrichanalai 2007). It is labour-intensive and time-
consuming and its interpretation requires considerable expertise, especially when parasite density 
is low (Warhurst and Williams, 1996). In pregnant women, P. falciparum malaria is associated 
with sequestration of the parasites in the placenta, thereby reducing the sensitivity of microscopic 
diagnosis, as the parasites often cannot be found in a peripheral blood film. 
2.6.2.2 Rapid diagnostic tests (RDTs) 
Since the early 1990s, rapid diagnostic tests for the diagnosis of malaria have become available. 
The two main groups of RDT in use detect parasite histidine-rich protein 2 (HRP-2) or plasmodium 
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lactate dehydrogenase enzyme (pLDH). Some RDTs target the parasite glycolytic pathway 
enzyme aldolase, which is found in all plasmodium species. 
HRP 2 is a water soluble protein that is produced by the asexual stages and gametocytes of P. 
falciparum only, expressed on the erythrocyte cell membrane and shown to remain in the blood 
for up to 28 days after initiation of antimalarial therapy (Karbwang et al. 1996; Richter et al. 2004; 
Swarthout et al. 2007). Some parasites have a gene deletion for the production of HRP 2. Such 
mutants may give false negative test (Baker et al, 2005; Lee et al, 2006). Also, a positive 
rheumatoid factor has been associated with false positive results for HRP 2 (Laferi et al. 1997; 
Iqbal et al. 2000). However, these reactions are reported to be less frequent when monoclonal IgM 
antibodies are used instead of IgG antibodies to prepare the test (Grobusch et al. 1999; Mishra et 
al. 1999). 
Parasite lactate dehydrogenase (pLDH) is a soluble glycolytic enzyme produced by asexual and 
sexual stages of the live parasites and it is released from parasite infected red blood cells. It has 
been found in all five main human malaria species. The blood levels of pLDH and aldolase decline 
rapidly to undetectable levels after initiation of effective treatment, even though young plasmodial 
gametocytes produce pLDH and, therefore, a test based on this enzyme may remain positive 
despite clearance of the asexual forms of the parasite (Miller et al. 2001; Mueller et al. 2007).  
Rapid diagnostic tests detect malaria antigen in small amounts of blood, usually 5-15 microlitres, 
by immunochromatographic assays in which monoclonal or polyclonal antibodies are impregnated 
in a nitrocellulose membrane strip. The clinical sample moves across the membrane by capillary 
action (Bell et al. 2006; Wongsrichanalai et al. 2007; Murray et al. 2008). The result is usually a 
coloured line which is obtained within 5-20 minutes. RDTs are simple to perform, require no 
electricity, can be taught to lower-level village health workers and are easy to interpret. They have 
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been produced in different formats such as dipsticks, card tests and plastic cassettes to promote 
ease of use. The prices of RDTs have been declining since they first appeared on the market. The  
market price for RDTs in the mid-2000s in developing countries was between US $0.55- US$1.50 
per test, depending on the type of test and the quantities ordered, compared to microscopy which 
cost US$0.12-US$0.40 per smear (Wongsrichanalai et al. 2007).  RDT prices have since declined 
further with UNICEF, an organization which procures large quantities of RDTs annually, 
documenting a decline in prices from $0.60 per test in 2011 to $0.44 per test in 2015 (UNICEF, 
2016). 
The WHO estimates that to be a useful diagnostic, RDTs must achieve a sensitivity of greater than 
95% (WHO, 2000b). HRP-2 RDTs have given sensitivities of more than 90% in evaluations 
involving clinical cases (Kilian et al. 1999; Guthmann et al. 2002). However, when HRP-2 was 
combined with an aldolase assay the non-falciparum sensitivity was reported to be lower (Tjitra et 
al. 1999; Cho-Min-Naing et al. 2002). Sensitivity of pLDH RDTs has varied among studies. Their 
sensitivity for P. falciparum appears very good (>95%) in some studies whereas it is much lower 
(80%) in other studies (Gasser, 2000; Singh et al, 2003). 
Since RDTs became available, many brands have been produced and are being marketed. 
Consequently, the level of their use has also increased markedly in recent years. 
Initially, good quality performance data were unavailable to enable national malaria control 
programmes to make decisions on procurement and mass deployment. To address this deficiency, 
WHO and FIND (Foundation for Innovative New Diagnostics) launched a programme in 2006 to 
evaluate the performance of commercially available RDTs. A total of 247 products have since 
been tested in six rounds against prepared blood panels containing patient-derived P. falciparum 
and P. vivax parasites. Importantly, assessment has also been made of their thermal stability, as 
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these tests will be used mostly in countries with warm climate. The sixth round of testing was 
completed in 2015. 
The results from round 6 show consistency in the panel detection scores, positivity rate, false-
positive rates and heat stability in reference to those reported in the earlier rounds. The proportion 
of tests that achieved a panel detection score of ≥75% at low parasite density (200 
parasites/microliter) was higher than all the previous rounds for both P. falciparum and P. vivax. 
Several RDTs in the six rounds of testing consistently detected malaria at low parasite density had 
low false positive rates, were stable at tropical temperatures, were easy to use and could detect P. 
falciparum or P. vivax infections or both. Also, P. falciparum tests targeting HRP2 had higher 
panel detection scores than those targeting pLDH (WHO 2015). 
Some studies have tried to evaluate the use of RDTs among pregnant women. Tagbor et al. (2008) 
obtained a sensitivity of 97% and a specificity of 85% for the OptiMAL® RDT, a pLDH-type 
RDT, using peripheral blood microscopy as the standard among a group of pregnant women 
attending antenatal clinics who were participating in a clinical trial of anti-malarial drugs in 
pregnancy in Ghana. However, the assay was not compared to the prevalence of placental malaria. 
A study in Burkina Faso by Singer et al. (2004) found that the prevalence of placental parasitaemia 
in their study sample was 23% by placental blood microscopy, 51% by PCR and 43% by RDT 
(MAKROmed®). Using PCR as the gold standard they found that this particular RDT had a 
sensitivity of 89% and a specificity of 76% for placental malaria. 
Kyabayinze et al. (2016) also conducted a prospective study of 990 HIV-uninfected pregnant 
women attending antenatal clinics in Uganda and Burkina Faso, who were enrolled in the second 
or third trimester. They compared results obtained from testing blood sampled obtained from the 
study participants using expert microscopy, two combination types of RDTs (CareStart™ Malaria 
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pLDH [Pf/PAN] test and CareStart™ Malaria HRP2/pLDH [Pf/PAN] COMBO test) and nested 
PCR. In comparison with PCR, the HRP2-based RDT performed best, leading the investigators to 
suggest that HRP2-based tests are the most appropriate RDTs currently available for use during 
pregnancy even though they missed some PCR-positive tests. 
2.6.2.3 PCR and other methods 
PCR methods have been developed for the detection of malaria DNA from whole blood. The 
diagnostic problems associated with microscopy and RDTs and the need for accurate diagnoses of 
malaria in pregnancy led to the introduction of PCR (Malhotra et al. 2005; Mockenhaupt et 
al.2006). The small-subunit 18S rRNA and circumsporozoite (CS) genes have been used in the 
differentiation of plasmodial species (Moody, 2002). The greatest strength of PCR lies in its high 
sensitivity, demonstrated by its ability to detect five parasites or less per microlitre of blood 
(Snounou et al. 1993). PCR methods have consistently shown that at least twice as many pregnant 
women are infected with malaria compared to microscopy (Mockenhaupt et al. 2000; Adam et al. 
2005; Malhotra et al. 2005; Walker-Abbey et al. 2005; Mockenhaupt et al. 2006; Adegnika et al. 
2006). A good proportion of pregnant women in malaria-endemic areas suffer submicroscopic 
malaria infections detectable only by molecular methods. 
The two main variants of PCR that have been used for malaria detection are nested PCR (nPCR) 
and real-time quantitative PCR (RTQ-PCR). RTQ-PCR provides quantitative information about 
infection burden in an individual and has been shown to be more predictive of clinical and adverse 
perinatal outcomes of malaria than nPCR and RDT (Malhotra et al. 2005). 
PCR assays are confronted by some challenges. They are more labour-intensive, time-consuming 
and costly compared to microscopy. Also, contamination, which leads to the production of false 
positive results, is common unless tests are conducted under carefully controlled conditions 
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(Singer et al. 2004).This has, however, not proven to be a major problem when the test has been 
done with reasonable care.  
Another molecular method which has been developed and evaluated for the detection and 
quantification of malaria parasites is real-time quantitative nucleic acid sequence-based 
amplification (QT-NASBA). The real-time QT-NASBA for the detection of P. falciparum was 
developed by Schoone et al. (2000). This assay is based on the detection of the 18S rRNA under 
isothermal conditions. In comparison with RTQ-PCR, this assay has been shown to be faster to 
perform as results are available after 4 hours compared to 16 hours for RTQ-PCR (Schneider et al. 
2005). The sensitivity and specificity of the two types of assays for detecting malaria parasites are 
comparable. However, QT-NASBA like PCR, is also expensive and relatively labour-intensive 
compared to microscopy and requires a high level of expertise and a well-equipped laboratory. 
To address some of the disadvantages of PCR, loop-mediated isothermal amplification (LAMP) 
assays, which are cheaper, faster and simpler than PCR have been developed for the detection of 
malaria infections (Poschl et al. 2010). LAMP is a molecular method involving nucleic acid 
amplification that relies on autocycling strand-displacement DNA synthesis. The main advantage 
of this method is that no denaturation of the DNA template is required and therefore the assay can 
be conducted under isothermal conditions (Notomi et al. 2000). Species specific LAMP assays for 
the four common types of human malaria parasites have been developed (Poon et al. 2006; Han et 
al. 2007). Initial evaluations of the use of LAMP assays in malaria diagnosis are beginning to 
appear in the literature. Poschl et al. (2010),  working in northern Thailand applied three methods, 
microscopy, nested PCR and LAMP assay to 105 human blood samples and concluded that LAMP 
was as reliable as nPCR and more reliable than microscopy in the examined blood samples. Similar 
results and conclusions had earlier been obtained on a smaller sample size by Han et al. (2007), 
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also working in northern Thailand. More recent evaluations of malaria LAMP assays have 
concluded that: LAMP detected a higher number of malaria infections than RDT and was user-
friendly (Cook et al. 2015); LAMP had a diagnostic accuracy similar to that of nested PCR with a 
greatly reduced time to result and was superior to expert microscopy (Polley et al. 2013; Hopkins 
et al. 2013). LAMP assay use has so far not been evaluated in pregnant women. However, the 
potential for their use in the detection of malaria in pregnancy under field conditions appears 
promising. 
2.7. Placental malaria 
The presence of placental malaria can be detected by microscopy of thick or thin smears of 
placental blood, impression smears of placental tissue or histological examination of placental 
biopsies. 
2.7.1 Placental blood smears 
The diagnosis of placental malaria in many endemic areas, particularly in sub-Saharan Africa, still 
depends on microscopy of placental blood smears or placental impression smears (Uneke 2008). 
Placental blood smear microscopy permits the detection of malaria parasites and pigment and is 
easier, cheaper and faster to perform than histology (Brabin et al. 2004). They also allow the 
speciation of malaria parasites (Ismail et al. 2000; Galbraith et al. 1980), which is difficult with 
histological examination. They also avoid the confusion that often results from mix-ups between 
formalin pigment and malaria pigment in histological slides (Ismail et al. 2000). However, 
placental blood smears are often difficult to read because of the presence of cellular debris and 
larger numbers of white blood cells (Singer et al. 2004). Overall, placental microscopy is less 
sensitive for diagnosing placental malaria compared to placental histology (Okoko et al. 2002; 
Rogerson et al. 2003). 
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2.7.2. Placental histology 
Several histological changes in placentae infected by malaria parasites have been described. These 
involve the villi and villous surfaces and are considered a direct consequence of parasite 
accumulation in the placenta (Walter et al. 1982). These changes include perivillous fibrinoid 
deposits, excessive syncytial knotting, necrosis of the syncytiotrophoblast, proliferation of the 
cytotrophoblast, loss of syncytial microvilli and trophoblastic membrane thickening (Walter et al. 
1982; Bulmer et al. 1993; Ismail et al. 2000; Galbraith et al. 1980; Yamada et al. 1989). 
Placental malaria was first classified by Bulmer et al. in 1993. This classification has since been 
modified by Ismail et al. (2000) as follows: 
1. No infection: No malaria parasites or pigment present in the placenta 
2. Acute Infection: Malaria parasites present and pigment deposition minimal or absent 
3. Chronic Infection: Malaria parasites are present and pigment deposition is present in fibrin 
or cells within fibrin in significant quantities 
4. Past Infection: Malaria parasites are absent but pigment is present. 
Other authors have tried to modify this classification further or even offered new classifications. 
Rogerson et al. (2003) further divided the category of chronic active infections by the presence or 
absence of pigment in the cytoplasm of monocytes because of the strong association between 
pigment in macrophages and low birth weight. Muehlenbachs et al. (2010) have developed a 2-
parameter grading scheme for placental malaria, which measures inflammation and pigment 
deposition, based on studies of the placentas of women from Tanzania and Thailand. However, 
this scheme is yet to be evaluated in clinical trials to determine its suitability for use compared to 
the existing classification. 
Placenta infection is used widely as a standard indicator of malaria infections in pregnancy in 
epidemiological studies (Cottrell et al. 2005). In spite of its usefulness in research, placental 
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histology can only be done when pregnancy has come to an end and when the deleterious effects 
of malaria on the mother and foetus already have taken place. Also, placental histology is 
expensive and labour intensive and it is not available in most settings in sub-Saharan Africa 
(Rogerson et al. 2003). Therefore, alternative tests which can predict the presence of placental 
malaria during pregnancy are greatly needed. 
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CHAPTER THREE 
 
Materials and Methods 
 
3.1 Study Design 
This study was part of a non-inferiority trial of standard Intermittent Preventive Treatment (IPT) 
with Sulfadoxine-Pyrimethamine (SP) versus intermittent screening with RDTs and treatment with 
Coartem® for those who tested positive for malaria among pregnant women in Ghana, Burkina 
Faso, Mali and the Gambia. 
3.2 Main trial sample size 
The trial was powered to show that Intermittent Screening and Treatment (IST) is not inferior to 
SP-IPTp in preventing low birth weight (LBW). Review of the literature indicates that the 
prevalence of LBW (birth weight <2,500 g) in primigravidae or secundigravidae who received a 
full course of SP-IPTp is likely to be about 10% with some variation between the four sites.  To 
demonstrate with 90% power and at a 0.025% significance level that the prevalence of low birth 
weight among infants born to mothers in the IST arm is not more than 3% above that of infants 
born to mothers in the IPT arm, approximately 2,000 women were needed in each group. This 
sample size gave the study 90% power at a 0.025% significance level to show that the difference 
in mean birth weight between study groups was less than 50g, the largest difference between 
groups that would be acceptable as the basis for a change in policy. A study of this size had similar 
power to show that the difference in haemoglobin concentration between groups was less than 
0.2g/dl. A study of this size also had around 90 % power to show that the difference in the 
prevalence of placental malaria between groups was less than 5%. However, we estimated that 
only about 50% of women would deliver in a hospital or health centre and provide a placental 
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biopsy. With a reduced sample size of 2500, the study had 80% power to show that the difference 
in placental malaria between groups was less than 5%. The trial, therefore, recruited a total of 
5,000 women, 2,500 in each arm. Each of the four sites contributed 1,250 women recruited within 
an average of 16 months, to the trial sample. 
 
3.3 Sample size calculations for the sub-studies 
 
Objective 1: Determination of the accuracy of the First Response® Combo RDT for detecting 
placental malaria. 
Placentas were examined histologically for all the women whose samples were available. We 
estimated that a minimum of 50% of all the women in the trial would have their placental samples 
processed and examined. Using the histological diagnosis of malaria as the end-point, the 
sensitivity and specificity of the RDTs in diagnosing placental malaria was estimated. We also 
calculated the predictive power of positive and negative First Response® Combo tests in 
diagnosing placental malaria. 
 
Sample size calculation 
A recent study conducted in Uganda obtained a prevalence of placental malaria by histology of 
21.3%. The sensitivity of the RDT they used to detect placental malaria was 80.9% with a 
specificity of 87.5% (Kyabayinze et al. 2011). Assuming that the sensitivity of RDTs for detecting 
placental malaria is 81% with a specificity of 87% and that the prevalence of placental malaria is 
21%, the sample size required to estimate the sensitivity of the RDT used in detecting placental 
malaria at 95% confidence interval of +/- 5%  is 1,182 women. 
39 
 
Objective 2: Determination of the accuracy of the First Response® Combo RDT for detecting 
sub-microscopic peripheral malaria parasitaemia in pregnancy 
 
This analysis was restricted to the women enrolled at the Ghana site only. All women in the 
intermittent screening and testing (IST) arm of the study had rapid diagnostic tests done at each 
visit.  A total of 652 women in the IST arm had RDT testing at enrolment, decreasing to 564 at 
visit 1, 447 at visit 2 and 37 at visit 3 (refer table 5 for study visits). At delivery 379 women were 
tested. In addition, 191 women reported ill once. This number included 94 women in the IPTp arm 
of the study who also had RDTs done when they reported ill. Thirty women reported ill a second 
time, 15 of them belonging to the IPTp arm. Four women reported ill a third time, two of them 
from the IPTp arm. PCR assays were done on all blood spots collected at each study visit. A total 
of 4,100 blood spots obtained from women in both arms of the study were tested. These were made 
up of samples from all the five scheduled study visits [visits 0, 1, 2, 3 and 4 (delivery)] as well as 
unscheduled visits. The PCR assay results were used as the gold standard to assess the sensitivity 
and specificity of RDT to detect peripheral sub-microscopic parasitaemia.   
 
Sample size calculation 
A recent study by Kyabayinze et al. (2011) in Uganda obtained a sensitivity of 97% and a 
specificity of 74% for an HRP 2-type RDT for the diagnosis of MiP. Assuming that the level of 
sensitivity and specificity of the RDT for detecting malaria in pregnancy is similar, and the 
prevalence of submicroscopic parasitaemia will be 30%, to estimate the specificity of the RDT 
with a 95% confidence interval of +/- 5% a sample size of 990 women will be required. This same 
sample size will be sufficient to estimate a sensitivity of 97% with a 95% confidence limits of +/- 
2%. 
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Objective 3: Determination of the prevalence and effect of submicroscopic malaria infections 
on pregnancy outcomes in pauci-gravid pregnant women. 
We conducted PCR assays on all the blood spot samples collected from the women at one site 
(Ghana) of the trial. These included samples collected at both scheduled and unscheduled visits. 
Owing to the different gestational ages at which they were recruited, some women had made four 
ANC visits whiles others had made three or two visits before they delivered. The thick and thin 
blood films taken from this cohort at all the visits, both scheduled and unscheduled, until delivery 
were examined. PCR assays were done for all the blood spots from each visit for this cohort to 
determine the prevalence of submicroscopic infections among the cohort. The risk of placental 
malaria among women who had submicroscopic malaria during pregnancy but no RDT positive 
or blood slide positive malaria during ANC visits was estimated. The comparison of risk of other 
adverse outcomes (low birth weight and anaemia in pregnancy) was done for women who had 
submicroscopic infection during pregnancy, versus women who had microscopic malaria 
infections and those who had no malaria. 
Sample size calculation 
Several studies have obtained a prevalence of low birth weight among women who had placental 
malaria of around 20% (Steketee et al. 1996; McGregor et al. 1983). We assumed an incidence of 
low birth weight of 10% among women who had no malaria and 20% among women with 
submicroscopic malaria infections. To have 80% power and 95% significance to detect a 
difference in low birth weight between the two groups, a sample size of 392 women will be 
required. 
Objective 4: Determination of the prevalence of falciparum and non-falciparum malaria in 
pregnant women in West Africa 
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A total of 2,348 samples blood spot samples were obtained from study participants at enrolment 
before any interventions began, from all the four countries involved in the trial. The distribution 
of the samples by country is as follows in Table 2: 
Table 2 Distribution of women in sub-study by study country 
Country Number (%) 
Burkina Faso 476 (20.3) 
Gambia 725 (30.9) 
Ghana 683 (29.0) 
Mali 464 (19.8) 
Total 2,348 (100.0) 
 
 
Blood spot samples obtained from women were tested with a rapid diagnostic test for malaria, 
[First Response® Combo (pLDH/HRP2)].  Thick and thin blood films were prepared and filter 
paper samples for Nested PCR assays were also collected. The blood slides were examined twice 
by two microscopists at each site and if there were discrepancies in the results, slides were read by 
a third microscopist as described by Swysen et al (2011). For quality control, a 10% random sample 
of slides was selected and read by microscopists at an independent, designated centre. Speciation 
PCR assays were conducted at the MRC Unit laboratories in the Gambia. 
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Table 3: Sample size calculation scenarios for non-falciparum study 
Parameters Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
Estimated 
prevalence 
0.01 0.02 0.03 0.04 0.05 
Margin of 
error 
0.01 0.01 0.01 0.01 0.01 
Sample size 381 753 1,118 1,476 1,825 
 
It is estimated that the prevalence of non-falciparum in this population is likely to be around 3%. 
This is supported by the findings of Mockenhaupt et al. (2000) who obtained a prevalence of 5% 
for P. malariae and 3.6% for P. ovale among a group of pregnant women in Ghana. Therefore, to 
estimate the prevalence of non-falciparum malaria among pregnant women with a 95% confidence 
interval within a margin of error of 1% required a sample size of 1,118 women. This needed to 
increase to 1,825 women if the prevalence was 5% (Table 3). Therefore, testing 2,500 women gave 
greater precision for this estimate. Owing to the fact that the women were recruited into the study 
over a whole year, we were able to disaggregate their data by season and also by place of 
recruitment. 
 
Objective 5: Assessing the usefulness of a symptom and sign based score to predict MiP 
which could be used as a tool to select women needing RDT screening at antenatal clinics. 
At each visit (scheduled and unscheduled), signs and symptoms were elicited from each pregnant 
woman. Specific questions about whether the woman had any symptoms on that day or whether 
she had had any symptoms in the past week were asked. The presence of particular symptoms such 
as fever, headache, and malaise was compared with the RDT test results obtained at those visits to 
determine if particular symptoms could predict the need for RDT testing at each visit. The 
predictive values of different combinations of symptoms and signs was also tested in RDT positive 
women compared to RDT negative women and in PCR positive vs. PCR negative women. 
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Sample size calculation 
An earlier study in Ghana found that among a group of primigravidae, a history of sickness in the 
preceding five days before a clinic visit was predictive of parasitaemia in 57% of the women while 
a history of fever predicted parasitaemia in 44% of the women (Tagbor et al. 2008). We assumed 
therefore, that the sensitivity of clinical features to detect malaria in pregnancy was 50%, with a 
specificity of 50%. The sample size required to estimate the sensitivity of clinical features to detect 
MiP with a 95% confidence interval +/- 5% was 1,281. 
 
 3.4 Study Sites 
 
3.4.1 Burkina Faso; health district of Ziniaré (Province of Oubritenga)  
The Burkinabe component of the study was conducted in the health district of Ziniaré which is 
situated in the province of Oubritenga north of Ouagadougou, in Burkina Faso. The total 
population of the district was 261,892 in 2009 and the adult female population was 61,466. Twelve 
thousand pregnancies were expected per year. Child mortality fluctuates between 23 and 28 per 
1000 live births per year. The district has one district hospital (35 km from Ouagadougou) and 41 
health centres/dispensaries. The climate of the area is characteristic of the Sudan savannah with a 
dry, cool season from November to February, a dry, hot season from March to May and a rainy 
season from June to October. The mean annual rainfall is about 650 mm and the average annual 
temperature ranges between 23o and 33°C.  Malaria is endemic and is the first cause of consultation 
and hospitalization. The trial was conducted by the UFR / SDS (School of Medicine), University 
of Ouagadougou with some support from the Centre National de Recherche et de Formation sur le 
Paludisme (CNRFP). This site has expertise in conducting trials in malaria in pregnancy, malaria 
epidemiology and drug resistance. Recent studies include a treatment trial comparing SP and 
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chloroquine and a study of intestinal parasite in pregnancy (Coulibaly et al. 2006).  
3.4.2 Ghana: Navrongo Health Research Centre, Navrongo.  
The Ghanaian component of the study was conducted in the Kassena-Nankana district of northern 
Ghana, which lies within the Sudan savannah belt of West Africa. Navrongo, the district capital, 
has an annual rainfall of 850-950mm, most of which falls between May and September. The 
district has a population of about 150,000 and the economy is dominated by subsistence farming. 
Educational attainment is generally low. The district has 4 health centres, 3 clinics and a 140-bed 
hospital that serves as a referral centre. All these facilities provide antenatal care and have facilities 
for delivery. These are complemented by services provided by community-based community 
health officers who offer ante-natal services. Trained midwives undertake deliveries as well. The 
district serves as a national HIV sentinel site. The trial was based at the Navrongo Health Research 
Centre, a well-equipped centre which has extensive experience with large field trials, including 
trials of ITNs and meningococcal and rotavirus vaccines. A large trial of IPTp with amodiaquine 
and SP + amodiaquine was recently completed which involved over 3600 pregnant women (Clerk 
et al. 2008; Clerk et al. 2009).   
 
3.4.3 Mali: San and Kita field sites  
The study in Mali was based at the community health centres of two medium sized, semi-rural 
towns (San and Kita) in north-eastern Mali, with a total population of approximately 75,000 
inhabitants.  San is located 440 kilometres northeast of Bamako in the Segou region of Mali; Kita 
is 140 km north-west of Bamako.  Residents of both towns are of relatively similar socio-economic 
status.  These areas have a climate typical of the Sudan savannah with a long dry season and a 
shorter rainy season when most malaria transmission occurs, extending from June to August (San) 
or September (Kita). Staff of the Malaria Research and Training Centre, Bamako were responsible 
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for conduct of the trial. This well-equipped centre has extensive experience of malaria research 
including the conduct of treatment and vaccine trials. MRTC is involved in all aspects of research 
on malaria and has an excellent track record for running complex field and intervention studies 
(Kayentao et al. 2005). 
 
3.4.4 The Gambia: MRC Laboratories, Basse 
The trial was conducted in the Upper River Division. The study area comprised Basse town and 
the surrounding rural areas. A demographic surveillance system is in place covering a population 
of approximately 120,000. The climate of the area is typical of the Sudan savanna with an annual 
rainfall of around 700 mm a year, which falls predominantly during the months of July – 
November, a little later that in the other sites in this trial. P. falciparum is the dominant malaria 
parasite.  The study area is served by Basse Health Centre and by several dispensaries and health 
centres. Basse Health Centre has in-patient facilities for 100 patients. It has laboratory facilities 
for haematological, biochemical and parasitological investigations and X-ray facilities. Basse 
health centre is supported by the well-equipped MRC field station in Basse town. MRC is currently 
conducting surveillance studies on the causes of diarrhoea and acute respiratory infections in 
Upper River Division. Studies on the prevention of malaria in children using vaccination and 
intermittent preventive treatment have previously been conducted successfully in Upper River 
Division.  
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Table 4: Background information on the study sites or nearby areas 
Parameter Burkina Faso Ghana Mali The Gambia 
(1) EIR (bites/person/year) 100 – 300  200 19.23 – 21.1 during rainy 
season 
10 – 50  
(2) Malaria prevalence     
Children <5 years 53.5% 41.5% 39.5% 20% 
a) Antenatal     
All gravidae 20 – 25% 47% 23.9% 8% 
Primigravidae  25% 58% 62.1% 28% 
b) Placenta     
All gravidae 22% 32% 17.1 – 42.3% No recent data 
Primigravidae    8.8%  
(3) ANC attendance >90% 98% >90% 98% 
(4) SP-IPTp2 or more coverage Not available 35% 4% 32% 
(5) Antimalarial drug policy     
1st line Quinine Quinine Quinine Quinine 
2nd line AQ/AS; AL AQ/AS; AL AQ/AS; AL AQ/AS; AL 
(6) Folic acid supplementation dose 0.25mg 5mg 5mg 5mg 
(7) Iron supplementation dose 200mg 200mg 200mg 200mg 
(8) HIV control policy     
HIV prevalence among pregnant 
women 
1.6% 2.8% Low 2.8%  
HIV screening at ANC VCT VCT VCT VCT 
ART policy Refer to ART centre for 
drugs 
Refer to ART centre for 
drugs 
Refer to ART centre for 
drugs 
Refer to ART centre for 
drugs 
(9) ITN coverage / use among pregnant 
women 
Not available 40 – 52.5% 29% 50% 
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3.5 Study population 
The trial considered for recruitment all primigravidae and secundigravidae who reported to an 
ANC within the study areas for the first time during that current pregnancy from the time the 
trial started until the required sample size was reached. 
3.5.1 Inclusion criteria 
1. Presence of a first or second pregnancy. 
2. Gestational age between 16 to 30 weeks inclusive at first booking, as determined 
by symphysio-fundal measurements.  
3. Provision of written informed consent to join the trial.  
4.  Residence in the study area and intention to stay in the area for the duration of the 
pregnancy.  
3.5.2 Exclusion criteria 
1. Absence of informed consent.  
2. An intention to leave the study area before delivery.  
3. A history of sensitivity to sulphonamides.  
4. Clinical AIDS or known HIV positivity.  
5. Presence of any systemic illness likely to interfere with interpretation of the results 
of the trial.  
3.6 Study procedures 
All study participants were recruited at ANCs at the various study sites over a one year 
period. They were all followed-up at scheduled visits till six weeks after they had delivered 
when they exited from the study. Table 5 below shows the schedule of visits and procedures 
conducted for each study participant. 
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Table 5: A schedule of procedures at study visits 
 SCHEDULE OF FOLLOW-UP VISITS 
STUDY PROCEDURE Visit 0 
(enrolment 
day) 
Visit 1 
(24-26 
weeks) 
Visit 2 
(32 
weeks) 
Visit 3 (38 
weeks +/- 2 
weeks) 
Visit 4 
(delivery) 
Visit 5 
(postpartu
m) 
Unschedu
led visits  
Assess woman’s eligibility  X       
Obtain informed consent X       
Randomise eligible women 
into study arms 
X       
Obtain demographic, 
medical and obstetric data 
(including history and 
physical examination) 
X       
Symptoms assessment X X X X X X X 
Rapid diagnostic testing for 
malaria & treatment* 
X X X  X X X 
Provide SP IPTp^ X X X     
Obtain thin and thick blood 
smears for microscopy 
X X X X X X X 
Prepare filter paper blood 
spots 
X X X X X X X 
Assess Hb level X   X X   
Assess incidence adverse 
drug events  
 X X X X  X 
Collect placenta biopsies for 
impression smears and 
histology 
    X   
Record birth weight      X   
Assess gestational age using 
Ballard score 
    X   
Examine newborn and 
record any congenital 
abnormalities 
    X   
Assess neonatal and 
maternal outcomes  
     X  
* All women in intermittent screening and treatment arm and any woman at unscheduled visit 
^All women in IPT arm 
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3.7 Symptomatology 
A short questionnaire was administered to all women in the study to collect background 
information. Two short checklists were used to elicit symptoms and signs from women 
attending antenatal clinics. One of the checklists sought to obtain information on whether the 
woman had any symptoms at the time of being interviewed. The second checklist elicited 
symptoms which may have been present in the last seven days before the visit. This information 
was collected at every visit (scheduled and unscheduled). The relationship between these 
clinical features and a positive malaria RDT result were explored.  
 
3.8 Laboratory procedures 
3.8.1 Haemoglobin measurement  
• Haemoglobin concentrations was measured from finger prick blood samples using an 
Hb 301 Hemocue analysers (HemoCue, Anglom, Sweden). Measurements were 
done three times for each woman; first at recruitment, then at 38 weeks (+/-2 weeks) 
and at the time of delivery or shortly afterwards. The tests were performed according 
to the manufacturer’s instructions. Anaemia is defined as a haemoglobin 
concentration <11.0gm/dl (Goonewardene et al. 2012). 
. 
3.8.2 Blood film 
Thin and thick blood smears were obtained from all women on presentation (visit 0), at two 
subsequent visits when the project interventions were delivered (visits 1 and 2), at 38 weeks 
(+/- 2 weeks) [visit 3], at delivery (visit 4) and post-partum (visit 5). In addition, blood films 
were made at any time that a study woman presented at an unscheduled visit with suspected 
malaria as assessed by a member of the routine ANC clinic staff. Thick blood smears were 
stained with 2% Giemsa for 30 minutes and read by two trained microscopists independently 
50 
 
 
at each site. Parasite densities were calculated by counting the number of asexual parasites per 
200 leukocytes (or per 500 leukocytes if the count was <10 asexual parasites/200 leukocytes), 
assuming a leukocyte count of 8,000/µl. A blood smear was considered negative when the 
examination of 100 high power fields did not reveal asexual parasites. A third microscopist 
read each slide for which there was a discrepancy between the first two readers. For quality 
control, a 10% random sample of slides was read by microscopists from a designated referral 
centre in Kenya. These results were used to monitor the slide reading of individual 
microscopists and to retrain those who needed it. 
A limitation of the method for the quantification of malaria parasitaemia, which is based on an 
assumption of a white blood cell (WBC) count of 8000/microliter is the physiological 
leokocytosis that is observed in pregnancy (Sanci et al. 2017). This has the potential of resulting 
in a lower malaria parasite count than expected as there are more WBCs to count and therefore 
8000 WBCs are more quickly counted. This may limit the usefulness of this method of counting 
malaria parasites. If an accurate WBC count is known, a more accurate parasite count could be 
obtained (Moody, 2002). 
3.8.3 Rapid diagnostic tests (RDTs) 
First Response® Malaria Rapid Diagnostic Combo Test was used in this trial. The same RDT 
was used at all sites. Members of recruitment teams received hands-on instruction from local 
investigators in preparation and interpretation of the RDTs according to the manufacturer’s 
instructions. The test results from these RDTs were compared with PCR results for the same 
blood samples. 
The First Response® Malaria pLDH/HRP2 combo Test contains a nitrocellulose membrane 
strip which is pre-coated with two monoclonal antibodies in two separate lines across a 
test strip. One monoclonal antibody (test line 2) is specific to lactate 
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dehydrogenase (pLDH) of the Plasmodium species (P. falciparum, P.vivax, P.malariae, 
and P.ovale) and the other line (test line 1) consists of a monoclonal antibody specific to 
Histidine-Rich Protein 2 (HRP2) of the P. falciparum.  
The test is performed by taking a 5µl sample of blood with a calibrated sample pipette from a 
finger prick. The blood is dispensed into a sample well on the test cassette after which 60µl of 
assay buffer is added. The test result is read after 20 minutes. The presence of three bands on 
the cassette (control, test lines 1 & 2) indicates a positive test for P. falciparum or a mixed 
infection of P. falciparum and other non-falciparum species. The presence of two bands 
(control and test line 2) indicates a positive result for pan-plasmodium species possibly 
including P. falciparum. However, one would have expected the test line 1 to also be reactive 
if P. falciparum was to be present, unless for some reason, the HRP2 test strip gave a false 
negative result or the parasite did not produce HRP2. The presence of only the control band 
indicates a negative result. The test is invalid if the control band does not appear, irrespective 
of what the other bands show.  
3.8.4 Placental malaria: Preparation of placental smears and biopsies 
Immediately after delivery in a health facility, trained midwives obtained and washed placental 
samples with sterile normal saline.  A small piece of placental tissue (0.5 cm3) was excised 
from the centre of the maternal side of the placenta to prepare impression smears. A larger 
placenta biopsy (1.5 by 1.5 by 1 cm) was obtained and fixed in 50 ml of 10% neutral buffered 
formalin, adjusting the pH at 7.0, and individually labelled to help identification. Pending 
histological processing and evaluation, all biopsies were kept at 4 °C. The placental biopsies 
were embedded in paraffin wax by standard techniques in histopathology laboratories in each 
of the participating countries. In Ghana, the histopathological processing of the placenta blocks 
was done at the Histopathological Laboratory at the Korle Bu Teaching Hospital in Accra. 
Paraffin sections 4 μm thick were stained with hematoxylin and eosin (H&E) stain for 
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histopathological examination at the Medical Research Council (MRC) Unit laboratories in the 
Gambia by Ms. Fanta Njie who had been trained in this technique at the University of 
Barcelona. This allowed comparison of RDTs, microscopy, PCR and placental histology to be 
done. 
The classification of placental malaria used in this study is that of Bulmer et al. (1993) as 
modified by Ismail et al. (2000). 
For the purpose of these analyses, the definition of placental malaria was limited to active 
infection, comprising only those who had malaria parasites present in their placenta at the time 
of delivery. Past infections, characterised by the presence of malaria pigment but with parasites 
absent, were classified with those with neither pigment nor parasites as cases of ‘no placental 
malaria’. 
3.8.5 PCR 
Nested PCR assays with speciation were conducted on blood samples collected on filter paper 
from all the women in the IST arm of the study in all the four countries (n=2,500), to determine 
the prevalence of non-falciparum malaria among the women. PCR was also done to detect 
submicroscopic infections and to compare the sensitivity and specificity of RDTs and 
microscopy in the diagnosis of malaria in pregnancy. PCR testing was conducted at the MRC 
Unit laboratories in the Gambia according to their SOPs (annex 1). In preparation for the PCR 
assays, parasite DNA was extracted from dried blood spots collected at the various sites.  A 
summary of the nested PCR assay is as follows: 
i. The first stage of the procedure involves a PCR assay with the primers rPLU5 + 
rPLU6. The assay includes positive controls for each of the four species 
(falciparum, vivax, ovale and malariae) and negative control without DNA. 
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ii. The second PCR reaction is to detect the presence of Plasmodium infection using 
the genus-specific primers, Plasmo-1 + Plasmo-2. 
iii. The third stage seeks to determine the specific species in positive samples by 
running four parallel PCR assays using the primers below: 
P. falciparum: rFAL 1 + rFAL 2 
P. malariae: rMAL 1 + rMAL 2 
P. ovale: rOVA 1 + rOVA 2 
P. vivax:rVIV 1 + rVIV 2 
For further differentiation of P. ovale into the two distinct species P. ovale curtisi and P. ovale 
wallikeri, the P. ovale sp. Tryptophan-rich antigen (PoTRA) nested PCR assay (Sutherland et 
al., 2010) was used. 
In this thesis I assume that the finding of a PCR positive result for malaria is equivalent to 
infection with the malaria parasite. This position was adopted owing to the fact that PCR has 
so far had the highest sensitivity and specificity compared to all the currently available tests 
for malaria. It has been shown to detect five parasites or less per microliter of blood 
(Snounou et al, 1993). However, it must be noted that even though its sensitivity and 
specificity are high, absolute figures (100%) have never been obtained in any testing regime. 
Accordingly, there will be some false positive test results meaning that PCR positive test 
results will not always be equivalent to infection. The risk of this is however, quite low. 
The PhD candidate was based at the MRC Unit in the Gambia from October to November 
2012 and also for two weeks in March 2013 to take part in the PCR analyses of filter paper 
samples obtained for testing in the trial.  
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3.9 Socio-economic data collection and analysis 
The socio-economic status of study participants was defined using principal component 
analysis of durable household assets and amenities. The data for this analysis was obtained 
from study participants at enrolment using the “Demography form” (Form 10.2) found in 
Appendix 1. The principal component analysis was used to create five wealth quintiles 
among the women, who were categorised as: 
Wealthiest 
Wealthy 
Medium 
Poor 
Poorest 
The student investigator supervised data collection at the Ghana site of the main trial 
including household assets and durable amenities which was obtained at enrolment. 
3.10 Data management plan 
This study was conducted within the context of the trial of IPT with SP versus intermittent 
screening and treatment for malaria in pregnancy conducted in four West African countries. 
Data in this trial were captured using Teleform (Cardiff Software Inc., Vista CA) an optical 
character recognition-based data management system that scans paper case report forms (CRF) 
and exports data to a computer database. The same pre-printed CRFs were used to capture 
enrolment and follow up data at all trial centres. All CRFs were received, checked and 
registered by the data management teams. Once the data were captured by Teleform, at each 
site, they were stored in a local database and an anonymised copy submitted to the central 
database in London for further checks and cleaning. STATA (version 13) software was used 
for performing the main analysis of all the data captured. 
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3.11 Data analysis 
The baseline characteristics of all the study women were summarised with descriptive statistics. 
All categorical variables were presented as percentages while continuous variables were 
presented as means. The sensitivity and specificity analysis was conducted using the “diagt” 
command, a utility on STATA which generates 2 X 2 tables as well as the sensitivity, 
specificity, positive and negative predictive values. The analysis of sub-microscopic infections 
involved three outcomes of interest; placental malaria incidence, low birth weight and anaemia 
prevalence at 38 weeks of gestation. For these outcomes, the ‘per protocol’ populations were 
used. In logistic regression modeling for risk factors of sub-microscopic infections certain 
variables were assessed ‘a priori’ for their effects on the outcomes of interest. These include 
the age group of the women, educational status, gravidity, season of enrolment, intervention 
group and socio-economic status. For the modeling of malaria prevalence, these same variables 
were assessed in addition to country of residence and religion. 
 3.12 Ethical considerations 
The main study protocol and its amendments were approved by the London School of Hygiene 
and Tropical Medicine Ethical Committee (Application number 5275). In Ghana, approvals 
were granted by the Ghana Health Service Ethical Review Committee and the Navrongo Health 
Research Centre Institutional Review Board; in Burkina Faso ethical approval was granted by 
the Ethical Committee of the Ministry of Health; in The Gambia approval was granted by the 
Gambia Government/Medical Research Council Laboratories Joint Ethical Committee and in 
Mali the University of Bamako Ethical Committee reviewed and approved the study protocol 
and its amendments. Ethical approvals obtained for this trial are attached as appendices. 
Informed consent was obtained from all eligible women at the antenatal clinics before they 
were enrolled into the study. 
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 3.13 Definitions 
• Low birth weight: the weight of a live singleton newborn baby of less than 2,500 
grammes obtained within seven days of delivery. 
• Anaemia: Haemoglobin concentration of less than 11.0g/dl (Goonewardene et al. 
2012) 
• Season of enrolment: 
o Early wet: June-August. 
o Late wet: September-November. 
o Early dry: December-February.  
o Late dry: March-May. 
The season of enrolment was included in this PhD sub-study because malaria 
transmission in the four study areas is occurs mainly during the rainy season or shortly 
afterwards and is therefore highly seasonal. Accordingly, I tried to explore associations 
between the season of enrollment and some of my outcomes of interest. However, the 
categories used could reflect slightly different rainfall patterns in each of the countries. 
This potential misclassification is a limitation of this method of categorising rainfall 
seasons in the study countries. 
• Paucigravida(e): In this thesis, this refers to women pregnant for the first or second 
time only. 
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CHAPTER FOUR 
 
Sensitivity and Specificity of Rapid Diagnostic Tests 
(RDTs) in the Diagnosis of Malaria in Pregnancy 
 
4.1 Introduction 
This chapter presents the findings of analyses of the sensitivity and specificity of RDTs to 
detect malaria infection in the peripheral blood and placenta of Ghanaian pregnant women 
participating in a trial of IPT with sulfadoxine- pyrimethamine versus IST. 
First the prevalence of malaria infection of the placenta and of a positive RDT test is reported. 
Then, the sensitivity and specificity of the RDT used in the study to detect placental malaria 
are presented. Subsequently, the sensitivity and specificity of the RDT are estimated for 
individual study visits. The sensitivity and specificity of the RDT to detect malaria infection in 
peripheral blood compared with PCR and blood smear microscopy is then presented. 
4.2 Diagnosis of placental malaria by RDT 
4.2.1 Prevalence of placental malaria 
Table 6 shows the prevalence of malaria infection in 851 Ghanaian women whose placentae 
were examined histologically. Eight percent had acute placental malaria (malaria parasites 
without pigment) while 21.9% had chronic placental malaria (parasites and pigment), a total of 
30.1% active placental malaria infections according to our definition (presence of malaria 
parasites with or without pigment and/or macrophages in the placenta) at the time of delivery. 
Even though past malaria infections are important clinically, they cannot be detected by RDT. 
Therefore, in assessing RDT sensitivity, active malaria infections where parasites are present 
with or without pigment is of interest. 
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Table 6: Distribution of active placental malaria among study participants  
Characteristic Number Percent 
No placental malaria 595 69.9 
Active placental malaria   
 Acute 70 8.2 
 Chronic 186 21.9 
   
Total 851 100.0 
 
4.2.2 Prevalence of malaria by Rapid Diagnostic Testing 
The study participants who were in the IST arm of the study had scheduled rapid diagnostic 
testing done whenever they visited an ANC for a routine scheduled visit. Accordingly, they 
were tested at visits 0 (day of enrolment), 1, 2, 3 and 4 (delivery). In addition, any study subject 
irrespective of study arm, who reported sick at a scheduled or unscheduled visit also had a 
malaria rapid diagnostic test done. Two composite groups of women were created to estimate 
the prevalence RDT positive malaria in pregnancy. One group comprised women who had ever 
tested positive with an RDT at any time during the study, at a scheduled or an unscheduled 
visit (Ever RDT Positive), and the other group comprised women who had tested positive at 
any scheduled ANC visit (Any ANC RDT Positive). The results this analysis are presented in 
table 7 below. Nearly three quarters of women (73.5%) had at least one positive RDT during 
scheduled ANC visits. The majority of women had a positive RDT at the first ANC visit 
(58.3%) and the rate of RDT positivity decreased in the subsequent ANC visits, the last ANC 
visit had the lowest positive RDT (23.5%) 
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Table 7 Results of Rapid Diagnostic Tests 
Characteristic Number Percent 
Ever RDT positive   
 No 321 34.8 
 Yes 601 65.2 
   
Any ANC RDT Positive   
 No 177 26.5 
 Yes 490 73.5 
   
RDT Visit 0   
 Negative 272 41.7 
 Positive 380 58.3 
   
RDT Visit 1   
 Negative 366 64.9 
 Positive 198 35.1 
   
RDT Visit 2   
 Negative 308 68.9 
 Positive 139 31.1 
   
   
RDT Visit 3   
 Negative 23 62.2 
 Positive 14 37.8 
   
   
RDT Visit 4   
 Negative 290 76.5 
 Positive 89 23.5 
   
First illness RDT   
 Negative 81 42.4 
 Positive 110 57.6 
   
Second illness RDT   
 Negative 14 46.7 
 Positive 16 53.3 
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4.2.3 Sensitivity and specificity of RDTs in detecting placental malaria. 
Prevalence of active placental malaria was 30.0% (95% CI 27.0%, 34.2%). The number of 
RDT done per women during antenatal period ranged from 1 to 7. Six hundred and forty women 
had at least one RDT and had a placental histology result. In this group of women (Ever RDT 
positive group) the sensitivity of RDT to detect active placental malaria was 63.1% (95% CI 
55.9%- 69.9%) and the Specificity was 35.1% (95% CI 30.6%- 39.7%) (Table 8). The positive 
predictive value of Ever RDT Positive was 29.9% (95% CI 25.5%- 34.5%) and the negative 
predictive value was 68.4% (95% CI 62.0%- 74.4%). 
Table 8: Ever RDT Positive versus Active Placental Malaria 
Ever RDT Positive Active Placental Malaria  
Positive Negative Total 
Positive 123 289 412 
Negative 72 156 228 
Total 195 445 640 
Four hundred and thirty-seven women had a RDT at scheduled ANC visit (Any ANC RDT) 
and a placental histology result. Sensitivity of Any ANC Positive RDT to detect placental 
malaria was 72.0% (95% CI 63.3%- 79.7%) and specificity was 25.3% 95% CI 20.6%- 
30.5%) (Table 9). The positive predictive value was 27.9% (95% CI 23.0%- 33.1%) and 
negative predictive value was 69.3% (95% CI 60.0%- 77.6%). 
Table 9: Any ANC Positive RDT versus Active Placental Malaria 
Any ANC Positive 
RDT 
Active Placental Malaria  
Positive Negative Total 
Positive 90 233 323 
Negative 35 79 114 
Total 125 312 437 
Among the 424 women who had a RDT done at enrolment and had a placental histology 
result, the sensitivity of RDT to detect placental malaria was 55.7% (95% CI 46.5%- 64.7%) 
and specificity was 42.4% (95% CI 36.7%- 48.2%) (Table 10). The positive predictive value 
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was 28.1% (95% CI 22.5%- 34.2%) and negative predictive value is 70.3% (95% CI 63.1%- 
76.9%) 
Table 10: ANC Visit 0 RDT versus Active Placental Malaria 
RDT visit 0 Active Placental Malaria  
Positive Negative Total 
Positive 68 174 242 
Negative 54 128 182 
Total 122 302 424 
Among the 378 women who had a RDT done at ANC visit 1 post enrolment and had a 
placental histology result,  the sensitivity of the RDT to detect placental malaria was 39.1% 
(95% CI 29.9%- 48.9%) and the specificity was 66.8% (95% CI 60.8%- 72.4%) (Table 11). 
The positive predictive value was 32.6% (95% CI 24.7%- 41.3%) and negative predictive 
value was72.8% (95% CI 66.7%- 78.2%). 
Table 11: Visit 1 RDT versus Active Placental Malaria 
RDT visit 1 Active Placental Malaria  
Positive Negative Total 
Positive 43 89 132 
Negative 67 179 246 
Total 110 268 378 
Among the 310 women who had a RDT done at ANC visit 2 post enrolment and had a 
placental histology result, the sensitivity to detect active placental malaria was 33.3% (95% 
CI 23.4%- 44.5%) and the specificity was 71.2% (95% CI 64.9%- 77.0%) (Table 12).  The 
positive predictive value was 30.1% (95% CI 21.0%- 40.5%) and negative predictive value 
was 74.2% (95% CI 67.8%- 79.9%). 
Table 12: Visit 2 RDT versus Active Placental Malaria 
RDT visit 2 Active Placental Malaria  
Positive Negative Total 
Positive 28 65 93 
Negative 56 161 217 
Total 84 226 310 
Among the 317 women who had a RDT done at delivery and had a placental histology result, 
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the sensitivity of RDT to detect active placental malaria was 35.4% (95% CI 26.6%- 45.0%) 
and the specificity was 80.9% (95% CI 74.8%- 86.0%) (Table 13). The positive predictive 
value was 50.6% (95% CI 39.1%- 62.1%) and the negative predictive value was 69.3% (95% 
CI 63.0%- 75.1%). 
Table 13: Visit 4 (delivery) RDT versus Active Placental Malaria 
RDT visit 4 Active Placental Malaria  
Positive Negative Total 
Positive 40 39 79 
Negative 73 165 238 
Total 113 204 317 
 
4.3 Diagnosis of malaria infection in pregnancy by RDT testing of 
peripheral blood. 
This section presents the analyses of the sensitivity and specificity of the RDT when 
compared with PCR results obtained from testing of peripheral blood spots on filter paper or 
with blood smear microscopy. The analysis in this section is in reference to any malaria 
infection detected by PCR and not in reference to any particular species. 
4.3.1 Sensitivity and specificity of the RDT in detecting PCR positive 
peripheral malaria parasitaemia. 
Among 592 women who had a blood slide and PCR assay at enrolment the prevalence of 
PCR positive malaria was 57.0% (95% CI 53.0%-61.0%). The Sensitivity of RDT to detect 
PCR positive malaria was 89.3% (95% CI 85.5%-92.4%) and the specificity was 88.2% (95% 
CI 83.6%-91.9%) (Table 14). The positive predictive value was 90.9% (95% CI 87.3%-
93.8%) and the negative predictive value was 86.2% (95% CI 81.4%-90.1%) 
 
 
63 
 
 
Table 14: Visit 0 RDT versus PCR results on a blood spot 
V0 RDT Result V0 PCR Result  
Positive Negative Total 
Positive 301 30 331 
Negative 36 225 261 
Total 337 255 592 
Among 499 women who had a blood slide and PCR assay done at the visit 1 post enrolment 
the prevalence of PCR positive malaria was 23.0% (95% CI 19.0%-26.8%). The sensitivity of 
RDT to detect malaria was 85.1% (95% CI 77.2%-91.1%) and the specificity was 86.0% 
(95% CI 82.1%-89.3%) (Table 15). The positive predictive value was 64.2% (95% CI 56.0%-
71.9%) and the negative predictive value was 95.1% (95% CI 92.3%-97.1%). 
Table 15: Visit 1 RDT versus PCR results on a blood spot 
V1 RDT Result V1 PCR Result  
Positive Negative Total 
Positive 97 54 151 
Negative 17 331 348 
Total 114 385 499 
Among 393 women who had a blood slide and PCR assay done at the visit 2 post enrolment 
the prevalence of PCR positive malaria was 18.0% (95% CI 15.0%-22.5%). The sensitivity of 
RDT to detect PCR positive malaria was 79.2% (95% CI 68.0%-87.8%) and the specificity 
was 82.9% (95% CI 78.3%-96.8%) (Table 16). The positive predictive value was 50.9% 
(95% CI 41.3%-60.5%) and negative predictive value was 94.7% (95% CI 91.4-97.0%) 
Table 16: Visit 2 RDT versus PCR results on a blood spot 
V2 RDT Result V2 PCR Result  
Positive Negative Total 
Positive 57 55 112 
Negative 15 266 281 
Total 72 321 393 
Among 348 women who had a blood slide and PCR assay done at delivery the prevalence of 
PCR positive malaria was 15.0% (95% CI 11.0%-19.1%). The sensitivity of RDT to detect 
PCR positive malaria was 57.7% (95% CI 43.2%-71.3%) and the specificity was 83.1 (95% 
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CI 78.3%-87.2%) (Table 17). The positive predictive value was 37.5% (95% CI 26.9%-
49.0%) and the negative predictive value was 91.8% (95% CI 87.8%-94.8%). 
Table 17: Visit 4 RDT versus PCR result on a blood spot 
V4 RDT Result V4 PCR Result  
Positive Negative Total 
Positive 30 50 80 
Negative 22 246 268 
Total 52 296 348 
 
4.3.2 Sensitivity and specificity of RDT in detecting malaria parasitaemia as 
detected by microscopy 
Among 651 women who had a RDT and blood slide at enrolment the prevalence of blood 
slide positive malaria was 47.0% (95% CI 43.0%-50.9%).  The sensitivity of RDT to detect 
blood slide positive malaria was 95.8% (95% CI 92.8%-97.7%) and the specificity was 
75.1% (95% CI 70.2%-79.5%) (Table 18). The positive predictive value was 77.3% (95% CI 
72.8%-81.4%) and the negative predictive value was 95.2% (95% CI 92.0%-97.4%). 
 
Table 18: Visit 0 RDT versus blood smear microscopy results 
V0 RDT Result V0 Blood Smear Result  
Positive Negative Total 
Positive 293 86 379 
Negative 13 259 272 
Total 306 345 651 
Among 363 women who had a RDT and blood slide done at visit 1 post enrolment the 
prevalence of blood slide positive malaria was 22.0% (95% CI 19.0%-26.0%). The sensitivity 
of RDT to detect malaria in pregnancy was 91.2% (95% CI 84.4%-95.5%) and the specificity 
was 81.1% (95% CI 77.1%-84.7% (Table 19). The positive predictive value was 58.2% (95% 
CI 50.9%-65.2%) and the negative predictive value was 97.0% (95% CI 94.6%-98.5%). 
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Table 19: Visit 1 RDT versus blood smear microscopy result 
V1 RDT Result V1 Blood Smear Result  
Positive Negative Total 
Positive 114 82 196 
Negative 11 352 363 
Total 125 434 559 
Among 438 women who had a RDT and blood slide done at visit 2 post enrolment the 
prevalence of blood slide positive malaria was 18.0% (95% CI 14.0%-21.5%). The  
sensitivity of RDT to detect malaria in pregnancy was 92.2% (95% CI 83.8%-97.1%) and the 
specificity was 82.3% (95% CI 77.9%-86.1%) (Table 20). The positive predictive value was 
52.6% (95% CI 43.8%-61.2%) and the negative predictive value was 98.0% (95% CI 95.7%-
99.3%). 
Table 20: Visit 2 RDT versus blood smear microscopy results 
V2 RDT Result V2 Blood Smear Result  
Positive Negative Total 
Positive 71 64 135 
Negative 6 297 303 
Total 77 361 438 
Among 344 women who had a RDT and blood slide done delivery the prevalence blood slide 
positive malaria was 17.0% (95% CI 13.0%-21.2%). The sensitivity of RDT to detect malaria 
in pregnancy was 60.3% (95% CI 46.6%-73.0 %%) and the specificity was 85.0% (95% CI 
80.3%-88.9%) (Table 21).  The positive predictive value was 44.9% (95% CI 33.6%-56.6%) 
and the negative predictive value was 91.4% (95% CI 87.3%-94.4%). 
Table 21: Visit 4 RDT versus blood smear microscopy results 
V4 RDT Result V4 Blood Smear Result  
Positive Negative Total 
Positive 35 43 78 
Negative 23 243 266 
Total 78 256 344 
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4.4 Summary 
The sensitivity of any positive RDT test at scheduled and unscheduled visits to detect placental 
malaria was 63.1%  (Ever RDT positive) and it increased to 72.0% when the RDT done at 
scheduled visits alone were used (ANC RDT positive).  However, the specificity of the RDT 
to detect placental malaria was much lower as it ranged between 25.3% for Any RDT Positive 
to 35.1% for Ever RDT Positive. The sensitivity of the RDT to detect placental malaria at 
individual study visits ranged between 55.7% at the enrolment to 33.3% during the 2nd visit 
post enrolment. At the same time, the specificity of the test result ranged from a low of 42.4% 
at enrolment to a high of 80.9% during the delivery visit. The sensitivity of the RDT to detect 
PCR positivity in peripheral blood ranged between 57.7% at delivery to 89.3% at enrolment 
and specificity ranged between 82.9% obtained during 2nd visit post enrolment to 88.2% at 
enrolment.  When blood smear microscopy was used as the gold standard, the sensitivity of the 
RDT to detect malaria in pregnancy ranged between 60.3% for the delivery visit to 95.8% at 
enrolment. The specificity ranged between 75.1% at enrolment to 85.0% at delivery.   
Table 22: Summary of RDT sensitivity and specificity with various reference tests 
Reference test RDT N Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
% (95% 
CI) 
% (95% 
CI) 
% (95% 
CI) 
% (95% 
CI) 
Placental 
histology 
      
 Ever RDT 
Positive 
640 63.1 (55.9-
69.9) 
35.1 (30.6-
39.7) 
29.9 
(25.5-
34.5) 
68.4 
(62.0-
74.4) 
 Any ANC 
Positive 
437 72.0 (63.3-
79.7) 
25.3 (20.6-
30.5) 
27.9 
(23.0-
33.1) 
69.3 
(60.0-
77.6) 
 Visit 0 424 55.7 (46.5-
64.7) 
42.4 (36.7-
48.2) 
28.1 
(22.5-
34.2) 
70.3 
(63.1-
76.9) 
 Visit 1 378 39.1 (29.9-
48.9) 
66.8 (60.8-
72.4) 
32.6 
(24.7-
41.3) 
72.8 
(66.7-
78.2) 
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 Visit 2 310 33.3 (23.4-
44.5) 
71.2 (64.9-
77.0) 
30.1 
(21.0-
40.5) 
74.2 
(67.8-
79.9) 
 Visit 4 317 35.4 (26.6-
45.0) 
80.9 (74.8-
86.0) 
50.6 
(39.1-
62.1) 
69.3 
(63.0-
75.1) 
       
Blood spot 
PCR 
      
 Visit 0 592 89.3 (85.5-
92.4) 
88.2 (83.6-
91.9) 
90.9 
(87.3-
93.8) 
86.2 
(81.4-
90.1) 
 Visit 1 499 85.1 (77.2-
91.1) 
86.0 (82.1-
89.3) 
64.2 
(56.0-
71.9) 
95.1 
(92.3-
97.1) 
 Visit2 393 79.2 (68.0-
87.8) 
82.9 (78.3-
96.8) 
50.9 
(41.3-
60.5) 
94.7 
(91.4-
97.0) 
 Visit 4 348 57.7 (43.2-
71.3) 
83.1 (78.3-
87.2) 
37.5 
(26.9-
49.0) 
91.8 
(87.8-
94.8) 
       
Microscopy       
 Visit 0 651 95.8 (92.8-
97.7) 
75.1 (70.2-
79.5) 
77.3 
(72.8-
81.4) 
95.2 
(92.0-
97.4) 
 Visit 1 559 91.2 (84.4-
95.5) 
81.1 (77.1-
84.7) 
58.2 
(50.9-
65.2) 
97.0 
(94.6-
98.5) 
 Visit 2 438 92.2 (83.8-
97.1) 
82.3 (77.9-
86.1) 
52.6 
(43.8-
61.2) 
98.0 
(95.7-
99.3) 
 Visit 4 344 60.3 (46.6-
73.0) 
85.0 (80.3-
88.9) 
44.9 
(33.6-
56.6) 
91.4 
(87.3-
94.4) 
PPV: positive predictive value, NPV: negative predictive value 
 
 In summary the RDT used in this study failed to detect a number of malaria infections of 
both peripheral blood and placenta compared to more sensitive assays (PCR and placental 
histology). The significance of these failures is considered in the next two chapters.  
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CHAPTER FIVE 
The influence of sub-microscopic and RDT negative malaria 
infections on the outcome of pregnancy 
 
5.1 Introduction 
This chapter analyses the impact of malaria infections that were not detected by an RDT or by 
microscopy on the outcome of pregnancy in the Ghanaian women enrolled in a trial of IPTp-
SP versus IST. The analyses include all the 1,306 women enrolled at the Ghana site into both 
the IPTp-SP and IST arms of the study. 
In this analysis of sub-patent malaria infections, infections detected by PCR and not by RDT 
(classified sub-RDT infections) are presented first followed by infections detected by PCR but 
not by microscopy (sub-microscopic). The women were studied separately for the first three 
antenatal clinic visits when study interventions were being provided for those in the 
intervention arm (v0-v2) and also for all the visits including the delivery visit (v0-v4).   
5.2 Background characteristics of study participants 
Table 23 presents the background characteristics of participants in this part of the study. The 
mean age of the women in the sample was 21.6 years with a minimum of 14 years and a 
maximum of 37 years. Almost 80% of the women were aged less than 25 years old. More than 
one-third were housewives with a significant proportion of others being traders or farmers. A 
fifth of the women had received no formal education while 65% had received only basic 
education. A little more than half of the women in the sample were carrying their first 
pregnancy. Most of the women were poor, with 53% of them being within the lowest two levels 
of the socio-economic scale (poor and poorest). 
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Table 23: Background characteristics of study participants 
Characteristic Number Percent 
Age group (years)   
 <20 443 33.9 
 20-24 590 45.2 
 25+ 273 20.9 
   
Occupation   
 Housewife 485 37.1 
 Farmer 263 20.1 
 Trader 368 28.2 
 Salaried worker 76 5.8 
 Other 114 8.7 
   
Education   
 None 266 20.4 
 Basic 849 65.0 
 Secondary 191 14.6 
   
Gravidity   
 1 727 55.8 
 2 576 44.2 
   
Socio-economic status    
 Wealthiest 162 12.4 
 Wealthy 167 12.8 
 Medium 278 21.4 
 Poor 453 34.8 
 Poorest 242 18.6 
   
Season of enrolment   
 Early wet 456 34.9 
 Late wet 280 21.4 
 Early dry 225 17.2 
 Late dry 345 26.4 
   
Total 1,306 100.0 
 
 
5.3 Prevalence of sub-patent malaria infections 
5.3.1 Sub-RDT malaria infections 
Table 24 shows the distribution of RDT positive malaria and sub-RDT infections (RDT –ve 
but PCR +ve) detected at the first three scheduled ANC visits as well as at the delivery visit. 
This analysis is restricted to the women in the IST arm only, as only they had RDTs done at 
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scheduled visits. The table also shows the risk of sub-RDT infections calculated for the first 
three study visits (v0-v2) and also for all the study visits combined (v0-v4). 
Table 24: Distribution of sub-RDT infections among women in IST arm by study visit 
Study Visit n Percent 
First visit (v0) (N=592)  
 Uninfected 225 38.0 
 RDT positive 331 55.9 
 Sub-RDT 36 6.1 
   
Second visit (v1) (N=499)  
 Uninfected 331 66.3 
 RDT positive 151 30.3 
 Sub-RDT 17 3.4 
   
Third visit (v2) (N=393)  
 Uninfected 266 67.7 
 RDT positive 112 28.5 
 Sub-RDT 15 3.8 
   
Delivery visit (v4) (N=348)  
 Uninfected 246 70.7 
 RDT positive 80 23.0 
 Sub-RDT 22 6.3 
   
Risk of infection (v0-v2) (N=625)  
 Uninfected 139 22.2 
 RDT positive 423 67.7 
 Sub-RDT 63 10.1 
   
Risk of infection (v0-v4) (N=636)  
 Uninfected 123 19.3 
 RDT positive  427 67.1 
 Sub-RDT 86 13.5 
 
At first ANC visit, 55.9% of women had malaria infections detected by RDT and PCR; an 
additional 6.1% had sub-RDT infections. At delivery, 23.0% of study women had RDT positive 
malaria infections which were also positive by PCR. However, there were an additional 6.3% 
of women who had sub-RDT infections.  
The risk of a positive RDT from the first to the third scheduled (v0-v2) visit was 67.7% while 
the risk for additional sub-RDT malaria infection was 10.1%. However, when all the scheduled 
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visits including delivery are combined (v0-v4), the risk of a positive RDT was 67.1% while 
that of sub-RDT infections increased to 13.5%.  
Table 25 shows the influence of various background characteristics on the prevalence of sub-
RDT infections at the first two scheduled visits and also at the delivery visit. A trend towards 
increasing prevalence of sub-RDT infections with increasing age was observed at the first two 
visits. The prevalence increased from 4.0% (95% CI 1.9-8.1) among women aged less than 20 
years to 7.8% (95% CI 4.2-13.9) among women 25 years and above during the first visit. 
During the second visit, the sub-RDT prevalence increased from 2.8% (95% CI 1.0-7.2) among 
the youngest women to 4.6% (95% CI 1.9-10.6) among the oldest women. This trend was not 
so clear during the delivery visit when the prevalence decreased from 6.1% (95% CI 3.1-11.8) 
among the women less than 20 years to 5.0% (95% CI 2.4-10.2) among the women 20-24 years 
and then increased to 9.1% (95% CI 4.4-18.0) among the oldest women 25 years and above.  
From the second scheduled visit, there was a trend towards a decreasing prevalence of sub-
RDT infection with increasing education of the women. The prevalence of sub-RDT infections 
decreased from 6.4% (95% CI 3.1-12.8) among women with no education to 2.2% (95% CI 
0.5-8.3) among women with secondary education or more. A similar pattern was observed at 
delivery where sub-RDT infections decreased from 7.8% (95% CI 3.3-17.6) among women 
with no education to 4.3% (95% CI 1.1-15.8) among women with secondary education or more.  
However, it must be noted that the confidence intervals for this analysis overlap and therefore 
these observations may not be significant. 
At the first two scheduled visits, secundigravid women had a higher prevalence of sub-RDT 
infections compared to primigravid women. However, at the delivery visit, this observation 
was reversed, with primigravid women having a higher prevalence of sub-RDT infections 
compared to secundigravid women. At their first visit, 9.6% (95% CI 6.6-13.7) of 
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secundigravid women had a sub-RDT malaria infection compared to 3.2% (95% CI 1.7-5.8) of 
primigravid women. At the delivery visit, the secundigravid women had a sub-RDT prevalence 
of 5.8% (95% CI 3.1-10.9) compared to 6.7% (95% CI 3.9-11.2) for the primigravid women. 
There was no clear trend or pattern for the prevalence of sub-RDT infections by season of 
enrolment or socio-economic status of the women as observed in the three study visits analysed. 
 
Table 25: Prevalence of sub-RDT malaria infection by background characteristics of 
study women at various visits 
Characteristic First visit (v0) Second visit (v1) Delivery visit (v4) 
 n (%) 95% CI n (%) 95% CI n (%) 95% CI 
Age group (years) (N=592)  (N=499)  (N=348)  
 <20 7(4.0) 1.9-8.1 4(2.8) 1.0-7.2 8(6.1) 3.1-11.8 
 20-24 19(6.6) 4.3-10.2 8(3.3) 1.6-6.4 7(5.0) 2.4-10.2 
 25+ 10(7.8) 4.2-13.9 5(4.6) 1.9-10.6 7(9.1) 4.4-18.0 
       
Educational status (N=592)  (N=499)  (N=348)  
 None 10(7.5) 4.1-13.4 7(6.4) 3.1-12.8 5(7.8) 3.3-17.6 
 Basic 20(5.5) 3.6-8.4 8(2.7) 1.4-5.3 15(6.3) 3.8-10.3 
 Secondary 6(6.3) 2.9-13.4 2(2.2) 0.5-8.3 2(4.3) 1.1-15.8 
       
Gravidity (N=589)  (N=497)  (N=348)  
 1 10(3.2) 1.7-5.8 7(2.6) 1.2-5.4 13(6.7) 3.9-11.2 
 2 26(9.6) 6.6-13.7 10(4.4) 2.4-8.0 9(5.8) 3.1-10.9 
       
Season of 
enrolment 
(N=592)  (N=499)  (N=348)  
 Early wet 11(5.6) 3.1-9.9 4(2.8) 1.0-7.2 11(9.2) 5.2-16.0 
 Late wet 10(7.6) 4.1-13.7 5(3.9) 1.6-9.2 1(3.6) 0.5-22.2 
 Early dry 8(7.9) 3.8-14.3 2(2.1) 0.5-8.0 4(4.9) 1.9-12.5 
 Late dry 7(4.4) 2.1-9.0 6(4.6) 2.1-9.9 6(5.0) 2.3-10.7 
       
Socio-economic 
status 
(N=591)  (N=498)  (N=347)  
 Wealthiest 5(6.2) 2.6-14.1 1(1.4) 0.2-9.6 5(12.2) 5.1-26.4 
 Wealthy 2(2.9) 0.7-11.1 4(7.1) 2.7-17.7 3(7.7) 2.5-21.6 
Medium 6(4.8) 2.2-10.4 0(0.0) - 6(8.0) 3.6-16.8 
 Poor 17(8.4) 5.3-13.1 9(4.9) 2.6-9.2 5(4.0) 1.7-9.3 
 Poorest 6(5.2) 2.4-11.2 3(3.3) 1.0-9.9 3(4.5) 1.4-13.1 
5.3.2 Sub-microscopic malaria infections 
At their first ANC visit, 47.9% of study women tested positive for malaria by microscopy as 
shown in table 26. However, 58.5% tested positive by PCR, indicating a sub-microscopic 
infection rate of 10.6%. The prevalence of sub-microscopic infections declined in subsequent 
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visits as the prevalence of malaria overall declined. The prevalence of sub-microscopic 
infections was 7.1% at the second visit, 5.8% at the third visit and 5.1% at delivery. 
The overall risk of sub-microscopic infections for the first three scheduled ANC visits when 
interventions were provided was 17.6%. However, when all scheduled visits including delivery 
are combined, the risk of a sub-microscopic infection at any time within the pregnancy was 
21.8%. 
Table 26: Distribution of microscopic and sub-microscopic infections by study visit 
among study participants 
Study Visit N Percent 
First visit (v0) (N=1,223)  
 Uninfected 507 41.5 
 Microscopic 586 47.9 
 Sub-microscopic 130 10.6 
   
Second visit (v1) (N=1,014)  
 Uninfected 730 72.0 
 Microscopic 212 20.9 
 Sub-microscopic 72 7.1 
   
Third visit (v2) (N=794)  
 Uninfected 613 77.2 
 Microscopic 135 17.0 
 Sub-microscopic 46 5.8 
   
Fourth visit (v3) (N=506)  
 Uninfected 421 83.2 
 Microscopic 61 12.1 
 Sub-microscopic 24 4.7 
   
Delivery visit (v4) (N=897)  
 Uninfected 723 80.6 
 Microscopic 128 14.3 
 Sub-microscopic 46 5.1 
   
Risk of infection (v0-v2) (N=1,265)  
 Uninfected 386 30.5 
 Microscopic 657 51.9 
 Sub-microscopic 222 17.6 
   
Risk of infection (v0-v4) (N=1,273)  
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 Uninfected 313 24.6 
 Microscopic 682 53.6 
 Sub-microscopic 278 21.8 
 
Table 27 shows the influence of various background characteristics on the prevalence of sub-
microscopic infections at the three ANC and delivery visits. There were no clear trends or 
patterns influencing the prevalence of sub-microscopic infections according to age group, 
educational status, intervention arm, season of enrolment or socio-economic status. However, 
secundigravid women had a higher prevalence of sub-microscopic malaria infection compared 
to primigravid women at all the three ANC visits.  At the first visit, 12.4% (95% CI 9.9-15.4) 
of secundigravid women had sub-microscopic infections compared to 9.24% (95% CI 7.3-11.7) 
of primigravid women. However, at delivery this difference had largely disappeared and 5.4% 
(95% CI 3.5-8.1) of secundigravid women had sub-microscopic malaria infections compared 
to 5.0% (95% CI 3.4-7.2) of primigravid women. There was no difference in the prevalence of 
sub-microscopic infection in women in the two study arms. At first visit, 9.1% (95% CI 7.0-
11.6) of women in the IPT arm had sub-microscopic infections compared to 12.3% (95% CI 
9.9-15.2) of women in the IST arm. However, at second visit, women in the IST arm had a 
lower prevalence of sub-microscopic infections [6.3% (95% CI 4.5-8.8) vs. 7.9% (95% CI 5.8-
10.5)]. At delivery, the prevalence of sub-microscopic infections was similar; women in the 
IPT arm had a prevalence of 5.0% (95% CI 3.4-7.4) while those in the IST arm had a prevalence 
of 5.3% (95% CI 3.5-7.8).
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Table 27: Prevalence of sub-microscopic malaria infection by background characteristics of study women at various visits 
Characteristic First visit (v0) Second visit (v1) Delivery visit (v4) 
 n (%) 95% CI n (%) 95% CI n (%) 95% CI 
Age Group (years) (N=1,223)  (N=1,014)  (N=897)  
 <20 35(8.6) 6.3-11.8 23(6.9) 4.6-10.1 15(4.9) 2.9-7.9 
 20-24 65(11.6) 9.2-14.6 38(8.3) 6.1-11.2 20(5.0) 3.3-7.7 
 25+ 30(11.6) 8.2-16.1 11(5.0) 2.8-8.8 11(5.8) 3.2-10.2 
       
Educational status (N=1,223)  (N=1,014)  (N=897)  
 None 26(10.4) 7.1-14.8 19(9.2) 5.9-14.0 13(7.3) 4.3-12.1 
 Basic 84(10.7) 8.7-13.1 46(7.2) 5.5-9.5 23(4.0) 2.7-6.0 
 Secondary 20(10.6) 7.0-15.9 7(4.1) 2.0-8.4 10(7.0) 3.8-12.5 
       
Intervention Arm (N=1,223)  (N=1,014)  (N=897)  
 IPT 57(9.1) 7.0-11.6 41(7.9) 5.8-10.5 23(5.0) 3.4-7.4 
 IST 73(12.3) 9.9-15.2 31(6.3) 4.5-8.8 23(5.3) 3.5-7.8 
       
Gravidity (N=1,220)  (N=1,012)  (N=896)  
 1 62(9.2) 7.3-11.7 35(6.4) 4.6-8.7 25(5.0) 3.4-7.2 
 2 68(12.4) 9.9-15.4 37(8.0) 5.9-10.9 21(5.4) 3.5-8.1 
       
Season of enrolment (N=1,223)  (N=1,014)  (N=897)  
 Early wet 32(7.8) 5.6-10.8 27(8.4) 5.8-12.0 21(7.5) 5.0-11.3 
 Late wet 41(15.3) 11.5-20.1 19(7.8) 5.0-11.9 12(5.5) 3.1-9.4 
 Early dry 26(12.0) 8.3-17.1 7(3.8) 1.8-7.7 7(4.1) 2.0-8.4 
 Late dry 31(9.4) 6.7-13.1 19(7.2) 4.6-11.0 6(2.6) 1.2-5.8 
       
Socio-economic 
status 
(N=1,220)  (N=1,011)  (N=894)  
 Wealthiest 18(11.5) 7.4-17.6 6(4.7) 2.1-10.1 7(5.5) 2.6-11.2 
 Wealthy 14(8.9) 5.3-14.5 2(1.5) 0.4-5.9 5(4.4) 1.8-10.2 
Medium 22(8.2) 5.5-12.2 17(8.3) 5.2-12.9 10(5.4) 2.9-9.8 
 Poor 54(13.0) 10.1-16.6 27(7.3) 5.1-10.5 14(4.5) 2.7-7.4 
 Poorest 22(9.9) 6.6-14.6 20(11.4) 7.5-17.1 10(6.5) 3.5-11.7 
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5.4 Predictors of sub-patent malaria infections 
A number of factors were evaluated for their association with sub-patent malaria infections 
among the study women at any stage of their pregnancy. For sub-RDT infections, the same 
factors with the exception of intervention arm were assessed. The intervention arm was not 
assessed because RDTs were conducted routinely only for women in the IST arm and not the 
ITPp-SP arm. For sub-microscopic infections, the age group, educational status, intervention 
arm, gravidity, season of enrolment and socio-economic status of the study women were 
assessed for their ability to predict sub-microscopic infections.  
5.4.1 Predictors of sub-RDT malaria infections 
Table 28 shows the influence of various background characteristics on the prevalence of sub-
RDT malaria estimated for the first three visits as well as for all the visits combined. 
There was a trend of increasing prevalence of sub-RDT infection with increasing age group.  
Women who were less than 20 years old had the lowest prevalence of sub-RDT infection 
(7.9%, 95% CI 4.8-12.6) which increased to 11.0% (95% CI 6.7-17.4) among women 25 years 
and above during the first three visits. The same trend was observed when all the visits are 
combined, with the youngest women having a prevalence of 8.5% (95% CI 5.7-12.5) and the 
oldest women 12.6% (95% CI 8.4-18.4). Women who had had basic education only, had the 
lowest prevalence of sub-RDT infection (8.3%, 95% CI 5.9-11.5) compared to women who 
had received no education, who had the highest prevalence (14.4%, 95% CI 9.6-21.1) during 
the first three study visits. A similar trend emerged when all the study visits were combined; 
women with basic education had a prevalence of 9.2% (95% CI 7.0-12.0) compared with 
women who had received no education who had a prevalence of 14.8% (95% CI 10.2-20.8). 
Secundigravid women had a higher prevalence of sub-RDT infection compared to primigravid 
women. The prevalence for secundigravid women was 13.5% (95% CI 10.0-17.9) during the 
first three visits compared to 7.0% (95% CI 4.8-10.3) for primigravid women; the same 
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observation was made when all the visits were combined with secundigravid women having a 
sub-RDT infection prevalence of 13.4% (95% CI 10.3-17.3) and primigravid women a 
prevalence of 8.2% (95% CI 6.0-11.2). Women enrolled during the late wet season had a 
prevalence of sub-RDT infection of 12.7% (95% CI 8.1-19.3) while women enrolled during 
the late dry season had a prevalence of 8.4% (95% CI 5.1-13.8) for the first three visits; when 
all the visits were combined the same pattern emerged with the highest prevalence being among 
women enrolled in the late wet season (11.9%, 95% CI 7.7-17.9) compared to 9.1% (95% CI 
6.0-13.6) for women enrolled in the late dry season. There was no clear pattern in the risk of 
sub-RDT infection when the women are examined by their socio-economic status. 
Table 28: Prevalence of sub-RDT malaria infections by background characteristics of 
women in IST arm 
Characteristic First three visits (v0-v2) All visits (v0-v4) 
 n (%) 95%CI n (%) 95% CI 
Age group (years) (N=634)  (N=819)  
 <20 15(7.9) 4.8-12.6 23(8.5) 5.7-12.5 
 20-24 33(10.8) 7.8-14.8 41(11.0) 8.2-14.6 
 25+ 15(11.0) 6.7-17.4 22(12.6) 8.4-18.4 
     
Educational status (N=634)  (N=819)  
 None 21(14.4) 9.6-21.1 26(14.8) 10.2-20.8 
 Basic 32(8.3) 5.9-11.5 48(9.2) 7.0-12.0 
 Secondary 10(9.8) 5.4-17.5 12(9.8) 5.7-16.6 
     
Gravidity (N=631)  (N=816)  
 1 24(7.0) 4.8-10.3 37(8.2) 6.0-11.2 
 2 39(13.5) 10.0-17.9 49(13.4) 10.3-17.3 
     
Season of enrolment (N=634)  (N=819)  
 Early wet 19(9.0) 5.8-13.7 30(10.9) 7.7-15.1 
 Late wet 18(12.7) 8.1-19.3 19(11.9) 7.7-17.9 
 Early dry 12(10.5) 6.1-17.7 16(10.5) 6.5-16.5 
 Late dry 14(8.4) 5.1-13.8 21(9.1) 6.0-13.6 
     
Socio-economic status (N=633)  (N=817)  
 Wealthiest 7(8.1) 3.9-16.2 12(11.4) 6.6-19.1 
 Wealthy 7(10.0) 4.8-19.6 10(10.9) 5.9-19.1 
Medium 10(7.6) 4.1-13.7 16(9.0) 5.6-14.2 
 Poor 28(12.7) 8.9-17.8 34(11.9) 8.6-16.3 
 Poorest 11(8.8) 4.9-15.2 14(8.9) 5.3-14.5 
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5.4.2 Risk factors associated with sub-RDT malaria infection in pregnant 
women 
Table 29 shows the results of logistic regression analyses of the risk of sub-RDT infections 
detected at the first three visits and all the visits combined.  
Secundigravid women were twice as likely as primigravid women to have sub-RDT 
infections (OR 2.00, 95% CI 1.05-3.84, P=0.036) when the first three visits only were 
considered. When all the visits were combined the association between gravidity and sub-
RDT infections was lost.
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Table 29: Risk factors associated with sub-RDT malaria infections among pregnant women in Ghana 
Characteristic First three visits (v0-v2) All visits (v0-v4) 
 Crude OR 95% CI P-value Adjusted OR 95% CI P-value Crude 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value 
Age group(years)             
<20 years 1.00   1.00   1.00   1.00   
20-24 years 1.42 0.75-2.69 0.284 0.96 0.46-2.01 0.916 1.33 0.78-2.28 0.295 1.07 0.59-1.94 0.829 
25+ years 1.44 0.68-3.06 0.340 0.88 0.34-2.25 0.785 1.55 0.84-2.88 0.164 1.10 0.52-2.34 0.799 
             
Educational status             
None 1.00   1.00   1.00   1.00   
Basic 0.54 0.30-0.96 0.038 0.66 0.35-1.24 0.193 0.59 0.35-0.98 0.040 0.66 0.38-1.14 0.140 
Secondary 0.65 0.29-1.46 0.298 0.96 0.38-2.41 0.926 0.63 0.30-1.30 0.212 0.65 0.29-1.50 0.317 
             
Gravidity             
1 1.00   1.00   1.00   1.00   
2 2.05 1.20-3.50 0.008 2.00 1.05-3.84 0.036 1.73 1.10-2.71 0.018 1.54 0.90-2.63 0.116 
             
Season of enrolment             
Early wet 1.00   1.00   1.00   1.00   
Late wet 1.47 0.74-2.92 0.265 1.48 0.74-2.97 0.266 1.10 0.60-2.04 0.749 1.10 0.59-2.04 0.765 
Early dry 1.20 0.56-2.56 0.647 1.07 0.49-2.32 0.865 0.96 0.51-1.83 0.913 0.86 0.45-1.66 0.657 
Late dry 0.94 0.45-1.93 0.857 0.90 0.43-1.88 0.787 0.82 0.46-1.48 0.508 0.80 0.44-1.44 0.456 
             
Socio-economic Status             
Wealthiest 1.00   1.00   1.00   1.00   
Wealthy 1.25 0.42-3.76 0.686 1.47 0.48-4.53 0.505 0.95 0.39-2.30 0.901 1.03 0.41-2.58 0.956 
Medium 0.93 0.34-2.55 0.892 1.04 0.36-2.96 0.945 0.77 0.35-1.69 0.508 0.76 0.33-1.76 0.526 
Poor 1.64 0.69-3.90 0.266 1.80 0.70-4.66 0.226 1.05 0.52-2.11 0.892 1.02 0.47-2.23 0.946 
Poorest 1.09 0.40-2.93 0.866 1.08 0.37-3.18 0.888 0.76 0.34-1.71 0.506 0.68 0.28-1.66 0.395 
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5.4.3 Predictors of sub-microscopic infections 
Table 30 presents the prevalence of sub-microscopic infections by various background 
characteristics, estimated for the first three visits combined.   
The prevalence for the first three visits was 19.9% (95% CI 16.9-23.4) and 24.1% (95% CI 
20.8-27.8) for all five visits combined. The highest risk of sub-microscopic malaria infection 
was in the age group 20-24 years. Women with no formal education had the highest risk of 
sub-microscopic malaria infection in comparisons between socio-economic groups. During the 
first three visits the prevalence in women in this group was 20.7% (95% CI 16.2-26.1) 
increasing to 26.1% (95% CI 21.1-31.7) when all the visits were combined. Women in the 
IPTp-SP arm of the study had a lower risk of sub-microscopic infection compared to women 
in the IST arm. During the first three visits the risk of sub-microscopic infection was 16.7% 
(95% CI 14.0-19.8) for women in the IPTp-SP group compared to 18.4% (95% CI 15.6-21.6) 
for women in the IST group. A similar pattern emerged when all the visits were combined, 
with women in the IPTp-SP group having a prevalence of 20.9% (95% CI 17.9-24.2) compared 
to 22.8% (95% CI 19.7-26.3) for women in the IST group but for both of these sets of 
observations confidence limits substantially overlapped. Secundigravid women also had a 
greater risk of sub-microscopic infection compared to primigravid women. Secundigravid 
women had a prevalence of 20.0% (95% CI 16.9-23.6) during the first three visits while 
primigravid women had a prevalence of 15.5% (95% CI 13.0-18.4); for all the visits combined, 
secundigravid women had a prevalence  of 24.2% (95% CI 20.9-27.9) while primigravid 
women had a prevalence of 19.9% (95 % CI 17.1-23.0). The risk of sub-microscopic infection 
was greatest among the women who were enrolled into the study in the late wet season followed 
by those enrolled early in the wet season. Women enrolled in the late wet season had a 
prevalence of sub-microscopic infection of 21.9% (95% CI 17.4-27.1) during the first three 
visits and 26.5% (95% CI 21.7-32.0) for all the visits combined while those enrolled early in 
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the wet season had a prevalence of 17.3% (95% CI 13.9-21.2) during the first three visits and 
24.0% (95% CI 20.2-28.3) for all the visits combined. No clear pattern for the prevalence of 
sub-microscopic infection was seen when women were categorised by socio-economic status. 
It must be noted that even though some trends were observed as described above, the 
confidence intervals overlapped for nearly all the comparisons done. 
Table 30: Risk of sub-microscopic malaria infections by background characteristics of 
study participants 
Characteristic First three visits (v0-v2) All visits (v0-v4) 
 n (%) 95%CI n (%) 95%CI 
Age group (years) (N=1,265)  (N=1,273)  
 <20 65(15.4) 12.3-19.2 82(19.3) 15.9-23.4 
 20-24 115(19.9) 16.9-23.4 140(24.1) 20.8-27.8 
 25+ 42(15.8) 11.9-20.7 56(20.8) 16.4-26.1 
     
Educational status (N=1,265)  (N=1,273)  
 None 54(20.7) 16.2-26.1 68(26.1) 21.1-31.7 
 Basic 138(17.0) 14.5-19.7 168(20.5) 17.8-23.4 
 Secondary 30(15.7) 11.2-21.6 42(22.0) 16.7-28.4 
     
Intervention Arm (N=1,265)  (N=1,273)  
 IPT 107(16.7) 14.0-19.8 134(20.9) 17.9-24.2 
 IST 115(18.4) 15.6-21.6 144(22.8) 19.7-26.3 
     
Gravidity (N=1,262)  (N=1,270)  
 1 108(15.5) 13.0-18.4 140(19.9) 17.1-23.0 
 2 113(20.0) 16.9-23.6 137(24.2) 20.9-27.9 
     
Season of enrolment (N=1,265)  (N=1,273)  
 Early wet 73(17.3) 13.9-21.2 102(24.0) 20.2-28.3 
 Late wet 61(21.9) 17.4-27.1 74(26.5) 21.7-32.0 
 Early dry 34(15.2) 11.0-20.5 40(17.8) 13.3-23.4 
 Late dry 54(15.9 12.4-20.2 62(18.1) 14.3-22.5 
     
Socio-economic status (N=1,262)  (N=1,269)  
 Wealthiest 25(15.7) 10.8-22.3 33(20.6) 15.0-27.6 
 Wealthy 21(13.1) 8.7-19.3 28(17.5) 12.4-24.2 
Medium 43(15.6) 11.8-20.4 57(20.7) 16.3-25.9 
 Poor 89(20.4) 16.9-24.5 103(23.5) 19.7-27.7 
 Poorest 44(19.0) 14.4-24.6 57(24.4) 19.3-30.3 
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5.4.4 Risk factors associated with sub-microscopic malaria infection in 
pregnant women 
Table 31 shows the results of logistic regression analysis modelling of the effects of various 
background characteristics on sub-microscopic malaria infections among women in the study. 
The analysis was done separately for the first three study visits when interventions were given 
and also for all the visits including delivery. For the first three study visits, none of the risk 
factors examined was significantly associated with sub-microscopic infections. In univariate 
logistic regression, gravidity appeared to be related to sub-microscopic infection but this effect 
was attenuated in multivariate analysis. 
When all the study visits were combined, women who were enrolled in the late dry season were 
less likely to have sub-microscopic infection compared to women enrolled in the early wet 
season (OR 0.70, 95% CI 0.49-0.99, P=0.047) but as a large number of comparisons were made 
this may be a chance finding.  
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Table 31: Risk factors associated with sub-microscopic malaria infections among pregnant women in Ghana 
Characteristic First three visits (v0-v2) All visits (v0-v4) 
 Crude OR 95% CI P-value Adjusted OR 95% CI P-value Crude 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value 
Age Group             
<20 years 1.00   1.00   1.00   1.00   
20-24 years 1.37 0.98-1.91 0.067 1.23 0.85-1.79 0.271 1.33 0.98-1.80 0.071 1.22 0.86-1.71 0.265 
25+ years 1.03 0.67-1.57 0.892 0.90 0.54-1.50 0.686 1.10 0.75-1.60 0.635 0.95 0.60-1.50 0.820 
             
Educational status             
None 1.00   1.00   1.00   1.00   
Basic 0.78 0.55-1.11 0.174 0.88 0.61-1.28 0.515 0.73 0.53-1.01 0.057 0.81 0.58-1.15 0.241 
Secondary 0.71 0.43-1.17 0.180 0.88 0.50-1.53 0.641 0.80 0.52-1.24 0.320 0.94 0.57-1.55 0.813 
             
Gravidity             
1 1.00   1.00   1.00   1.00   
2 1.37 1.02-1.83 0.034 1.33 0.95-1.87 0.100 1.29 0.99-1.68 0.064 1.24 0.91-1.69 0.181 
             
Intervention arm             
IPT 1.00   1.00   1.00   1.00   
IST 1.12 0.84-1.50 0.432 1.07 0.80-1.44 0.641 1.12 0.86-1.46 0.400 1.08 0.82-1.42 0.577 
             
Season of enrolment             
Early wet 1.00   1.00   1.00   1.00   
Late wet 1.34 0.92-1.96 0.129 1.38 0.94-2.03 0.097 1.14 0.81-1.62 0.450 1.17 0.82-1.66 0.378 
Early dry 0.86 0.55-1.34 0.499 0.84 0.54-1.32 0.461 0.68 0.46-1.03 0.069 0.68 0.45-1.02 0.063 
Late dry 0.91 0.62-1.34 0.625 0.90 0.61-1.33 0.612 0.70 0.49-0.99 0.045 0.70 0.49-0.99 0.047 
             
Socio-economic Status             
Wealthiest 1.00   1.00   1.00   1.00   
Wealthy 0.91 0.50-1.64 0.743 0.79 0.42-1.51 0.483 0.82 0.47-1.43 0.477 0.82 0.46-1.46 0.496 
Medium 1.06 0.63-1.77 0.838 0.94 0.54-1.66 0.839 1.00 0.62-1.62 0.995 0.99 0.59-1.64 0.960 
Poor 1.34 0.84-2.16 0.221 1.29 0.76-2.20 0.342 1.18 0.76-1.84 0.464 1.17 0.72-1.90 0.529 
Poorest 1.28 0.76-2.15 0.361 1.17 0.65-2.11 0.597 1.24 0.76-2.01 0.386 1.22 0.72-2.08 0.465 
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5.5 Effects of sub-patent malaria infections 
This section presents the results of analyses of the effects of sub-patent malaria infection on 
three outcomes of interest: birth weight/low birth weight, placental malaria and blood 
haemoglobin/anaemia. The results are presented for both sub-microscopic infections and sub-
RDT infections for the first three visits and then for all the visits combined. 
5.5.1 Risk factors of low birth weight  
Table 32 shows the incidence of low birth weight among women in the study by various 
background characteristics as well as by their malaria infection status determined by 
microscopy and PCR on one hand and RDT and PCR on the another hand. Primigravid women 
had a higher incidence of low birth weight babies (19.3%, 95% CI 16.3-22.7) compared to 
secundigravid women (13.9%, 95% CI 11.1-17.3).  Women enrolled during the late dry season 
had the highest incidence of low birth weight (23.6%, 95% CI 18.9-29.1) while the women 
enrolled during the late wet season had the lowest prevalence (13.2%, 95% CI 9.5-18.1). 
Malaria infection status as determined by RDT appeared to have an inverse association with 
the incidence of low birth weight. Women who were uninfected had a higher incidence of low 
birth weight compared to women who had RDT positive malaria or even sub-RDT infections 
considering the first three visits alone and all the visits combined. 
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Table 32: Incidence of low birth weight by background characteristics of study 
participants 
Characteristic n Incidence (%) 95%CI p-value 
Age group (years) (N=1,078)   0.122 
 <20 73 19.8 16.0-24.2  
 20-24 79 16.5 13.5-20.1  
 25+ 31 13.4 9.6-18.5  
     
Educational status (N=1,078)   0.151 
 None 27 12.6 8.7-17.7  
 Basic 126 18.2 15.5-21.3  
 Secondary 30 17.4 12.5-23.9  
     
Intervention Arm (N=1,078)   0.632 
 IPT 86 16.4 13.5-19.8  
 IST 97 17.5 14.6-20.9  
     
Gravidity (N=1,076)   0.019 
 1 116 19.3 16.3-22.7  
 2 66 13.9 11.1-17.3  
     
Season of enrolment (N=1,078)   0.006 
 Early wet 61 16.1 12.8-20.2  
 Late wet 32 13.2 9.5-18.1  
 Early dry 26 14.0 9.7-19.8  
 Late dry 64 23.6 18.9-29.1  
     
Socio-economic status (N=1,075)   0.662 
 Wealthiest 27 19.3 13.6-26.7  
 Wealthy 20 14.1 9.3-20.9  
Medium 42 18.8 14.2-24.4  
 Poor 64 17.3 13.8-21.5  
 Poorest 30 15.1 10.7-20.8  
     
Microscopy status v0-v2 (N=1,047)   0.368 
 Uninfected 58 18.9 14.9-23.7  
 Microscopic 83 15.2 12.4-18.4  
 Sub-microscopic 33 17.1 12.4-23.1  
     
RDT status v0-v2 (N=532)   0.034 
 Uninfected 29 25.4 18.2-34.3  
 RDT positive 57 15.8 12.4-19.9  
 Sub-RDT 7 12.3 5.9-23.8  
     
Microscopy statusv0-v4 (N=1,049)   0.376 
 Uninfected 48 19.4 14.9-24.8  
 Microscopic 86 15.4 12.6-18.6  
 Sub-microscopic 40 16.5 12.4-21.8  
     
RDT status v0-v4 (N=539)   0.037 
 Uninfected 26 26.0 18.3-35.5  
 RDT positive 58 16.0 12.6-20.1  
 Sub-RDT 10 13.2 7.2-22.9  
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5.5.2 Effect of sub-patent malaria infection on birth weight 
 Table 33 shows the results of linear regression analysis of mean birth weight and malaria 
infection status by RDT/PCR and microscopy/PCR. Adjusting for age group, education, 
gravidity, socio-economic status and season of enrolment, there was no significant 
association between mean birth weight and malaria infection status by RDT/PCR. Similarly, 
adjusting for the same factors, in addition to the intervention arm of the study women, there 
was no significant association between mean birth weight and malaria infection status by 
microscopy/PCR. 
However, women who had microscopic malaria infection at delivery were 2.05 times more 
likely to have a low birth weight baby compared to women who had no malaria infection 
(95% CI 1.25-3.37, P=0.005) controlling for age group, education gravidity, socio-economic 
status and season of enrolment (Table 34). There was no significant association between sub-
RDT malaria infection at any time or period in pregnancy and low birth weight.  
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Table 33: Effect of malaria infection status on birth weight among pregnant women in Ghana 
Characteristic Mean birth 
weight(kg) 
95% CI Crude 
coefficient 
95% CI P-value Adjusted 
coefficient 
95% CI P-value Covariates adjusted for 
Microscopy status v0-v2         Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment Intervention arm 
Uninfected 2.80 2.74-2.84 0.00   0.00   
Microscopic 2.77 2.73-2.80 -0.02 -0.08-0.04 0.444 -0.002 -0.06-0.06 0.949 
Sub-microscopic 2.77 2.71-2.84 -0.01 -0.09-0.06 0.712 -0.009 -0.09-0.7 0.819 
          
Microscopy status v0-v4         Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment, Intervention 
arm 
Uninfected 2.79 2.73-2.85 0.00   0.00   
Microscopic 2.77 2.73-2.80 -0.02 -0.09-0.04 0.445 0.004 -0.06-0.07 0.903 
Sub-microscopic 2.77 2.72-2.83 -0.02 -0.10-0.06 0.605 -0.009 -0.09-0.07 0.820 
          
Microscopy status  at 
deliver (v4) 
        Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment Intervention arm 
Uninfected 2.79 2.75-2.82 0.00   0.00   
Microscopic 2.70 2.61-2.79 -0.08 -0.17-0.01 0.070 -0.04 -0.13-0.05 0.382 
Sub-microscopic 2.69 2.55-2.84 -0.09 -0.23-0.05 0.195 -0.10 -0.25-0.04 0.146 
          
RDT status v0-v2         Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment 
Uninfected 2.73 2.64-2.82 0.00   0.00   
RDT positive 2.76 2.71-2.80 0.03 -0.06-0.12 0.515 0.06 -0.04-0.15 0.251 
Sub-RDT 2.84 2.74-2.94 0.11 -0.03-0.25 0.115 0.10 -0.04-0.24 0.179 
          
RDT status v0-v4         Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment 
Uninfected 2.71 2.61-2.82 0.00   0.00   
RDT positive 2.76 2.72-2.81 0.05 -0.05-0.15 0.329 0.08 -0.02-0.19 0.118 
Sub-RDT 2.83 2.73-2.93 0.12 -0.02-0.25 0.090 0.11 -0.02-0.25 0.099 
          
RDT status at delivery 
(v4) 
        Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment 
Uninfected 2.79 2.74-2.85 0.00   0.00   
RDT positive 2.75 2.65-2.86 -0.04 -0.16-0.07 0.467 -0.02 -0.14-0.10 0.767 
Sub-RDT 2.79 2.48-3.10 0.00 -0.20-0.20 0.999 -0.01 -0.22-0.20 0.934 
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Table 34: Effect of malaria infection status on low birth weight among pregnant women in Ghana 
Characteristic Crude OR 95% CI P-value Adjusted OR 95% CI P-value Covariates adjusted for 
Microscopy status v0-v2       Age group, Education, 
Gravidity, Socio-economic 
status, Season of 
enrolment, Intervention 
arm 
Uninfected 1.00   1.00   
Microscopic 0.77 0.53-1.11 0.161 0.78 0.53-1.16 0.225 
Sub-microscopic 0.89 0.55-1.42 0.613 0.92 0.56-1.51 0.752 
        
Microscopy status v0-v4       Age group, Education, 
Gravidity, Socio-economic 
status, Season of 
enrolment, Intervention 
arm 
Uninfected 1.00   1.00   
Microscopic 0.76 0.51-1.12 0.163 0.74 0.49-1.11 0.145 
Sub-microscopic 0.83 0.52-1.31 0.416 0.85 0.52-1.37 0.504 
        
Microscopy status at 
delivery (v4) 
      Age group, Education, 
Gravidity, Socio-economic 
status, Season of 
enrolment, Intervention 
arm 
Uninfected 1.00   1.00   
Microscopic 2.36 1.47-3.78 <0.001 2.05 1.25-3.37 0.005 
Sub-microscopic 1.45 0.65-3.26 0.362 1.57 0.69-3.57 0.278 
        
RDT status v0-v2       Age group, Education, 
Gravidity, Socio-economic 
status, Season of enrolment 
Uninfected 1.00   1.00   
RDT Positive 0.55 0.33-0.91 0.021 0.58 0.33-1.01 0.056 
Sub-RDT 0.41 0.17-1.01 0.051 0.50 0.20-1.26 0.143 
        
RDT status v0-v4       Age group, Education, 
Gravidity, Socio-economic 
status, Season of enrolment 
Uninfected 1.00   1.00   
RDT Positive 0.54 0.32-0.92 0.023 0.57 0.32-1.01 0.055 
Sub-RDT 0.43 0.19-0.96 0.040 0.49 0.21-1.12 0.090 
        
RDT status at delivery 
(v4) 
      Age group, Education, 
Gravidity, Socio-economic 
status, Season of enrolment Uninfected 1.00   1.00   
RDT positive 1.55 0.77-3.12 0.217 1.63 0.76-3.47 0.208 
Sub-RDT 1.18 0.32-4.29 0.807 1.31 0.34-5.04 0.698 
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5.5.3 Active placental malaria prevalence by background characteristics of 
study participants 
Table 35 shows the prevalence of active placental malaria by background characteristics of the 
study participants. The season of enrolment of the women was significantly associated with 
active placental malaria (P<0.001). Women who had microscopic or sub-microscopic 
peripheral parasitaemia at any one of the 4 antenatal visits also had higher prevalence of active 
placental malaria compared to women who did not have peripheral parasitaemia in all four 
ANC visits (P=0.028).  
Table 35: Prevalence of active placental malaria by background characteristics of study 
participants 
Characteristic n Prevalence (%) 95%CI p-value 
Age group (years) (N=786)   0.085 
 <20 91 34.1 28.6-40.0  
 20-24 97 27.6 23.2-32.6  
 25+ 42 25.0 19.0-32.1  
     
Educational status (N=786)   0.248 
 None 34 23.8 17.5-31.5  
 Basic 155 30.0 26.2-34.2  
 Secondary 41 32.3 24.7-40.9  
     
Intervention Arm (N=786)   0.783 
 IPT 115 29.7 25.4-34.5  
 IST 115 28.8 24.6-33.5  
     
Gravidity (N=785)   0.105 
 1 141 31.6 27.5-36.1  
 2 89 26.3 21.8-31.2  
     
Season of enrolment (N=786)   <0.001 
 Early wet 112 42.1 36.3-48.2  
 Late wet 27 15.8 11.0-22.1  
 Early dry 29 19.9 14.1-27.2  
 Late dry 62 30.5 24.6-37.2  
     
Socio-economic status (N=785)   0.804 
 Wealthiest 31 30.1 22.0-39.7  
 Wealthy 39 33.1 25.1-42.1  
Medium 47 27.8 21.6-35.1  
 Poor 80 29.7 24.6-35.5  
 Poorest 33 26.2 19.2-34.6  
     
Microscopy status v0-v2 (N=764)   0.690 
 Uninfected 65 28.0 22.6-34.2  
 Microscopic 110 28.0 23.8-32.6  
 Sub-microscopic 44 31.7 24.4-39.9  
     
RDT status v0-v2 (N=386)   0.817 
 Uninfected 25 29.8 20.9-40.5  
 RDT positive 72 27.6 22.5-33.4  
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 Sub-RDT 10 24.4 13.5-40.0  
     
Microscopy status v0-v4 (N=765)   0.028 
 Uninfected 40 22.2 16.7-28.9  
 Microscopic 117 28.7 24.5-33.3  
 Sub-microscopic 62 35.0 28.3-33.3  
     
RDT status v0-v4 (N=392)   0.421 
 Uninfected 22 31.0 21.3-42.7  
 RDT positive 71 26.9 21.9-32.6  
 Sub-RDT 20 35.1 23.8-48.4  
 
5.5.4 Effect of sub-patent malaria on active placental malaria prevalence 
Table 36 shows the association between peripheral malaria infection status detected at ANC 
visits and presence of active placental malaria  adjusted for the effects of age group, educational 
status, gravidity, intervention arm, season of enrolment and socio-economic status. Women 
with sub-microscopic malaria infections detected at any one of the 4 visits combined were 2.01 
times more likely to have active placental malaria compared to women who were uninfected 
(95% CI 1.23-3.30, P=0.006) but women with microscopic infections were only 1.35 times 
more likely to have active placental infection and this was not statistically significant.   
Adjusting for the same factors, women who had sub-microscopic malaria infection at the time 
of delivery were 3.11 times more likely to have active placental malaria infection (95% CI 
1.37-7.06, P=0.007) while women who had microscopic malaria infection at delivery were 6.21 
times more likely to have active placental malaria (95% CI 3.75-10.30, P<0.001). 
RDT infection status for the first three visits and all the visits combined was not associated 
with active placental malaria. However, adjusting for age group, education, gravidity, season 
of enrolment and socio-economic status, women who had a positive RDT at delivery were 2.04 
times more likely to have active placental malaria (95% CI 1.06-3.90, P=0.032) while women 
who had a sub-RDT malaria infection were 5.23 times more likely to have active placental 
malaria (95% CI 1.68-16.29, P=0.004). 
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Table 36: Effect of malaria infection status on active placental malaria among pregnant women in Ghana 
Characteristic Crude OR 95% CI P-value Adjusted OR 95% CI P-value Covariates adjusted for 
Microscopy status v0-v2       Age group, Education, 
Socio-economic status 
Gravidity, Season of 
enrolment, Intervention 
arm 
Uninfected 1.00   1.00   
Microscopic 1.00 0.70-1.43 0.994 1.00 0.68-1.47 0.999 
Sub-microscopic 1.19 0.75-1.88 0.457 1.34 0.82-2.18 0.239 
        
Microscopy status v0-v4       Age group, Education, 
Socio-economic status 
Gravidity, Season of 
enrolment, Intervention 
arm 
Uninfected 1.00   1.00   
Microscopic 1.41 0.93-2.12 0.104 1.35 0.87-2.08 0.180 
Sub-microscopic 1.89 1.18-3.01 0.008 2.01 1.23-3.30 0.006 
        
Microscopy status at 
delivery (v4) 
      Age group, Education, 
Socio-economic status 
Gravidity, Season of 
enrolment, Intervention 
arm 
Uninfected 1.00   1.00   
Microscopic 6.26 3.93-9.96 <0.001 6.21 3.75-10.30 <0.001 
Sub-microscopic 3.61 1.67-7.84 0.001 3.11 1.37-7.06 0.007 
        
RDT status v0-v2       Age group, Education, 
Socio-economic status 
Gravidity, Season of 
enrolment 
Uninfected 1.00   1.00   
RDT positive 0.90 0.52-1.54 0.700 0.86 0.48-1.55 0.626 
Sub-RDT 0.76 0.32-1.79 0.531 0.83 0.34-2.06 0.693 
        
RDT status v0-v4       Age group, Education, 
Socio-economic status 
Gravidity, Season of 
enrolment 
Uninfected 1.00   1.00   
RDT positive 0.82 0.46-1.45 0.495 0.79 0.43-1.47 0.463 
Sub-RDT 1.20 0.57-2.53 0.623 1.29 0.58-2.87 0.529 
        
RDT status at delivery 
(v4) 
      Age group, Education, 
Socio-economic status 
Gravidity, Season of 
enrolment 
Uninfected 1.00   1.00   
RDT positive 2.25 1.23-4.13 0.008 2.04 1.06-3.90 0.032 
Sub-RDT 4.59 1.59-13.30 0.005 5.23 1.68-16.29 0.004 
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5.5.5 Effects of sub-patent malaria infection on the prevalence of anaemia  
The prevalence of anaemia in pregnancy (haemoglobin< 11grams/dl) among the women in the 
study was significantly associated with age group (P=0.018), gravidity (P=0.042) and season 
of enrolment (P=0.001) [Table 37]. Younger and primigravid women had a higher prevalence 
of anaemia compared to older and secundigravid women. There was no significant difference 
in prevalence of anaemia by study intervention arm. 
Table 37: Prevalence of anaemia by background characteristics of study participants 
Characteristic n Prevalence (%) 95%CI p-value 
Age group (years) (N=528)   0.018 
 <20 93 58.1 50.3-65.6  
 20-24 130 57.0 50.5-63.3  
 25+ 61 43.6 35.6-51.9  
     
Educational status (N=528)   0.783 
 None 56 54.9 45.1-64.3  
 Basic 181 54.4 49.0-59.7  
 Secondary 47 50.5 40.4-60.6  
     
Intervention Arm (N=528)   0.638 
 IPT 135 52.7 46.6-58.8  
 IST 149 54.8 48.8-60.6  
     
Gravidity (N=526)   0.042 
 1 158 57.9 51.9-63.6  
 2 124 49.0 42.9-55.2  
     
Season of enrolment (N=528)   0.001 
 Early wet 104 54.7 47.6-61.7  
 Late wet 60 47.6 39.0-56.4  
 Early dry 44 43.6 34.2-53.4  
 Late dry 76 68.5 59.2-76.5  
     
Socio-economic status (N=528)   0.075 
 Wealthiest 32 39.5 29.4-50.6  
 Wealthy 42 56.0 44.6-66.9  
Medium 71 58.2 49.2-66.7  
 Poor 95 54.3 46.8-61.6  
 Poorest 44 58.7 47.2-69.3  
     
Microscopy status v0-v2 (N=515)   0.426 
 Uninfected 76 49.0 41.2-56.9  
 Microscopic 150 55.2 49.2-61.0  
 Sub-microscopic 49 55.7 45.1-65.8  
     
RDT status v0-v2 (N=262)   0.703 
 Uninfected 25 49.0 35.5-62.7  
 RDT positive 100 55.3 47.9-62.4  
 Sub-RDT 17 56.7 38.5-73.2  
     
Microscopy status v0-v3 (N=515)   0.249 
 Uninfected 65 47.45 39.2-55.9  
 Microscopic 151 56.13 50.1-62.0  
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 Sub-microscopic 59 54.13 44.7-63.3  
     
RDT status v0-v3 (N=262)   0.708 
 Uninfected 25 49.0 35.5-62.7  
 RDT positive 100 55.6 48.2-62.7  
 Sub-RDT 17 54.8 337.1-71.4  
 
5.5.6 Effect of sub-patent malaria infection on anaemia in pregnancy 
Table 38 shows the association between peripheral malaria infection status and maternal 
anaemia adjusted for the effect of age group, education, gravidity, intervention arm, socio-
economic status, and season of enrolment. Women who had microscopic malaria infection at 
38 weeks (visit 3) when anaemia was assessed, were 2.38 times more likely to have anaemia 
(95% CI 1.19-4.76, P=0.014) compared to women who were uninfected. Sub-patent malaria 
infections was not associated with maternal anaemia in this study population.   
 
5.5.7 Effect of sub-patent malaria infection on blood haemoglobin 
concentration in pregnancy 
Table 39 shows association between peripheral malaria infection status and mean blood 
haemoglobin concentration measured at 38 weeks of gestation (visit 3). Adjusting for age 
group, educational status, gravidity, intervention arm, socio-economic status and season of 
enrolment, the mean haemoglobin level of women who had microscopic malaria infection at 
38 weeks gestation was on the average 0.54grams/dl less [95% CI -0.91-(-)0.18, P=0.004] than 
that of women who had no malaria infection. There was no significant relationship between 
sub-patent malaria infections and blood haemoglobin in pregnancy.
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Table 38: Effect of malaria infection status on anaemia in pregnancy among pregnant women in Ghana 
Characteristic Crude OR 95% CI P-value Adjusted 
OR 
95% CI P-value Covariates adjusted 
for 
Microscopy status 
v0-v2 
      Age group, Education, 
Socio-economic 
status, Gravidity, 
Season of enrolment 
Intervention arm 
Uninfected 1.00   1.00   
Microscopic 1.28 0.86-1.90 0.224 1.33 0.86-2.06 0.200 
Sub-microscopic 1.31 0.77-2.21 0.319 1.38 0.78-2.42 0.264 
        
Microscopy status 
v0-v3 
      Age group, Education, 
Socio-economic 
status, Gravidity, 
Season of enrolment, 
Intervention arm 
Uninfected 1.00   1.00   
Microscopic 1.42 0.94-2.14 0.098 1.38 0.88-2.17 0.158 
Sub-microscopic 1.31 0.79-2.16 0.298 1.28 0.74-2.19 0.375 
        
Microscopy status 
at 38 weeks (v3) 
      Age group, Education, 
Socio-economic 
status, Gravidity, 
Season of enrolment, 
Intervention arm 
Uninfected 1.00   1.00   
Microscopic 3.06 1.59-5.90 0.001 2.38 1.19-4.76 0.014 
Sub-microscopic 1.00 0.44-2.27 0.991 0.90 0.38-2.13 0.818 
        
RDT status v0-v2       Age group, Education, 
Socio-economic 
status, Gravidity, 
Season of enrolment 
Uninfected 1.00   1.00   
RDT positive 1.28 0.69-2.39 0.431 1.36 0.66-2.81 0.408 
Sub-RDT 1.36 0.55-3.37 0.506 1.49 0.54-4.09 0.442 
        
RDT status v0-v3       Age group, Education, 
Socio-economic 
status, Gravidity, 
Season of enrolment 
Uninfected 1.00   1.00   
RDT positive 1.30 0.70-2.42 0.409 1.39 0.67-2.89 0.371 
Sub-RDT 1.26 0.52-3.09 0.609 1.32 0.49-3.57 0.588 
 
95 
 
 
Table 39: Effect of malaria infection status on blood haemoglobin among pregnant women in Ghana 
Characteristic Mean 
Hb g/dl 
95% CI Crude 
coefficient 
95% CI P-
value 
Adjusted 
coefficient 
95% CI P-value Covariates adjusted for 
Microscopy status 
v0-v2 
        Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment Intervention 
arm 
Uninfected 10.9 10.7-11.1 0.00   0.00   
Microscopic 10.8 10.6-10.9 -0.13 -0.38-0.12 0.298 -0.13 -0.39-0.13 0.316 
Sub-microscopic 10.8 10.6-11.1 -0.10 -0.43-0.24 0.567 -0.09 -0.42-0.24 0.602 
          
Microscopy status 
v0-v3 
        Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment, Intervention 
arm 
Uninfected 11.0 10.8-11.2 0.00   0.00   
Microscopic 10.8 10.6-10.9 -0.24 -0.50-0.02 0.075 -0.20 -0.46-0.07 0.148 
Sub-microscopic 10.8 10.6-11.1 -0.18 -0.50-0.14 0.276 -0.12 -0.44-0.20 0.454 
          
Microscopy status 
at 38 weeks (v3) 
        Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment, Intervention 
arm 
Uninfected 10.9 10.8-11.1 0.00   0.00   
Microscopic 10.2 9.9-10.5 -0.72 -1.08-(-)0.37 <0.001 -0.54 -0.91-(-
)0.18 
0.004 
Sub-microscopic 10.9 10.2-11.6 -0.09 -0.59-0.42 0.741 0.00 -0.50-0.51 0.993 
          
RDT status v0-v2         Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment 
Uninfected 10.9 10.5-11.2 0.00   0.00   
RDT positive 10.7 10.5-10.9 -0.13 -0.53-0.28 0.535 -0.19 -0.60-0.22 0.364 
Sub-RDT 10.8 10.3-11.2 -0.11 -0.70-0.47 0.703 -0.16 -0.72-0.40 0.577 
          
RDT status v0-v3         Age group, Education, 
Socio-economic status, 
Gravidity, Season of 
enrolment 
Uninfected 10.9 10.5-11.2 0.00   0.00   
RDT positive 10.7 10.5-10.9 -0.13 -0.54-0.27 0.517 -0.20 -0.61-0.21 0.333 
Sub-RDT 10.8 10.3-11.3 -0.08 -0.66-0.50 0.787 -0.11 -0.66-0.44 0.700 
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5.6 Summary 
The prevalence of sub-microscopic malaria declined from 10.6% at the first ANC visit to 5.1% 
at delivery as the prevalence of malaria declined. The risk of sub-microscopic malaria infection 
for the first three scheduled ANC visits combined was 17.6% and it was 21.8% when all four 
ANC visits were combined. The highest prevalence of sub-RDT infection was observed at 
delivery (6.3%). The risk of sub-RDT infection was 10.1% for the first three ANC visits and 
13.5% for all four ANC visits combined. 
The season of enrolment was the only predictor of sub-microscopic infection. Gravidity 
predicted sub-RDT infection when only the first three visits were considered. 
There was no significant association between malaria infection status during pregnancy and 
mean birth weight of babies. There was no significant association between sub-patent malaria 
infection and low birth weight. Microscopic peripheral malaria parasitaemia was however, 
associated with low birth weight. Women with microscopic or sub-microscopic malaria 
infections at delivery were more likely to have active placental malaria. Also, women who had 
RDT positive malaria at delivery were 2.04 times more likely to have active placental malaria 
while women who had sub-RDT malaria at delivery were 5.23 times more likely to have active 
placental malaria. 
Women who had microscopic malaria infections at 38 weeks of gestation were more likely to 
have anaemia compared to women who were uninfected. There was no significant association 
between sub-patent malaria and anaemia in pregnancy. 
 
 
 
97 
 
 
CHAPTER SIX 
 
Prevalence of Falciparum and Non-falciparum Malaria 
Infection in Pregnancy in Four West African Countries 
 
6.1 Introduction 
This chapter presents the findings from an analysis of the prevalence of falciparum and non-
falciparum malaria infections in a sub-set of pregnant women who were enrolled into a clinical 
trial of IPTp-SP versus IST conducted in Burkina Faso, the Gambia, Ghana and Mali. This 
subset comprises women who were tested for malaria on their day of recruitment into the study. 
An analysis of the prevalence of non-falciparum malaria as detected by PCR is first presented 
for all the four countries combined. Analysis of the non-falciparum infections missed by RDT 
testing is then presented. Blood smear microscopy detected very few non-falciparum infections 
in this study. Each of the two microscopists detected only six (6) cases of non-falciparum 
malaria compared to forty (40) cases detected by PCR. Out of the cases detected by the two 
microscopists, only one case of P. malariae mono infection was detected by both readers 
independently and therefore confirmed. The prevalence of non-falciparum malaria was too low 
to allow meaningful country-level analyses. The analyses of non-falciparum malaria is 
followed by presentation of findings from analyses of malaria infection (all species) detected 
by microscopy and PCR. 
 
6.2 Prevalence of falciparum and non-falciparum malaria as detected by 
PCR  
Table 40 shows the prevalence of Plasmodium species (mono and mixed) by country as 
detected by PCR. A total of 39.01% of the women had malaria infection, a great majority of 
them being P. falciparum mono infections (38.39%), with the remainder being largely mixed 
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infections of P. falciparum with other species and a few non-falciparum mono infections. Only 
four cases of P. malariae mono infections were found among the 2,347 women, giving a 
prevalence of 0.17%. There were 5 cases of P. ovale mono infections among the women in this 
sub-sample, giving a prevalence of 0.22%; three of these were cases of P. ovale curtisi (0.13%) 
while two were cases of P. ovale wallikeri (0.09%). There were 2 cases of P. vivax mono 
infections accounting for a prevalence of 0.09%. These two cases of P. vivax mono infections 
were women enrolled at the Mali site of the trial. In total therefore, there were only 11 cases of 
non-falciparum mono infections among the 2,347 women. In contrast, there were 29 women 
who had mixed infections of falciparum and non-falciparum malaria infections. Thirteen 
women (0.55%) had mixed infections of P. falciparum and P. malariae, while 12 women 
(0.51%) had mixed infections of P. falciparum and P. ovale infections; there were five cases 
of P. falciparum mixed with P. ovale curtisi (0.21%) and seven cases of P. falciparum mixed 
with P. ovale wallikeri (0.30%). Two women (0.09%) had mixed infections of P. falciparum 
and P. vivax. These women were all enrolled at the Mali site as observed with the 2 cases of P. 
vivax mono infections presented earlier. There were also two cases of three-specie mixed 
infections of P. falciparum, P. malariae and P. ovale curtisi. One of these women was enrolled 
in Ghana and the other in Mali. 
On country level the prevalence of P. falciparum infections ranged from 13.38% in the Gambia 
to 26.08% in Mali, to 58.86% in Ghana to 59.16% in Burkina Faso. Of the four cases of P. 
malariae mono infection, 3 were from Mali and one was from Burkina Faso. Of the five P. 
ovale mono infections, two were from women enrolled in the Gambia (comprising one each of 
P. ovale curtisi and P. ovale wallikeri) and one each from each of the other three countries in 
the trial. Ten of the thirteen mixed P. falciparum and P. malariae infections were obtained 
from women enrolled in Mali while the remaining three cases were from women enrolled in 
Ghana. Of the 12 mixed P. falciparum and P. ovale cases detected, 5 were obtained from 
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women enrolled in Ghana (two cases of P. ovale curtisi mixed with P. falciparum and three 
cases of P. ovale wallikeri mixed with P. falciparum) while 4 were from women enrolled in 
Mali (one P. ovale curtisi mixed with P. falciparum and three cases of P. ovale wallikeri mixed 
with P. falciparum) and 3 were from women from the Burkina Faso site. Apart from the 2 cases 
of P. ovale mono infections detected in women enrolled in the Gambia there were no other 
cases of non-falciparum malaria, mono or mixed detected among the women in that country. 
Mali had the highest incidence of non-falciparum malaria with 23 cases out of a total of 40 
women who either had mono or mixed infections. Ghana was next with a total of 10 mono and 
mixed infections while Burkina Faso had 5 non-falciparum infections in all. 
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Table 40: Prevalence of Plasmodium species (mono and mixed) by country as detected by PCR 
Species Overall (%) Burkina Faso n (%) Gambia n (%) Ghana n (%) Mali n (%) 
Plasmodium 
falciparum 
901(38.39) 281(59.16) 97(13.38) 402(58.86) 121(26.08) 
Plasmodium malariae 4(0.17) 1(0.21) 0(0.00) 0(0.00) 3(0.65) 
Plasmodium ovale 
curtisi 
3(0.13) 1(0.21) 1(0.14) 0(0.00) 1(0.22) 
Plasmodium ovale 
wallikeri 
2(0.09) 0(0.00) 1(0.14) 1(0.15) 0(0.00) 
Plasmodium vivax 2(0.09) 0(0.00) 0(0.00) 0(0.00) 2(0.43) 
Pf + Pm 13(0.55) 0(0.00) 0(0.00) 3(0.44) 10(2.16) 
Pf + Poc 5(0.21) 2(0.42) 0(0.00) 2(0.29) 1(0.22) 
Pf+ Pow 7(0.30) 1(0.21) 0(0.00) 3(0.44) 3(0.65) 
Pf + Pv 2(0.09) 0(0.00) 0(0.00) 0(0.00) 2(0.43) 
Pf + Pm + Poc 2(0.09) 0(0.00) 0(0.00) 1(0.15) 1(0.22) 
Plasmodium negative 1,406(59.91) 189(39.79) 626(86.34) 271(39.68) 320(68.97) 
Total 2,347(100.00) 475(100.00) 725(100.00) 683(100.00) 464(100.00) 
Legend: Pf: Plasmodium falciparum; Pm: Plasmodium malariae; Poc: Plasmodium ovale curtisi; Pow: Plasmodium ovale wallikeri; Pv: Plasmodium vivax 
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6.3 Falciparum and non-falciparum malaria undetected by RDT 
Table 41 show proportions of women who had PCR positive malaria which was detected (and 
undetected) by RDT. Out of a total of 740 women who had malaria infections detected by PCR, 
the RDT used was able to detect 86.9% of these infections leaving 13.1% undetected. The type 
of RDT used in this trial, the First Response® Combo HRP2/pLDH test can detect the presence 
of falciparum and non-falciparum species. 
However, the test did not detect 12.6% of falciparum malaria detected by PCR.  
Of 3 cases of P. malariae mono infections detected by PCR, the RDT detected 2 (66.6%) 
leaving 1 (33.3%) undetected. Out of 4 cases of P. ovale detected by PCR the RDT did not 
detect 3 cases (75.0%). Similarly, all the 2 cases of P. vivax detected by PCR were not detected 
by the RDT. 
The picture is different for the mixed infections of falciparum and non-falciparum malaria. 
With the exception of two cases (18.2%) of P. falciparum and P. malariae mixed infections 
out of 11 cases which were detected by PCR but missed by RDT, all the remaining mixed 
infections, comprising 9 cases of P. falciparum mixed with P. ovale, 2 cases of P. falciparum 
mixed with P. vivax, and 2 cases of P. falciparum mixed with P. malariae and P. ovale were 
all detected by the RDT. 
Table 41: PCR positive malaria detected by RDT 
Species(PCR Results) RDT Negative(%) RDT Positive(%) 
P. falciparum 89(12.6) 618(87.4) 
P. malariae 1(33.3) 2(66.7) 
P. ovale curtisi 1(50.0) 1(50.0) 
P. ovale wallikeri 2(100.0) 0(0.0) 
P. vivax 2(100.0) 0(0.0) 
Pf + Pm 2(18.2) 9(81.8) 
Pf + Poc 0(0.0) 3(100.0) 
Pf+Pow 0(0.0) 6(100.0) 
Pf + Pv 0(0.0) 2(100.0) 
Pf + Pm + Poc 0(0.0) 2(100.0) 
Total 97(13.1) 643(86.9) 
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6.4 Characteristics of pregnant women with a non-falciparum infection 
detected by PCR at first antenatal clinic attendance. 
Because of the paucity of information on the epidemiology of non-falciparum malaria in 
pregnancy in sub-Saharan Africa a separate series of analyses were undertaken for women 
identified to have a  non-falciparum malaria infection by PCR (40 out of 2,348 women).  The 
background characteristics of these women are shown in Table 42. Study participants resident 
in Mali had the highest prevalence of non-falciparum malaria (5.0%; 95% CI 3.3-7.4) while 
study participants resident in the Gambia had the lowest prevalence (0.3%; 95% CI 0.1-1.1). 
The highest prevalence of non-falciparum malaria was obtained in the late wet season (3.0%; 
95% CI 1.7-5.2). The highest prevalence was in the age group 25 years and over (2.0%; 95% 
CI 0.9-4.4). Women in their first pregnancy had a slightly higher prevalence of non-falciparum 
malaria (1.8%; 95% CI 1.2-2.7) than women in their second pregnancy (1.6; 95% CI 1.0-2.6). 
There was no clear association between the prevalence of non-falciparum malaria and 
educational status and wealth index  
 
Table 42: Characteristics of women with a non-falciparum malaria infection detected at 
first antenatal clinic attendance by PCR 
Parameter n Prevalence 
(%) 
95%CI p-value 
Country N=2,348   <0.001 
   Burkina Faso  5 1.1 0.4-2.5  
   Gambia 2 0.3 0.1-1.1  
   Ghana 10 1.5 0.8-2.7  
   Mali 23 5.0 3.3-7.4  
     
Season of enrolment N=2,348   0.102 
   Early wet 8 1.0 0.5-2.0  
   Late wet 12 3.0 1.7-5.2  
 Early dry 8 1.5 0.8-3.0  
 Late dry 12 1.88 1.1-3.3  
     
Age group (years) N=2,348   0.657 
 <20  20 1.9 1.2-2.9  
 20-24 14 1.4 0.8-2.4  
 +25 6 2.0 0.9-4.4  
103 
 
 
     
Gravidity N=2,345   0.709 
 1 23 1.8 1.2-2.7  
 2 17 1.6 1.0-2.6  
     
Education N=2,323   0.588 
 None 16 1.6 1.0-2.5  
 Basic 20 2.0 1.3-3.1  
 Secondary 4 1.3 0.5-3.4  
     
Socio-economic 
status 
N=2,244    
 Wealthiest 8 1.8 0.9-3.5 0.011 
 Wealthy 14 3.1 1.8-5.1  
 Medium 2 0.4 0.1-1.7  
 Poor 12 2.7 1.6-4.7  
 Poorest 4 0.9 0.4-2.4  
 
 
 
 
6.5 Risk factors for a non-falciparum malaria infection during pregnancy 
detected at first antenatal clinic attendance by PCR. 
Country of enrolment  and the season of enrolment were the only variables associated 
significantly with the presence of non-falciparum malaria at first antenatal clinic attendance;  
age group, gravidity, educational and socioeconomic status were not significantly associated 
with non-falciparum malaria. In multivariate analysis (shown in table 43), the country and 
season of enrolment were entered into the model. The risk of women resident in Mali being 
infected with non-falciparum malaria was 23.9 times (95% CI 5.51-103.73, P<0.001) higher 
compared to women resident in the Gambia while that for women resident in Ghana was 5.02 
times higher  (95% CI 1.09-23.03, P=0.038) compared to the women enrolled in the Gambia.  
However, the confidence intervals for these analyses are large indicating the imprecision of 
these estimates due to small numbers of infected women.  Women who were enrolled in the 
late wet season were 4.83 times (95% CI 1.87-12.43, P=0.001) more likely to have non-
falciparum malaria compared to women enrolled in the early wet season. 
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Table 43: Risk of non-falciparum malaria infection at first antenatal clinic attendance 
as detected by PCR 
Characteristic Crude OR 95% CI P-value Adjusted 
OR 
95% CI P-value 
Country       
 Gambia 1.00   1.00   
 Burkina Faso 3.84 0.74-
19.86 
0.109 3.99 0.77-20.71 0.100 
 Ghana 5.37 1.17-
24.60 
0.030 5.02 1.09-23.03 0.038 
 Mali 18.85 4.42-
80.36 
<0.001 23.92 5.51-
103.73 
<0.001 
       
Age group (years)       
 >=25  1.00      
 20-24  0.70 0.27-1.85 0.475    
 <20  0.94 0.37-2.35 0.889    
       
Season of enrolment       
 Early wet 1.00   1.00   
 Late wet 2.92 1.19-7.26 0.019 4.83 1.87-12.43 0.001 
 Early dry 1.49 0.55-3.98 0.432 1.85 0.68-5.03 0.277 
 Late dry 1.85 0.75-4.55 0.181 1.70 0.68-4.21 0.254 
       
Gravidity       
 2 1.00      
 1 1.13 0.60-2.12 0.709    
       
Education       
 None 1.00      
 Basic 1.31 0.67-2.54 0.424    
 Secondary 0.83 0.27-2.49 0.735    
       
Socio-economic status       
 Wealthiest 1.00      
 Wealthy 1.77 0.73-4.26 0.203    
 Medium 0.25 0.05-1.17 0.078    
 Poor 1.57 0.64-3.89 0.326    
 Poorest 0.52 0.16-1.75 0.293    
 
 
 
6.6 Characteristics of pregnant women with a malaria infection detected by 
microscopy at first antenatal clinic attendance and risk factors for 
infection by country 
An analysis was undertaken to investigate whether there were any significant differences in the 
characteristics of women with a malaria infection detected by microscopy or in the risk factors 
for a microscopic infection by country.  The characteristics of women who had a positive blood 
film at first antenatal clinic attendance are shown by country in Table 44. 
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With the exception of the Gambia, all the other three countries in the study showed inverse 
trends of decreasing prevalence with increasing age of the women. Malaria prevalence in the 
Gambia was much lower than in the other countries in the trial; also, the differences in the 
prevalence of malaria in the three age groups do not vary very much, with their confidence 
intervals overlapping greatly. The prevalence of malaria among the women aged less than 20 
years was 10.2% (95% CI 7.4-14.0), decreasing to 6.6% (95% CI 4.2-10.1) among those aged 
20-24 years, then increasing slightly to 7.1% (95% CI 3.0-16.2) among the oldest women. In 
all the four countries in the study, the primigravid women had a higher prevalence of malaria 
by microscopy compared to the secundigravid women. Among the women enrolled in Burkina 
Faso, Gambia and Ghana, the highest prevalence of malaria by microscopy was found in the 
women who had received only basic education. However, among the women resident in Mali, 
those who had had no education had a slightly higher prevalence even though the confidence 
intervals overlap. There is however, no clear pattern to the observation on the lowest 
prevalence; in Burkina Faso and Mali the lowest prevalence of malaria by microscopy was 
found among the women who had had secondary education or more while in Gambia and 
Ghana, the lowest prevalence was among those who had had no formal education. The highest 
prevalence of malaria by microscopy was found in the late wet season in Burkina Faso (75.0%, 
95% CI 63.7-83.7) and Ghana (61.6%, 95% CI 53.8-68.9). In Mali (32.1%, 95% CI 22.8-43.1) 
and Gambia (15.1%, 95% CI 10.3-21.8) the highest prevalence was slightly later, occurring in 
the early dry season months of December to February. In Ghana (41.7%, 95% CI 34.4-49.3) 
and Mali (14.5%, 95% CI 9.9-20.7) the lowest prevalence was found in the late dry season 
months of March to May while in Burkina Faso (37.4%, 95% CI 29.5-46.0) and Gambia (5.6%, 
95% CI 3.3-9.2) the lowest prevalence was in the early wet season months of June to August. 
In all the four countries in the study, the highest prevalence of malaria by microscopy was 
found among the poor or poorest women. In Burkina Faso (45.6%, 95% CI 38.5-52.9) and 
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Ghana (57.7%, 95% CI 49.0-65.9) the poorest women had the highest prevalence; in Gambia 
(14.1%, 95% CI 7.7-24.4) and Mali (47.1%, 95% CI 24.9-70.4) the poor women had the highest 
prevalence. With the exception of Burkina Faso, the lowest  malaria prevalence by microscopy 
was found among the wealthiest women; in Burkina Faso, the women classified wealthy had 
the lowest prevalence (34.6%, 95% CI 18.8-54.7). In Mali, the three sub-sites were analysed 
separately; the San sub-site had the highest prevalence of malaria by microscopy (34.6%, 95% 
CI 28.1-41.6) while the Kita sub-site had the lowest prevalence of 7.3% (95% CI 3.9-13.0). 
A number of risk factors were examined a priori to determine if they had an effect on malaria 
infection detected by microscopy among study women as shown in table 45. 
In Burkina Faso, women who were less than 20 years old were 2.90 times (95% CI 1.14-7.38, 
P=0.026) more likely to have microscopic malaria compared to women 25 years or older. 
Similarly, women enrolled in Ghana who were less than 20 years old were 2.53 times (95% CI 
1.46-4.40, P=0.001) more likely than women 25 years or older, to have microscopic malaria 
infection. In Gambia and Mali, age group was not a risk factor for microscopic malaria 
infection. Season of enrolment was a risk factor for microscopic malaria infection in all the 
four countries in the study. In Burkina Faso, women who were enrolled in the late wet season 
were 5.89 times (95% CI 2.86-12.11, P<0.001) more likely to have microscopic malaria 
compared to women enrolled during the early wet season. In Gambia women who were 
enrolled during the early dry season were 2.63 times (95% CI 1.27-5.43) more likely to have 
microscopic malaria compared to women enrolled during the early wet season. In Ghana 
women enrolled during the late wet season were 2.63 times (95% CI 1.66-4.15, P<0.001) more 
likely to have microscopic malaria when compared with women enrolled during the early wet 
season while women enrolled during the early dry season were also 1.61 times (95% CI 1.02-
2.53, P=0.039) more likely to have microscopic malaria; women enrolled during the early dry 
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season in Mali were 2.26 times (95% CI 1.09-4.69, P=0.028) more likely to have microscopic 
malaria compared to those enrolled during the early wet season. 
Primigravid women in Burkina Faso were 2.59 times (95% CI 1.52-4.42, P<0.001) more likely 
to have microscopic malaria compared to secundigravid women. A similar observation was 
made among Ghanaian women in the study where primigravid women were 1.57 times (95% 
CI 1.08-2.29, P=0.018) more likely to have microscopic malaria. Gravidity however, was not 
a risk factor for microscopic malaria among the Gambian and Malian women. The educational 
status of the women did not predict microscopic malaria in any of the countries in the study. 
With the exception of Burkina Faso, the socioeconomic status of the women was associated 
with microscopic malaria in the remaining countries. In Gambia, women who were poor were 
3.63 times (95% CI 1.29-10.23, P=0.015) more likely to have microscopic malaria compared 
to the wealthiest women; women who were of medium socio-economic status were also 2.64 
times (95% CI 1.04-6.71, P=0.041) more likely to have microscopic malaria. In Ghana, 
compared to the wealthiest women, all the socio-economic strata of women were more likely 
to have microscopic malaria; women who were poorest were 3.76 times (95% CI 1.94-7.30, 
P<0.001) more likely to have microscopic malaria. In Mali, women of medium socio-economic 
status were 2.56 times (95% CI 1.04-6.26, P=0.040) more likely to have microscopic malaria. 
Also in Mali, women enrolled at the San sub-site were 3.48 times (95% CI 1.49-8.10, P=0.004) 
more likely to have microscopic malaria compared to women enrolled at the Bamako suburban 
site. 
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Table 44: Characteristics of women with a malaria infection (all species) detected at first antenatal clinic attendance by microscopy by 
country. 
Characteristic Country 
Burkina Faso Gambia Ghana Mali 
 n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI 
Age group(years) (N=476)  (N=693)  (N=681)  (N=455)  
<20 110(53.9) 47.0-60.7 34(10.2) 7.4-14.0 144(67.0) 60.4-73.0 66(23.0) 18.5-28.2 
20-24 83(36.2) 30.3-42.7 19(6.6) 4.2-10.1 140(43.9) 38.5-49.4 19(14.2) 9.2-21.2 
25+ 11(25.6) 14.6-40.8 5(7.1) 3.0-16.2 49(33.3) 26.2-41.4 4(11.8) 4.4-27.8 
         
Gravidity (N=476)  (N=693)  (N=678)  (N=455)  
1 126(55.8) 49.2-62.1 37(9.5) 7.0-12.9 207(58.0) 52.8-63.0 67(23.7) 19.1-29.0 
2 78(31.2) 25.7-37.2 21(6.9) 4.5-10.4 124(38.6) 33.4-44.1 22(12.8) 8.6-18.7 
         
Education (N=472)  (N=675)  (N=681)  (N=454)  
None 145(41.8) 36.7-47.1 24(6.7) 4.5-9.8 62(41.3) 33.7-49.4 32(21.9) 15.9-29.4 
Basic 41(56.2) 44.6-67.1 26(10.7) 7.4-15.3 232(53.0) 48.3-57.6 47(21.4) 16.4-27.3 
Secondary 16(30.8) 19.7-44.7 7(9.6) 4.6-18.9 39(41.9) 32.3-52.2 10(11.4) 6.2-19.9 
         
Season of enrolment (N=476)  (N=693)  (N=681)  (N=455)  
Early wet 49(37.4) 29.5-46.0 14(5.6) 3.3-9.2 88(43.1) 36.5-50.1 29(16.5) 11.7-22.8 
Late wet 54(75.0) 63.7-83.7 11(8.0) 4.5-14.0 98(61.6) 53.8-68.9 10(31.3) 17.5-49.3 
Early dry 50(39.7) 31.5-48.5 23(15.1) 10.3-21.8 77(51.3) 43.3-59.3 26(32.1) 22.8-43.1 
Late dry 51(34.7) 27.4-42.8 10(6.6) 3.6-11.8 70(41.7) 34.4-49.3 24(14.5) 9.9-20.7 
         
Socio-economic 
status 
(N=446)  (N=643)  (N=678)  (N=440)  
Wealthiest 6(42.9) 20.0-69.3 7(4.7) 2.3-9.6 24(27.6) 19.2-38.0 22(11.2) 7.5-16.5 
Wealthy 9(34.6) 18.8-54.7 10(6.3) 3.4-11.3 43(48.9) 38.5-59.3 39(22.5) 16.9-29.4 
Medium 54(48.2) 39.1-57.5 17(10.9) 6.9-16.9 68(49.3) 41.0-57.6 15(33.3) 21.1-48.4 
Poor 43(38.4) 29.8-47.8 10(14.1) 7.7-24.4 120(51.1) 44.7-57.4 8(47.1) 24.9-70.4 
Poorest 83(45.6) 38.5-52.9 12(11.2) 6.5-18.8 75(57.7) 49.0-65.9 3(33.3) 10.3-68.6 
    
Sub-site (N=455)  
Bamako sub-urban 13(10.3) 6.1-17.0 
Kita 10(7.3) 3.9-13.0 
San 66(34.6) 28.1-41.6 
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Table 45: Risk factors for malaria infection (all species) detected at first antenatal clinic attendance by microscopy by country; adjusted 
ORs are shown 
Characteristic Country 
Burkina Faso Gambia Ghana Mali 
 Adjusted 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value 
Age group (years)             
>=25 1.00   1.00   1.00   1.00   
20-24 2.22 0.94-5.26 0.070 0.67 0.23-1.95 0.464 1.22 0.78-1.92 0.374 1.46 0.41-5.21 0.561 
<20 2.90 1.14-7.38 0.026 0.86 0.28-2.60 0.788 2.53 1.46-4.40 0.001 2.88 0.86-9.71 0.087 
             
Season of enrolment             
Early wet 1.00   1.00   1.00   1.00   
Late wet 5.89 2.86-12.11 <0.001 1.59 0.69-3.69 0.276 2.63 1.66-4.15 <0.001 2.57 0.93-7.10 0.069 
Early dry 1.16 0.67-2.02 0.591 2.63 1.27-5.43 0.009 1.61 1.02-2.53 0.039 2.26 1.09-4.69 0.028 
Late dry 0.80 0.47-1.38 0.423 1.06 0.45-2.50 0.891 0.98 0.63-1.52 0.913 1.19 0.61-2.31 0.608 
             
Gravidity             
2 1.00   1.00   1.00   1.00   
1 2.59 1.52-4.42 <0.001 1.48 0.75-2.92 0.262 1.57 1.08-2.29 0.018 1.75 0.93-3.30 0.084 
             
Education             
None 1.00   1.00   1.00   1.00   
Basic 1.67 0.92-3.00 0.089 1.50 0.81-2.76 0.197 1.32 0.86-2.00 0.201 0.88 0.48-1.62 0.683 
Secondary 0.65 0.31-1.36 0.253 1.63 0.65-4.07 0.296 1.49 0.80-2.77 0.207 0.45 0.18-1.13 0.088 
             
Socio-economic status             
Wealthiest 1.00   1.00   1.00   1.00   
Wealthy 0.34 0.07-1.58 0.168 1.45 0.53-3.98 0.470 2.35 1.20-4.58 0.012 1.27 0.65-2.47 0.488 
Medium 0.71 0.19-2.68 0.616 2.64 1.04-6.71 0.041 2.37 1.27-4.44 0.007 2.56 1.04-6.26 0.040 
Poor 0.51 0.13-1.94 0.319 3.63 1.29-10.23 0.015 2.76 1.52-5.02 0.001 2.68 0.78-9.15 0.177 
Poorest 0.71 0.19-2.64 0.604 2.63 0.97-7.13 0.058 3.76 1.94-7.30 <0.001 1.73 0.31-9.59 0.528 
             
Sub-site     
Bamako sub-urban 1.00   
Kita 0.36 0.13-1.02 0.055 
San 3.48 1.49-8.10 0.004 
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6.7 Characteristics of women with a malaria infection detected by PCR at 
first antenatal clinic attendance and risk factors for infection by 
country 
An analysis was undertaken to investigate whether there were any significant differences in the 
characteristics of women with a malaria infection detected by PCR or in the risk factors for an 
infection by country.  The characteristics of women who had a positive PCR test at first 
antenatal clinic attendance are shown by country in table 46. 
With the exception of Gambia, all the other countries in the study showed decreasing malaria 
prevalence by PCR with increasing age of the women.  Among the women from Burkina Faso, 
women under 20 years of age had a prevalence of 72.9% (95% CI 66.4-78.6) decreasing to 
39.5% (95% CI 26.0-54.9) among those aged 25 years and over; similar trends were observed 
among the Ghanaian and Malian women. However, in the Gambia, the highest prevalence was 
among the women aged 25 years and above (17.8%, 95% CI 10.6-28.4) while the lowest 
prevalence was among those aged 20-24 years (9.2%, 95% CI 6.4-13.0).  Consistently, 
primigravid women had higher prevalence in all the countries in the study, than secundigravid 
women. In Burkina Faso, Ghana and Mali, women who had had basic education only had the 
highest prevalence of malaria while those who had received secondary education or more had 
the lowest prevalence. In the Gambia, women who had not received any formal education had 
the highest prevalence (14.3%, 95% CI 11.1-18.2). However, this was just slightly higher than 
those who had received basic education (14.1%, 95% CI 10.3-19.0) with overlapping 
confidence intervals; women who had received secondary education or more had the lowest 
prevalence in the Gambia (10.4%, 95% CI 5.4-20.0), as in the other countries in the study. In 
Burkina Faso (88.7%, 95% CI78.9-94.3) and Ghana (77.4%, 95% CI 70.2-83.2) the highest 
prevalence of malaria by PCR was observed during the late wet season while in the Gambia 
(18.3%, 95% CI 13.2-24.9) and Mali (51.2%, 95% CI 40.4-61.9) the highest prevalence was 
during the early dry season. In Burkina Faso (49.6%, 95% CI 41.1-58.2) and Mali (23.0%, 95% 
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CI 17.4-29.6) the lowest prevalence was during the early wet season; in Ghana (50.9%, 95% 
CI 43.4-58.4) the lowest prevalence was in the late dry season while in the Gambia (11.4%, 
95% CI 7.1-17.8) this was in the late wet season. In Gambia (18.8%, 95% CI 12.5-27.1), Mali 
(66.7%, 95% CI 31.4-89.7) and Ghana (66.2%, 95% CI 60.0-72.0) the highest prevalence was 
found among the poor or poorest women in the study. In Burkina Faso the women with the 
highest prevalence belonged to the medium socio-economic group (64.6%, 95% CI 55.1-73.0). 
The lowest prevalence of malaria by PCR was found among the wealthiest women in Burkina 
Faso (50.0%, 95% CI 25.2-74.8), Ghana (40.2%, 95% CI 30.4-50.9), and Mali (18.3%, 95% 
CI 13.6-24.3) while in Gambia the wealthy women had the lowest prevalence (9.5%, 95% CI 
5.9-15.0). 
In Mali, women enrolled at the San sub-site had the highest prevalence (46.9%, 95% CI 40.0-
54.0) while the women enrolled at the Bamako sub-urban sub-site had the lowest prevalence 
(16.9%, 95% CI 11.4-24.4). 
Women who were less than 20 years old who were enrolled in Burkina Faso were 3.42 times 
(95% CI 1.43-8.21, P=0.006) more likely to have a positive malaria PCR compared to women 
who were 25 years or above (table 47). Similar findings were obtained in Ghana (adjusted OR 
2.63, 95% CI 1.49-4.66, P=0.001) and Mali (adjusted OR 2.59, 95% CI 1.02-6.59, P=0.046). 
However, in the Gambia women who were less than 20 years old were 57% (adjusted OR 0.43, 
95% CI 0.19-0.95, P=0.037) less likely to have a positive malaria PCR while women aged 20-
24 years were also 68% (adjusted OR 0.32, 95% CI 0.15-0.68, P=0.003) less likely to have a 
positive malaria PCR when compared with women 25 years and above. In the Gambia, the 
season of enrolment was not associated with positive malaria PCR. However in the other three 
countries in the study, positive malaria PCR was associated with season of enrolment. In 
Burkina Faso, women enrolled in the late wet season were 9.92 times (95% CI 4.02-24.44, 
P<0.001) more likely to have a positive malaria PCR compared to women enrolled in the early 
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wet season; in the same country, women enrolled in the early dry season were also 2.08 times 
(95% CI 1.20-3.63, P=0.009) more likely to have a positive malaria PCR.  Findings similar to 
those in Burkina Faso were obtained in Ghana; women enrolled in the late wet season were 
4.14 times (95% CI 2.52-6.79, P<0.001) more likely to have a positive malaria PCR while 
women enrolled in the early dry season were 2.10 times (95% CI 1.32-3.33, P=0.002) more 
likely to have a positive malaria PCR. In Mali, women enrolled in the early dry season were 
3.19 times (95% CI 1.70-5.98, P<0.001) more likely to have a positive malaria PCR compared 
to women enrolled during the early wet season. 
Gravidity was a risk factor for positive malaria PCR only in Burkina Faso. Primigravid women 
there were 2.12 times (95% CI 1.24-3.64, P=0.006) more likely than secundigravid women to 
have a positive malaria PCR. Educational status was not associated with positive malaria PCR 
in Gambia, Ghana and Mali. However, in Burkina Faso, women who had received basic 
education were 1.96 times (95% CI 1.03-3.75, P=0.041) more likely to have positive malaria 
PCR when compared to women with no formal education. 
Socio-economic status was not associated with positive malaria PCR in Burkina Faso and 
Gambia. In Ghana, the poorest women were 3.01 times (95% CI 1.57-5.78, P=0.001) more 
likely to have positive malaria PCR compared to the wealthiest women; the poor women were 
also 3.19 times (95% CI 1.78-5.73, P<0.001) more likely to have positive malaria PCR. 
Similarly, in Mali, the poorest women were 6.71 times (95% CI 1.44-31.39, P=0.016) more 
likely to have positive malaria PCR compared to the wealthiest women. Also in Mali, women 
enrolled at the San sub-site were 2.73 times (95% CI 1.37-5.44, P=0.004) more likely to have 
positive malaria PCR compared to women enrolled at the Bamako sub-urban sub-site. 
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Table 46: Characteristics of women with a malaria infection (all species) detected at first antenatal clinic attendance by PCR by country 
Characteristic Country 
Burkina Faso Gambia Ghana Mali 
 n(%) 95% CI n(%) 95% CI n(%) 95% CI n(%) 95% CI 
Age group(years) (N=474)  (N=725)  (N=683)  (N=464)  
<20 148(72.9) 66.4-78.6 58(16.7) 13.1-21.0 167(77.0) 70.9-82.1 100(34.0) 28.8-39.6 
20-24 120(52.6) 46.1-59.1 28(9.2) 6.4-13.0 176(55.2) 49.7-60.6 37(27.6) 20.7-35.8 
25+ 17(39.5) 26.0-54.9 13(17.8) 10.6-28.4 69(46.9) 39.0-55.1 8(22.2) 11.4-38.9 
         
Gravidity (N=474)  (N=725)  (N=680)  (N=464)  
1 161(71.9) 65.6-77.4 65(15.9) 12.7-19.8 242(67.4) 62.4-72.1 94(32.9) 27.7-38.6 
2 124(49.6) 43.4-55.8 34(10.8) 7.8-14.7 168(52.3) 46.9-57.8 51(28.7) 22.5-35.8 
         
Education (N=470)  (N=705)  (N=683)  (N=463)  
None 204(59.1) 53.8-64.2 54(14.3) 11.1-18.2 81(54.0) 46.0-61.9 48(31.6) 24.7-39.4 
Basic 53(72.6) 61.2-81.7 35(14.1) 10.3-19.0 283(64.3) 59.7-68.7 75(33.6) 27.7-40.1 
Secondary 25(48.1) 34.1-61.6 8(10.4) 5.4-20.0 48(51.6) 41.5-61.6 22(25.0) 17.0-35.2 
         
Season of enrolment (N=474)  (N=725)  (N=683)  (N=464)  
Early wet 65(49.6) 41.1-58.2 34(13.1) 9.5-17.8 105(51.2) 44.4-58.0 42(23.0) 17.4-29.6 
Late wet 63(88.7) 78.9-94.3 16(11.4) 7.1-17.8 123(77.4) 70.2-83.2 13(39.4) 24.2-57.0 
Early dry 83(65.9) 57.1-73.7 31(18.3) 13.2-24.9 98(65.3) 57.3-72.6 42(51.2) 40.4-61.9 
Late dry 74(50.7) 42.6-58.8 18(11.6) 7.4-17.7 86(50.9) 43.4-58.4 48(28.9) 22.5-36.3 
         
Socio-economic 
status 
(N=444)  (N=669)  (N=680)  (N=449)  
Wealthiest 7(50.0) 25.2-74.8 16(10.4) 6.5-16.3 35(40.2) 30.4-50.9 37(18.3) 13.6-24.3 
Wealthy 14(53.9) 34.7-72.0 16(9.5) 5.9-15.0 50(56.8) 46.2-66.8 66(37.5) 30.6-44.9 
Medium 71(64.6) 55.1-73.0 30(18.6) 13.3-25.4 83(60.1) 51.7-68.0 22(48.9) 34.6-63.4 
Poor 63(56.3) 46.9-65.2 12(16.2) 9.4-26.5 157(66.2) 60.0-72.0 10(58.8) 34.5-79.5 
Poorest 113(62.1) 54.8-68.9 21(18.8) 12.5-27.1 84(64.6) 56.0-72.4 6(66.7) 31.4-89.7 
    
Sub-site (N=464)  
Bamako sub-urban 22(16.9) 11.4-24.4 
Kita 31(22.1) 16.0-29.8 
San 91(46.9) 40.0-54.0 
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Table 47: Risk factors for malaria infection (all species) detected at first antenatal clinic attendance by PCR by country; adjusted ORs 
are shown 
Characteristic Country 
Burkina Faso Gambia Ghana Mali 
 Adjusted 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value Adjusted 
OR 
95% CI P-value 
Age group (years)             
>=25 1.00   1.00   1.00   1.00   
20-24 2.00 0.91-4.39 0.083 0.32 0.15-0.68 0.003 1.15 0.74-1.79 0.530 1.41 0.54-3.67 0.485 
<20 3.42 1.43-8.21 0.006 0.43 0.19-0.95 0.037 2.63 1.49-4.66 0.001 2.59 1.02-6.59 0.046 
             
Season of enrolment             
Early wet 1.00   1.00   1.00   1.00   
Late wet 9.92 4.02-24.44 <0.001 0.87 0.45-1.67 0.667 4.14 2.52-6.79 <0.001 1.98 0.83-4.73 0.123 
Early dry 2.08 1.20-3.63 0.009 1.48 0.84-2.59 0.173 2.10 1.32-3.33 0.002 3.19 1.70-5.98 <0.001 
Late dry 1.04 0.62-1.75 0.885 0.77 0.41-1.47 0.433 1.00 0.64-1.54 0.987 1.70 0.98-2.94 0.057 
             
Gravidity             
2 1.00      1.00   1.00   
1 2.12 1.24-3.64 0.006 1.70 0.96-2.97 0.061 1.39 0.94-2.04 0.097 1.02 0.62-1.68 0.945 
             
Education             
None 1.00   1.00   1.00   1.00   
Basic 1.96 1.03-3.75 0.041 0.87 0.54-1.42 0.583 1.31 0.86-2.01 0.213 1.00 0.59-1.69 0.996 
Secondary 0.84 0.42-1.71 0.638 0.72 0.32-1.63 0.433 1.40 0.75-2.60 0.294 0.88 0.43-1.79 0.717 
             
Socio-economic status             
Wealthiest 1.00   1.00   1.00   1.00   
Wealthy 0.66 0.14-2.99 0.590 0.87 0.42-1.82 0.705 1.92 1.00-3.68 0.051 1.72 1.01-2.92 0.045 
Medium 1.25 0.34-4.67 0.737 1.89 0.97-3.70 0.062 2.19 1.19-4.02 0.012 2.95 1.37-6.32 0.005 
Poor 0.96 0.25-3.60 0.947 1.67 0.73-3.81 0.220 3.19 1.78-5.73 <0.001 3.44 1.08-10.96 0.037 
Poorest 1.25 0.34-1.09 0.741 2.09 1.01-4.33 0.048 3.01 1.57-5.78 0.001 6.71 1.44-31.39 0.016 
             
Sub-site     
Bamako sub-urban 1.00   
Kita 0.77 0.37-1.61 0.484 
San 2.73 1.37-5.44 0.004 
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6.8 Summary of findings 
This chapter presents prevalence of falciparum and non-falciparum malaria detected by 
microscopy or PCR among 2,348 women who were enrolled into the trial of IPT versus IST. The 
distribution of women in the sample was not uniform. Women from Gambia constituted 30.8% of 
the sample, with 29.1% from Ghana, 20.3% from Burkina Faso and 19.8% from Mali.  
The analysis showed that 39.01% of the women in this sub-sample had malaria infection with 
majority of these being P. falciparum infections (38.38%) while only 1.70% of the women had 
non-falciparum infections either as mono infections or as mixed infections with P. falciparum. 
Two women (0.09%) had triple species infection (P. falciparum, P. malariae and P. ovale curtisi).  
The analysis also showed that 13.1% of the malaria infections detected by PCR were not detected 
by RDT. Out of 707 women who had falciparum malaria detected by PCR, 12.6% were missed by 
the RDT used. Most of the non-falciparum malaria mono infections detected by PCR were not 
detected by RDT. However, the majority of the mixed infections were detected by the RDT used.  
The highest prevalence of non-falciparum malaria was found among the women enrolled in Mali 
(5.0%) while the lowest was in Gambia (0.3%). The risk factors of non-falciparum malaria among 
the women in the study were country of residence and season of enrolment. 
The prevalence of malaria detected by microscopy ranged from a minimum of 8.4% in Gambia to 
a maximum of 48.9% in Ghana. Significant risk factors of malaria infection detected by 
microscopy were the country of residence, age group, season of enrolment, gravidity educational 
status and socio-economic status. 
The prevalence of malaria detected by diagnostic PCR tests on blood spots ranged from a minimum 
of 13.7% in Gambia to a maximum of 60.3% in Ghana. The risk factors of malaria detected by 
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PCR among the women in the study were similar to those for malaria detected by microscopy 
except for educational status which was not associated with malaria detected by PCR. 
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CHAPTER SEVEN 
The ability of Symptoms to Predict Malaria in Pregnancy 
 
7.1 Introduction 
As many countries reach the point where they need to consider alternatives to IPTp with 
Sulfadoxine-Pyrimethamine, considerations will be given to intermittent screening and treatment 
(ISTp) as an option for adoption as a replacement policy. This will mean that all women attending 
ANC will undergo rapid diagnostic testing for malaria routinely. This procedure will require more 
of the time of health workers than is required to administer IPTp. In many developing countries 
health facilities are often under-staffed and the few health workers available are often over-worked 
and poorly-motivated and have to contend with having to perform several procedures for each 
woman attending ANC. In addition, the cost of rapid diagnostic testing also results in a marginal 
increase in the cost of ANC even though RDTs have become increasingly cheaper with time. The 
increased work load, and the cost of IST, could be reduced if it was possible identify women in 
whom screening was essential and others in whom it was not, as their risk of malaria was low. 
This chapter presents the results of an analysis of the ability of a set of symptoms solicited from  
pregnant women in the study each time they came to the clinic on a scheduled visit, to predict the 
likelihood that they might have a malaria infection. In view of the fact that the RDT screening was 
conducted only for the women in the IST arm of the study, the analysis is limited to this group of 
women. At scheduled clinic visits, the women were asked whether they had any of 15 symptoms 
listed on a checklist. The symptoms solicited on the first and second visits only were used in this 
analysis because of significant reduction in the number of women attending clinics at subsequent 
visits as well as the paucity of symptoms obtained from the women at later visits. In subsequent 
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sections of this chapter, the distribution of symptoms is presented followed by an analysis of which 
symptoms were associated with a positive RDT. Symptom scores were then created from 
symptoms which were associated with positive RDT in univariate logistic regression analysis. 
Multivariate logistic regression modeling was then used to establish the strength of the association 
between the symptom scores and positive RDT, controlling for some background characteristics 
of the study participants. 
7.2 Symptoms recorded frequently at antenatal clinic visits 
Table 48 shows the distribution of various symptoms solicited from women on their first and 
second study visits.  The commonest symptom that the women had on the day of enrolment was 
headache (17.6%). During the second study visit, 13.0% of the women said that they were 
‘currently sick’ and this was the commonest complaint. Other symptoms complained of on the first 
study visit were being easily tired (15.1%), currently sick (14.4%), lower abdominal pain (14.3%) 
and waist pain (11.0%). The least common symptom on the day of enrolment was diarrhoea 
(0.8%). 
During the second visit, in addition to many reporting that they were currently sick, headache was 
reported by 12.1% of the women. The least common complaint was again diarrhoea (1.1%). 
Table 48: Distribution of symptoms solicited at the first two study visits 
Symptom First visit (v0) 
n (%) 
Second visit (v1) 
n (%) 
Currently sick 188(14.4) 144(13.0) 
Fever 67(5.1) 42(3.8) 
Chills 66(5.1) 34(3.1) 
Headache 230(17.6) 134(12.1) 
Nausea 48(3.7) 21(1.9) 
Vomiting 35(2.7) 21(1.9) 
Diarrhoea 11(0.8) 12(1.1) 
General weakness 98(7.5) 57(5.1) 
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Dizziness 107(8.2) 47(4.2) 
Easily tired 197(15.1) 48(4.3) 
General malaise 73(5.6) 27(2.4) 
Lower abdominal pain 187(14.3) 70(6.3) 
Painful urination 96(7.4) 17(1.5) 
Waist pain 144(11.0) 87(7.8) 
Cough 75(5.7) 61(5.5) 
Total (N) 1,306 1,111 
 
 
7.3 Symptoms associated with a positive RDT result 
At the first visit, four symptoms were significantly associated with a positive RDT using a 
significance level of P< 0.100. These symptoms were fever, chills, headache and waist pain. Table 
49 shows the proportions of women presenting with various symptoms who had positive or 
negative RDT results at both the first and second visits. 
Of the women who admitted to having fever on the first study visit, 73.5% (95% CI 56.1-85.8) had 
a positive RDT result compared to 57.4% (95% CI 53.5-61.3) of the women who had no fever who 
also tested positive. For the women who had chills, 75.8% (95% CI 58.2-85.8) of them tested 
positive by RDT while 57.4% (95% CI 53.4-61.2) of those who did not have chills also tested 
positive by RDT. For the women who had headache, 66.7% (95% CI 58.0-74.4) of them tested 
positive by RDT compared to 56.3% (95% CI 52.0-60.5) of women who did not report headache 
who also tested positive by RDT. Of the women who had waist pain, 68.7% (95% CI 57.9-77.8) 
of them had positive RDT results while 56.8% (95% CI 52.7-60.8) of those who had no waist pain 
also had positive RDT. 
At the second visit, 9 of the solicited symptoms including all of the four symptoms observed at the 
first visit, were associated with positive RDT results. In addition to fever, chills, headache and 
waist pain, vomiting, generalised weakness, dizziness, painful urination and being currently sick 
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were found to be associated with a positive RDT. The proportions of women who had various 
symptoms who also tested positive by RDT at the second visit are shown in table 7.2. 
Table 50 shows univariate logistic regression results using RDT result as the dependent variable, 
with the various symptoms as independent variables to establish whether there is any association 
between these symptoms and a positive RDT result. 
Table 49: Table showing proportion of women presenting specific symptoms and their 
RDT results 
Symptom First visit (v0) Second visit (v1) 
RDT 
+ve(%) 
95% CI P-value RDT +ve 95% CI P-value 
Currently 
sick 
(N=652)  0.279 (N=564)  0.027 
 Yes 65(63.1) 53.3-71.9  38(45.8) 35.3-56.6  
 No 315(57.4) 53.2-61.5  160(33.3) 29.2-37.6  
       
Fever (N=652)  0.064 (N=564)  0.013 
 Yes 25(73.5) 56.1-85.8  15(57.7) 38.1-75.1  
 No 355(57.4) 53.5-61.3  183(34.0) 30.1-38.1  
       
Chills (N=652)  0.037 (N=564)  0.031 
 Yes 25(75.8) 58.2-87.5  12(57.1) 35.4-76.4  
 No 355(57.4) 53.4-61.2  186(34.3) 30.4-38.4  
       
Headache (N=652)  0.034 (N=564)  <0.001 
 Yes 84(66.7) 58.0-74.4  41(54.0) 42.6-64.9  
 No 296(56.3) 52.0-60.5  157(32.2) 28.2-36.5  
       
Vomiting (N=652)  0.577 (N=564)  0.021 
 Yes 11(52.4) 31.4-72.6  8(66.7) 36.3-87.5  
 No 369(58.5) 54.6-62.3  190(34.4) 30.6-38.5  
       
Generalised 
weakness 
(N=652)  0.385 (N=564)  0.036 
 Yes 29(64.4) 49.4-77.1  15(53.6) 35.1-71.1  
 No 351(57.8) 53.8-61.7  183(34.1) 30.2-38.3  
       
Dizziness (N=652)  0.672 (N=564)  0.036 
121  
 Yes 34(55.7) 43.1-67.7  15(53.6) 35.1-71.1  
 No 346(58.5) 54.5-62.5  183(34.1) 30.2-38.3  
       
Painful 
urination 
(N=652)  0.232 (N=564)  0.001 
 Yes 35(66.0) 52.3-77.6  8(88.9) 46.8-98.7  
 No 345(57.6) 53.6-61.5  190(34.2) 30.4-38.3  
       
Waist pain (N=652)  0.040 (N=564)  0.015 
 Yes 57(68.7) 57.9-77.8  25(51.0) 37.1-64.8  
 No 323(56.8) 52.7-60.8  173(33.6) 29.6-37.8  
 
 
Table 50: Table showing univariate logistic regression results for various symptoms using 
RDT result as the dependent variable 
Symptom First visit (v0) Second visit (v1) 
Crude OR 95% CI P-value Crude OR 95% CI P-value 
Currently 
sick 
1.27 0.82-1.96 0.280 1.69 1.05-2.72 0.028 
Fever 2.05 0.94-4.48 0.069 2.65 1.19-5.88 0.017 
Chills 2.32 1.03-5.23 0.042 2.56 1.06-6.18 0.037 
Headache 1.55 1.03-2.34 0.034 2.47 1.51-4.03 <0.001 
Vomiting 0.78 0.33-1.87 0.578 3.81 1.13-12.82 0.031 
General 
weakness 
1.32 0.70-2.49 0.386 2.23 1.04-4.78 0.040 
Dizziness 0.89 0.52-1.52 0.672 2.23 1.04-4.78 0.040 
Painful 
urination 
1.43 0.79-2.59 0.234 15.37 1.91-
123.79 
0.010 
Waist pain 1.67 1.02-2.73 0.041 2.06 1.14-3.71 0.016 
 
7.4 Association of symptom scores with positive RDT 
Symptoms which were found to be associated with positive RDT in univariate analyses were used 
to construct simple symptom scores to determine if their predictive power for the presence of 
malaria in pregnancy could be used in determining women who require screening for malaria at 
antenatal clinics as a priority. Two scores were constructed using symptoms found to be associated 
with a positive RDT at the first two study visits. 
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The first score (score 1) used the four symptoms (fever, chills, headache and waist pain) detected 
at the first study visit (v0) to be associated with a positive RDT in univariate analyses. Table 51 
shows the distribution of study participants on the symptom score by RDT positivity. There is a 
linear trend with increasing proportions of RDT positive with increasing number of symptoms 
present. Of the women who had no symptoms, 55.3% (95% CI 50.7-59.7) had a positive RDT 
result compared to 85.0% (95% CI 61.6-95.2) of the women who had three or four symptoms 
present. 
The second score used the nine symptoms which were found during the second study visit to have 
an association with a positive RDT. These include being currently sick, fever, chills, headache, 
waist pain, vomiting, generalised weakness, dizziness and painful urination. Owing to small 
numbers in some categories, the score was divided into four categories; no symptoms, one 
symptom, two symptoms and 3 to 8 symptoms. Of the women who had no symptoms, 31.5% (95% 
CI 27.2-36.0) of them had a positive RDT while 65.2% (95% CI 50.4-77.6) of those who had 3 to 
8 symptoms had a positive RDT. 
Table 51: Symptom score by RDT result 
Symptom Score RDT Positive n (%) 95% CI P-value 
Score 1   0.018 
 No symptoms 258(55.3) 50.7-59.7  
 1 symptom 75(61.2) 53.0-70.2  
 2 symptoms 30(68.2) 53.0-80.3  
 3 or 4 symptoms 17(85.0) 61.6-95.2  
    
Score 2   <0.001 
 No symptoms 134(31.5) 27.2-36.0  
 1 symptom 17(38.6) 25.4-53.8  
 2 symptoms 17(35.4) 23.2-49.9  
 3 to 8 symptoms 30(65.2) 50.4-77.6  
 
123  
Table 52 shows the results of regression analyses conducted with the two scores independently in 
different models as predictors and RDT result for the specified visit as the dependent variable. 
Multivariate analyses controlled for age group, educational status, gravidity, socio-economic 
status and season of enrolment in each of the models.  
For score 1, women who had 3 or 4 symptoms were 3.87 times (95% CI 1.07-14.09, P=0.040) 
more likely to have a positive RDT when compared with women who had no symptoms adjusting 
for age group, educational status, gravidity, socio-economic status and season of enrolment. 
For score 2, women who had 3 to 8 symptoms were 3.43 times (95% CI 1.57-7.45, P=0.002) more 
likely to have a positive RDT compared to women who had no symptoms adjusting for the same 
covariates as with score 1. 
Table 52: Association between symptom scores and RDT results 
Symptom score Crude OR 95% CI P-value Adjusted 
OR* 
95% CI P-value 
Score 1       
No symptom 1.00   1.00   
1 symptom 1.32 0.88-1.99 0.183 1.37 0.87-2.14 0.169 
2 symptoms 1.73 0.90-3.36 0.102 1.73 0.84-3.55 0.137 
3 or 4 symptoms 4.59 1.33-15.88 0.016 3.87 1.07-14.09 0.040 
       
Score 2       
No symptom 1.00   1.00   
1 symptom 1.37 0.72-2.60 0.333 1.35 0.63-2.91 0.435 
2 symptoms 1.19 0.64-2.23 0.577 1.03 0.50-2.14 0.933 
3 to 8 symptoms 4.09 2.15-7.75 <0.001 3.43 1.57-7.45 0.002 
*Adjusted for age group, educational status, gravidity, socio-economic status and season of 
enrolment. 
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7.5 Sensitivity and specificity of Symptom scores 
To estimate the usefulness of these symptom scores in determining the necessity to conduct rapid 
malaria diagnostic testing when resources are limited, it was necessary to calculate the sensitivity 
and specificity of these scores using RDT tests as the gold standard. To enable this to be done, it 
was necessary to re-categorise the scores into dichotomous variables to allow 2x2 tables to be 
created. 
7.5.1 Sensitivity and specificity of Ma1_score 
Ma1_score was originally categorized into 4 levels: no symptom, 1 symptom, 2 symptoms and 3 
or 4 symptoms. In re-categorising this score, two options were tried. The first option is referred to 
as Ma1_score1 which dichotomises Ma1_score into: Positive (1) which refers to women who had 
any symptom and Negative (0) which refers to women who had no symptom. Table 53 shows a 
cross-tabulation of Ma1_score1 versus RDT result for visit 0. The sensitivity of this score is 27.4% 
(95% CI 32.1, 37.1) while the specificity is 71.4% (95% CI 76.8, 81.7). 
Table 53: Ma1_score1 vs RDT Visit 0 
Ma_1 Score1  RDT visit 0  
Positive Negative Total 
Positive (1) 122 63 185 
Negative (0) 258 209 467 
Total 380 272 652 
 
Sensitivity: 27.4% (95% CI 32.1, 37.1) 
Specificity: 71.4% (95% CI 76.8, 81.7) 
PPV: 65.8% (95% CI 58.6, 72.7 
NPV: 44.8% (95% CI 40.2, 49.4) 
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The second option which is referred to here as Ma1_score2 re-categorises Ma1_score into: Positive 
(1) which refers to women who had 3 or 4 symptoms and Negative (0) which refers to women who 
had 1 or 2 or no symptoms at all. Table 54 shows the cross-tabulation of Ma1_score2 with results 
of RDT visit 0. The sensitivity of this score reduced considerably to 4.5% (95% CI 2.6, 7.1) while 
the specificity increased to 98.9% (95% CI 96.8, 99.8). 
Table 54: Ma1_score2 versus RDT visit 0 
Ma_1 Score2  RDT visit 0  
Positive Negative Total 
Positive (1) 17 3 20 
Negative (0) 363 269 632 
Total 380 272 652 
Sensitivity: 4.5% (95% CI 2.6, 7.1) 
Specificity: 98.9% (95% CI 96.8, 99.8) 
PPV: 85.0% (95% CI 62.1, 96.8) 
NPV: 42.6% (95% CI 38.7, 46.5) 
 
7.5.2 Sensitivity and specificity of Ma2_score 
Ma2_score was initially categorised into four levels: no symptom, 1 symptom, 2 symptoms and 3 
to 8 symptoms. In creating a dichotomous variable, Ma2_score two options were explored. The 
first option created Ma2_score1 which has two outcomes: Positive (1) which refers to women who 
had one or more symptoms and Negative (0), which refers to women who had no symptoms. Table 
55 shows the cross-tabulation of Ma2_score1 with RDT for visit 1 result. The sensitivity of 
Ma2_score1 was 32.3% (95% CI 25.8, 39.3) while the specificity was 79.8% (95% CI 75.3, 83.8). 
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Table 55: Ma2_score1 versus RDT visit 1 
Ma_2 Score1 RDT visit 1  
Positive Negative Total 
Positive (1) 64 74 198 
Negative (0) 134 292 366 
Total 198 366 564 
 
Sensitivity: 32.3% (95% CI 25.8, 39.3) 
Specificity: 79.8% (95% CI 75.3, 83.8) 
PPV: 46.4% (95% CI 37.9, 55.1) 
NPV: 68.5% (95% CI 63.9, 72.9) 
  
The second option created Ma2_score2 which also has two outcomes: Positive (1) refers to women 
who had 3 to 8 symptoms while Negative (0) groups women who either had no symptoms or had 
one or two symptoms. Table 56 shows the cross-tabulation between Ma2_score2 and RDT visit 1 
results. The sensitivity of Ma2_score2 using RDT visit 1 results as the gold standard was 15.2% 
(95% CI 10.5, 20.9) while the specificity was 95.6% (95% CI 93.0, 97.5). 
Table 56: Ma2_score2 versus RDT visit 1 
Ma_2 Score2  RDT visit 1  
Positive Negative Total 
Positive (1) 30 16 46 
Negative (0) 168 350 518 
Total 198 366 564 
Sensitivity: 15.2% (95% CI 10.5, 20.9) 
Specificity: 95.6% (95% CI 93.0, 97.5) 
PPV: 65.2% (95% CI 49.8, 78.6) 
NPV: 67.6% (95% CI 63.3, 71.6) 
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7.6 Summary 
Nine symptoms were associated with a positive RDT result in initial analysis of symptoms 
solicited at the first two ANC visits.  These were being currently sick, fever, chills, headache, waist 
pain, vomiting, dizziness, generalised weakness and painful urination. Two symptom scores were 
constructed with the data from the two visits to establish whether these scores could predict the 
need for RDT testing in a situation where everyone cannot be tested and decisions have to be made 
about who to test.  The analyses indicated that of the nine symptoms mentioned above the presence 
of three or more of them was more than three times likely to result in a positive RDT compared to 
women who had no symptoms at all.  
However, analyses of the sensitivities of the scores using the results of the RDT tests as the gold 
standard indicate that the sensitivity of the scores are very low even though their specificities are 
much higher. Therefore their usefulness in deciding which women should benefit from RDT 
testing in the event that resources for testing are not available for all who require testing, is very 
limited. 
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CHAPTER EIGHT 
Discussion and Conclusion 
 
8.1 Introduction 
This chapter discusses the findings of this study in the light of currently available literature and 
examines the implications of these findings for policy, practice and further research. The order of 
discussion in this chapter follows the order in which the results were presented in the earlier 
chapters. 
8.2 Sensitivity and Specificity of RDT in the Diagnoses of Placental malaria  
First Response® Combo RDT  
A major consequence of placental malaria is low birth weight resulting from both prematurity and 
intrauterine growth retardation (Steketee et al. 2001; Bouvier et al. 1997). It is estimated that 
annually as many as 75,000-200,000 infant deaths worldwide, are linked to malaria in pregnancy 
(Dellicour et al. 2010; Desai et al. 2007; Steketee et al. 2001). This heavy mortality toll makes it 
imperative that efforts are made to enhance the early diagnosis of malaria in pregnancy and by 
extension placental malaria. Even though placental histology is often regarded as the gold standard 
for epidemiological research in malaria in pregnancy, its usefulness to the individual woman and 
her baby who have suffered the consequences of placental malaria is almost nil as the placenta can 
only be examined post-partum. Therefore laboratory tests which could accurately detect malaria 
in pregnancy leading to appropriate case-management may help to prevent placental malaria and 
its consequences.  
In this study, only active placental malaria infections were considered i.e. where malaria parasites 
were present in the placenta with or without malaria pigment. Women with malaria pigment only 
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in the placenta, indicative of past malaria infections were classified with those with no infection. 
In this trial, the prevalence of malaria infection among the women was very high, particularly 
during the first study visit. Therefore, most of the women in the study had experienced malaria 
infection sometime in the course of the pregnancy even though most would have been detected at 
some time in the course of the pregnancy and treated. Therefore the incidence of past placental 
infection was very high. However, even though past infection is a clinically relevant outcome 
(Kattenberg et al. 2011) and indicates that the participant has been infected during the course of 
the pregnancy, for the purpose of assessing the sensitivity of a diagnostic test such as an RDT, the 
presence of parasites as in active infections, with or without pigment is the most important factor 
even though in excluding past infections, one underestimates the incidence of placental malaria. 
The purpose of this analysis was to find out if rapid malaria diagnostic testing could adequately 
predict the presence of placental malaria. It has been established that Plasmodium falciparum 
parasites tend to sequestrate in the intervillous bed of the placenta and their presence in the placenta 
is not necessarily reflected by peripheral malaria parasitaemia. Accordingly, blood smear 
microscopy which detects peripheral malaria parasitaemia, when negative, may miss placental 
malaria. However, RDTs which depend on the detection of either histidine-rich protein 2 (HRP-
2), plasmodium lactate dehydrogenase (pLDH) or aldolase, the last two being enzymes in the 
glycolytic pathway of the malaria parasite, could theoretically be detected in peripheral blood even 
though they are being produced by malaria parasites sequestered in the placental bed. The RDT 
used in this study (First Response® Combo RDT) contained test reagents to detect HRP-2, (which 
can only detect P. falciparum) as well as reagents to detect pLDH which can detect the presence 
P. vivax, P. malariae and P. ovale as well as P. falciparum. The test strip has three bands; a control 
band, a band for P. falciparum only and another band for detecting any of the four plasmodium 
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species mentioned above (PAN). The First Response® Malaria pLDH/HRP2 Combo test is 
designed for the differential diagnosis between P. falciparum and other plasmodium species. 
However, it is unable to differentiate between the three different non-falciparum species which it 
captures on one test band. 
The sensitivity of the RDT to detect placental malaria at scheduled and unscheduled visits was 
63.1% (95% CI 55.9-69.9) while that for the scheduled visits alone was 72.0% (95% CI 63.3-79.7). 
This finding of sensitivity being higher among a mixture of women who were attending scheduled 
and unscheduled visits compared to women who were attending unscheduled visits and were 
therefore unwell, at initial glance may seem unexpected and implausible as one would usually 
expect that women who are sick are likely to have peripheral parasitaemia and therefore the 
sensitivity of the RDT would be expected to be higher among them than for women who are not 
sick. However, placental malaria is not always associated with systemic illness as the parasites are 
sequestered in the placenta and may not necessarily be found in peripheral blood where most of 
the clinical signs emanate from. Accordingly, the finding of higher sensitivity among women 
attending both scheduled and unscheduled visits may reflect the fact that even during scheduled 
visits parasites may be present in the placental bed and not necessarily producing any obvious 
clinical effects. It is also possible that most of the infections that could be detected by RDT were 
detected at first visit and as expected, and also found in this study, there were fewer infections in 
later visits. 
The sensitivity of the RDT to detect placental malaria was estimated for the RDTs done at various 
visits. This was done on the assumption that the women were exposed to malaria infections from 
the time of enrolment or earlier, till they delivered and therefore the time when the placental 
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malaria began could not be determined exactly. The sensitivity of the RDT conducted at various 
visits to detect placental malaria was: first visit: 55.7% (95% CI 46.5-64.7), second visit: 39.1% 
(95% CI 25.0-34.0), third visit: 33.3% (95% CI 23.4-44.5) and delivery visit: 35.4% (95% CI 26.6-
45.0). This shows a pattern of declining sensitivity with increasing gestational age, with the 
exception of the sensitivity of the RDT at delivery which is slightly higher than that of the third 
visit, which may not be significant at their confidence intervals overlap to a large extent. It is likely 
that as a pregnancy progresses the woman develops some level of immunity against malaria 
infection. This leads to an increase in the frequency of low-density infections as was found in this 
study and consequently lower sensitivity as pregnancy progresses (Williams et al. 2016). 
The major limitation of estimating the sensitivity of RDT at different ANC visit and the cumulative 
sensitivity of RDT done all ANC visits stems from the fact that women who tested positive to an 
RDT at any time of the study were given a course of Artemether Lumefantrine to treat the malaria 
infection and therefore even though these infections were detected they were all treated and if the 
treatment given was successful, those infections should not progress to the point of being detected 
as active infections in the placenta at delivery. The RDTs that were done at specified study visits 
just provide information about malaria infection at a point in time and do not provide adequate 
explanation for active placental malaria which could have begun after a particular study visit being 
referred to. Despite these limitations, studies have been conducted to try to establish whether rapid 
malaria diagnostic tests could detect placental malaria, with equivocal outcomes.  
In a study in eastern Sudan in an area of unstable malaria transmission, Kashif et al. (2013) testing 
a malaria RDT, the SD Bioline P.f/P.v (Bio Standard Diagnostics, Gurgaon, Korea), an HRP2 and 
P. vivax lactate dehydrogenase RDT, for its ability to detect placental malaria, found that the RDT 
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had a sensitivity of 17.4% (95% CI 8.4-30.4) and a specificity of 81.7% (95% CI 73.4-88.3) using 
placental histology as the gold standard. The authors concluded that the RDT performed poorly in 
the detection of placental malaria in their setting. In another study to assess the impact of HIV and 
malaria co-infection on mother-to-child HIV transmission and adverse birth outcomes in Uganda 
the authors obtained a sensitivity of 57% for RDT in peripheral blood using placental histology 
combined with HRP2 immunohistochemistry as gold standard. The RDT used in this study was 
the Binax NOW ICT (Binax, Portland, ME) which detects P. falciparum-specific HRP2 and pan-
Plasmodium aldolase antigens (Brahmbhatt et al. (2008). 
In a study conducted retrospectively with samples collected at delivery from pregnant women 
participating in a placebo-controlled trial with sulfadoxine-pyrimethamine in Manhica in southern 
Mozambique, an area of perennial malaria transmission with some seasonality mostly attributable 
to P. falciparum, the investigators, using the HRP2-based Malaria Antigen P.f. rapid diagnostic 
test from SD Bioline (Standard Diagnostics) obtained a sensitivity of 76% using placental 
histology as the reference standard (Mayor et al. 2012). A limitation of this study however, is that 
whole blood was not used as recommended by the manufacturer. The tests were performed on 
archived plasma samples, which may have affected the results of these tests. 
8.3 Sensitivity and specificity of First Response® Combo RDT to diagnose 
peripheral malaria in pregnancy 
Interest in the ability of RDTs to accurately detect malaria infections among persons in populations 
at risk of this infection has increased since tests started becoming commercially available well over 
a decade ago. This has stemmed largely from the limitations associated with the use of blood smear 
microscopy, which for decades had remained the main test available for malaria detection in most 
parts of the world where malaria is prevalent, and the ease of use of malaria rapid diagnostic tests, 
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often overcoming some of the difficulties associated with microscopy. Even though RDTs have 
shown promise as suitable replacement for blood smear microscopy, they have also come under 
intense scrutiny, to determine whether they are accurate enough in ordinary usage to allow them 
to be used in health facility laboratories in the management of cases of suspected malaria. 
Accordingly, many evaluations have been conducted of RDT performance to enable policy makers 
and programme managers to make appropriate choices among the increasing number of 
commercially available test kits. 
Since 2008, the World Health Organisation (WHO), the Foundation for Innovative New 
Diagnostics (FIND), the United States Centers for Disease Control and Prevention (CDC) and 
other partners have conducted six rounds of testing of malaria RDTs. The rationale for this 
evaluation is based on the recognition by WHO that the use of antigen detecting rapid diagnostic 
tests is a major cornerstone of its recommendation that malaria case management be based on 
parasite diagnosis in all cases (WHO, 2015). Companies manufacturing RDTs according to ISO 
13485:2003 were invited to submit one to three products for testing. The submitted products were 
tested against P. falciparum and P. vivax clinical samples diluted to 200 and 2,000 parasites/ 
microliter and with consistently comparable concentrations of HRP2, PLDH and aldolase 
determined by ELISA. In five rounds of testing, 210 products have been evaluated and 206 of 
these have progressed to testing against panels of patient derived parasites as well as a parasite-
negative panel. Also thermal stability of the RDTs was assessed after two months of storage at 
elevated temperatures and humidity; a description of ease of use was also made. The evaluation 
determined that several RDTs consistently detected malaria at low parasite density (200 
parasites/microlitre) in five rounds of testing, had low false-positive rates, were stable at tropical 
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temperatures, were relatively easy to use and can detect P. falciparum or P. vivax or both. Even 
though the performance of the products varied widely at low parasite density, all the products had 
a high rate of detection of P. falciparum at 2,000 or 5,000 parasites/microlitre. For P. vivax, 
majority of the products were able to detect parasites at 2,000 parasites/microlitre. The evaluation 
also showed that P. falciparum tests targeting the HRP2 antigen had the highest detection rates. 
The two poorest detecting tests for the detection of P. falciparum were based on P. falciparum-
specific pLDH detection (WHO, 2014). In this evaluation the panel detection score (PDS) was 
used in rating the RDTs. The PDS is the percentage of malaria samples in the panel that give a 
positive result in two RDTs per lot at the lower parasite density or by a single RDT per lot at the 
higher density. In round 5 of testing, the First Response® Malaria Ag. pLDH/HRP2 Combo test 
used in this study, had a PDS of 85.0%  and 74.3% for P. falciparum and P. vivax respectively at 
the lower parasite density (200 parasites/microlitre) and 100% for both P. falciparum and P. vivax 
at the higher parasite densities (2,000 or 5,000 parasites/microlitre). This RDT had 0.0% false-
positive rate for P. falciparum at both low and high parasite densities and 0.3% false-positive rate 
for non-falciparum infection at low parasite density and 0.0% at high parasite density. From the 
laboratory evaluation therefore, the RDT performed very well in detecting P. falciparum and non-
falciparum infections. 
Ever since RDTs started becoming commercially available, they have been the subject of many 
trials in geographically diverse malaria-endemic regions all over the world. In many such areas, 
blood smear microscopy, which had remained the recommended diagnostic test for decades, was 
either unavailable or of poor quality owing to logistical reasons. Therefore RDTs have been tested 
with a view to determining if in addition to their ease of use, they were accurate enough to be used 
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in patient management. Also, WHO recommendation for universal parasitological diagnosis 
before treatment has meant that many countries have put in place protocols which require testing 
of suspected cases before treatment. These protocols for testing before treatment rest largely on 
rapid diagnostic testing. Accordingly, RDTs have been evaluated often to determine if they can 
serve as suitable screening tests. To meet this criterion, their sensitivity should be high enough to 
detect most infections and therefore have a low false-negative rate.  
PCR, which was used as a reference test in this study, is known to have high sensitivity in the 
detection of malaria parasites with the ability to detect five parasites or less per microlitre of blood 
with 100% sensitivity and specificity (Snounou et al. 1993). In the last two decades several PCR-
based methods have been developed for the detection of malaria (Barker et al. 1992; Jelinek et al. 
1999; Kawamoto et al. 1996; Seesod et al. 1993; Sethabutr et al. 1992; Snounou et al.1993; Wataya 
et al. 1993; Wataya et al. 1991). Owing to their complexity, requirement of expensive equipment 
and labour-intensity PCR-based techniques have remained largely as sensitive standards against 
which other non-molecular methods are evaluated.  
In this study, the sensitivity of the RDT to detect peripheral malaria parasitaemia in pregnancy 
using PCR as the reference ranged between 57.7% (95% CI 43.2-71.3) obtained at the delivery 
visit when the prevalence of malaria was 15.0% (95% CI 11.0-19.1) to 89.3% (95% CI 85.5-92.4) 
at the first study visit, when the prevalence of malaria was 57.0% (95% CI 53.0-61.0). The 
specificity of the RDT to detect malaria with PCR as the reference test ranged between 82.9% 
(95% CI 78.3-96.8) obtained at the third study visit to 88.2% (95% CI 83.6-91.9) at the first study 
visit. The RDT performed better as a screening tool at higher malaria prevalence as the sensitivity 
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declined with decreasing malaria prevalence. The specificity of the test was also highest during 
the first study visit when the malaria prevalence was highest.  
When blood smear microscopy was used as the reference standard, the sensitivity of the RDT to 
detect peripheral malaria in pregnancy ranged between 60.3% (95% CI 46.6-73.0) obtained at the 
delivery visit when the prevalence of malaria by blood smear was 17.0% (95% CI 13.0-21.2) to 
95.8% (95% CI 92.8-97.7) obtained at the first study visit when the prevalence of malaria by blood 
smear was 47.0% (43.0-50.9). Some studies have shown that even under the best conditions, blood 
slides tend to miss a good proportion of malaria in pregnancy cases when peripheral blood is 
examined (Leke et al, 1999). Some of these infections missed by blood slides may be picked up 
by PCR or RDT, accounting for the phenomenon of submicroscopic (subpatent) infections. 
Because PCR tends to pick up more infections and is therefore more sensitive than blood slide 
(Barker et al, 1992; Snounou et al, 1993), sensitivity of RDTs tends to be lower when PCR is used 
as the gold standard compared to when blood slide is used as the reference.  
As presented in another section of this thesis, P. falciparum was the main species found among 
the pregnant women in this trial. In many of the evaluations of RDTs that have been done, the 
HRP2-based tests, which can only detect P. falciparum, were more sensitive in detecting this 
particular specie of parasite. Earlier laboratory trials of ParaSight F® RDT an HRP2-based test 
obtained average sensitivity of between 77 to 99% when the parasite density was >100 
parasites/microlitre with specificity also ranging between 83 to 98% for P. falciparum, when 
compared with thick blood smear microscopy (Dietz et al. 1995; Kilian et al. 1997; Kodisinghe et 
al. 1997; Premji et al. 1994; Snounou et al. 1993). When the same RDT was compared to PCR, 
the sensitivity and specificity was 88% and 97% respectively (Humar et al. 1997; Pieroni et al. 
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1998). These RDT evaluations were performed in non-pregnant populations. When the First 
Response® Combo (pLDH/HRP2) RDT was compared with blood smear microscopy in a sample 
of 291 persons aged between 1-60 years reporting to clinics with febrile illness in the Jabalpur 
district in central India, an area where P. falciparum and P. vivax are prevalent, sensitivity of the 
RDT overall was 93% and specificity was 85%. Specifically for P. falciparum, the RDT fared 
better with a sensitivity of 96% and a specificity of 95% (Bharti et al. 2008). Another study in 
central India was conducted by Singh et al. (2010) among a total of 372 patients with a clinical 
suspicion of malaria, who were tested with several RDTs including the First Response® Combo 
(pLDH/HRP2) RDT. The analysis revealed that the First Response® Combo (pLDH/HRP2) was 
94.7% (95% CI 89.5-97.7) sensitive and 69.9% (95% CI 63.6-75.6) specific for the detection of P. 
falciparum using blood smear microscopy as reference. For non-falciparum infections (P. vivax) 
the RDT was less sensitive [84.2% (95% CI 72.1-92.5)] but more specific [96.5% (95% CI 93.8-
98.2)]. The sensitivity of the RDT to detect P. falciparum was less [83.6% (95% CI 77.2-88.8)] 
when PCR was used as the reference test. 
A number of evaluations of RDTs have been conducted among pregnant women in various 
countries using different type of RDTs under different conditions with different outcomes.  Tagbor 
et al. (2008) assessed the performance of OptiMAL® dipstick RDT in the diagnosis of malaria 
infection in pregnancy. The OptiMAL® RDT is a pLDH detecting test produced by DiaMed AG-
Cressier, Switzerland under licence from Flow Inc., Portland, Oregon. In this evaluation, the 
performance of this RDT was compared to microscopy. A total of 6,370 OptiMAL® tests were 
conducted on 4,500 pregnant women attending antenatal clinics at Nkoranza in Ghana. The RDT 
obtained an overall sensitivity of 96.4% (95% CI 95.6-97.3) and a specificity of 85.5% (95% CI 
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83.9-87.1). The investigators were able to show that the diagnostic accuracy of the test declined 
with decreasing parasite density. For instance, the sensitivity of the test was only 57.1% (95% CI 
49.8-64.5) when the parasite density was below 50 parasites/microlitre. VanderJagt et al. (2005) 
working at the Jos teaching Hospital in central Nigeria also compared the OptiMAL® RDT with 
microscopy for detecting malaria in pregnancy among 268 women attending antenatal clinics. 
Positive results from either microscopy or RDT were confirmed with PCR. Even though the 
investigators did not present the sensitivity and specificity of the RDT in their analyses, they 
concluded that the OptiMAL® RDT did not detect malaria in the blood on pregnant women with 
low parasite densities but they also thought the test would be useful for detecting placental malaria. 
Similarly, Singer et al. (2004) also conducted an evaluation of MAKROmed®, an HRP2-based 
RDT among pregnant women in Burkina Faso. They showed that the sensitivity of the RDT 
compared to peripheral blood smear microscopy was 96% with specificity of 67%. However, when 
PCR was used as the reference standard, the sensitivity of the RDT was 89% with specificity of 
76%. 
Even though the sensitivity of the RDT to detect peripheral malaria parasitaemia ranged between 
89.3% when PCR was used as the reference standard and 95.8% when blood slide was the 
reference standard during the first visit when prevalence was highest, these fell slightly short of 
WHO recommendations that to be a useful diagnostic, RDTs must achieve 95% sensitivity (WHO, 
2000).This is particularly important given the potentially severe consequences of undetected 
malaria in pregnant women and their babies which makes it imperative that any screening test for 
malaria should achieve very high sensitivity. 
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8.4 Influence of sub-microscopic and RDT negative malaria infections on the 
Outcome of Pregnancy 
It is well established in literature that malaria in pregnancy has deleterious effects on both the 
mother and her developing foetus. In areas of stable and high malaria transmission, women in their 
first and second pregnancies are at a greater risk than multigravida women to suffer the 
consequences of malaria in pregnancy (Steketee et al. 1996). Malaria in pregnancy detected by 
microscopy has been shown not to be an adequate indicator of the extent of malaria infections in 
pregnancy. Desowitz and Alpers (1992) showed in a study in Papua New Guinea that peripheral 
parasitaemia was only present in 50% of women with proven placental malaria. 
In pregnancy, this may be due to the fact that red blood cells (RBCs) are sequestered in the placenta 
and not necessarily present in peripheral blood. This phenomenon is due to the adherence of 
infected RBCs expressing variant surface antigens (VSA) which selectively bind to chondroitin 
sulphate A in intervillous syncitiotrophoblasts in the placenta (Fried & Duffy, 1996; Maubert et 
al. 1997; Reeder et al. 1999). 
It is also known that low-density parasitaemia often cannot be detected by conventional light 
microscopy as its sensitivity is limited. In the last two decades however, the development of 
molecular techniques has improved the detection of malaria infection. Molecular detection 
techniques have much higher sensitivity for the detection of malaria (Snounou et al. 1993) and 
have revealed the widespread presence of infections with parasite densities below thresholds 
usually detected by microscopy or RDTs. Clinically these submicroscopic infections have been 
associated with adverse effects during pregnancy (Arango et al. 2010). 
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Submicroscopic malaria infections 
In many studies of malaria in pregnancy where both microscopy and PCR-based detection methods 
were used, it has often been found that twice as many women were infected with malaria as 
detected by PCR than those detected by microscopy (Mockenhaupt et al. 2000; Schleiermacher et 
al., 2001). This indicates that a large number of women habour sub-microscopic malaria infections 
i.e. parasite DNA is detected in their blood but parasites are not seen in blood smears (Walker-
Abbey et al. 2005). 
In this study, the prevalence of sub-microscopic malaria infections ranged from 10.6% obtained at 
first visit of the women in the study, to 4.7% at the fourth visit. These estimates are relatively low 
when compared with the prevalence of microscopic malaria infection of 47.9% at first visit and 
12.1% at the fourth visit respectively. 
In an earlier study in the forested hills in the Ashanti region of Ghana, Mockenhaupt et al. (2000) 
found that among a sample of 530 pregnant women, 32% had malaria parasites detectable by 
microscopy. However, the prevalence of malaria increased to 63% when PCR was used in 
examining the blood samples of the same women indicating a sub-microscopic malaria prevalence 
of 31%. In a similar study in Senegal, Schleiermacher et al. (2001) in a study of pregnant women, 
obtained malaria prevalence by microscopy of 29%, increasing to 85% when PCR was used, giving 
a submicroscopic infection prevalence of 56%. In Cameroon, Walker-Abbey et al. (2005) in a 
study of 278 women found that 27.5% of them were blood smear positive while 54.9% of them 
had sub-microscopic infections. In these reported studies therefore, the proportion of women with 
sub-microscopic infections was either about the same or more than those with microscopic 
infections. In this study however, the proportion of women with sub-microscopic infections was 
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smaller than those who had microscopic infections. Also, the proportion of sub-microscopic 
infections declined as the prevalence of malaria declined with subsequent antenatal clinic visits. 
When the prevalence of sub-microscopic infections was analysed by the background 
characteristics of the study women at various visits there was no clear trend or pattern to the 
prevalence by age group or educational status. There was also no clear difference between the 
women in the IPT group and those in the IST group. However, secundigravid women had higher 
prevalence of sub-microscopic infections compared to primigravid women, for each of the three 
visits analysed even though the confidence intervals overlapped. This may be due to the fact that 
by the second pregnancy, women already may have started developing some levels of immunity 
to malaria in pregnancy leading to lower parasite densities. This is in consonance with findings 
that immune mechanisms against malaria parasites are gradually acquired with successive 
pregnancies (Fried et al. 1998; Beeson et al. 1999). 
Sub-RDT malaria infections 
RDTs have become increasingly important in the early detection and management of malaria and 
their use is being promoted widely. WHO recommends that all persons of all ages in all 
epidemiological settings with suspected malaria should receive a parasitological confirmation of 
diagnosis by either microscopy or RDT. Owing to the difficulties associated with blood smear 
microscopy such as non-availability of electricity, lack of well-trained technicians to read slides 
and lack of logistics, the use of RDTs has become a more viable option for many in poor countries 
trying to try to achieve the WHO recommendation of universal testing for suspected malaria cases. 
In this study, the prevalence of sub-RDT infections, defined as the proportion of women who were 
negative by RDT but had PCR positive for any malaria infection ranged between 6.3% for women 
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at delivery visit to 3.4% for women attending their second scheduled antenatal clinic visit. 
Comparing the proportions of sub-microscopic infections described in the previous section to the 
proportions of sub-RDT infections, it is obvious that fewer sub-RDT infections picked up by PCR 
but not by RDT were being missed at the antenatal clinic visits compared to the sub-microscopic 
malaria infections being missed by microscopy. 
A possible reason for the higher proportion of missed infections at delivery may be the acquisition 
of some level of immunity as the pregnancy progressed resulting in a greater chance that infections 
around that time are more likely to be of lower density. Also, previous malaria treatment could 
also lower parasite densities as noted by Kyabayinze et al. (2016). Further, higher density 
infections would most likely have been picked up earlier by RDT and treated. It has to be noted 
though, that this study only enrolled primigravidae and secundigravidae and not multigravidae in 
whom mean parasite densities generally tend to be lower. 
A major purpose of this analyses was to determine whether RDTs could adequately be used for 
Intermittent Screening and Treatment (IST) should such regimens be adopted to replace existing 
IPTp programmes. The concerns expressed against such a potential change in programmes relate 
to the proportions of infections missed by the RDT used and whether there are any potential 
adverse consequences from such missed infections. However, in our analysis, sub-patent malaria 
infections (both sub-RDT and sub-microscopic) infections were neither associated with a reduction 
in birth weight nor with low birth weight. Sub-patent infections were also not associated with 
anaemia in pregnancy. However, these findings could have been influenced by iron and folate 
supplements which were given to the study participants as is done routinely by protocol in the 
study countries. This adds to the evidence which suggests that sub-patent infections have no 
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significant adverse effects on pregnancy as found by Cohee et al. (2014) and Singh et al. (2015). 
However, it must be noted that others have found significant association between sub-patent 
malaria infections and low birth weight (Mankhambo, Kanjala, Rudman, Lema and Rogerson, 
2002; Mohammed et al., 2013) while other have found an association between sub-patent malaria 
infections and maternal anaemia (Mockenhaupt et al., 2000; Adegnika et al., 2006 and Cottrell et 
al., 2015). The reasons for these different findings may be due to the fact that different types of 
RDT and PCR assays were used in the various studies. The differences may also be related to 
variations in the characteristics of the study populations and study sample sizes. Owing to 
conflicting findings from different studies, these findings need to be interpreted carefully, 
particularly so as the sample size for this analysis was not large and the study was not sufficiently 
powered to detect small effects of sub-patent malaria infections. 
8.5 Prevalence of malaria infection in pregnancy in four West African 
countries 
Non-falciparum malaria Infections 
It was quite apparent from this study that the diagnosis of non-falciparum malaria is difficult in 
ordinary practice. Two microscopists independently read the blood smears in each country. Six 
non-falciparum malaria cases were detected by the first readers while six cases were also detected 
by the second readers. However, there was only one confirmed case which was detected by both 
readers. This was a case of P. malariae which was detected in a woman enrolled at the Burkina 
Faso site of the study. 
The sensitivity of microscopy to detect non-falciparum malaria in our study was clearly very low 
when compared to PCR which detected 40 cases in this sub-sample of women. This finding 
underlies the potential for many non-falciparum malaria cases being missed in everyday practice 
144  
by microscopists in laboratories where microscopy remains the mainstay of malaria laboratory 
diagnosis and stresses the need for more sensitive but simple and cheap methods of malaria 
diagnosis to be developed. 
The prevalence of non-falciparum malaria at first ANC attendance in this study as detected by 
PCR was 1.72% overall, with mono infections accounting for 0.48% while mixed infections were 
found among 1.24% of the women. Compared to the overall prevalence of P. falciparum infection 
of 38.39% the prevalence of non-falciparum malaria is very low among pregnant women in the 
four countries in the study. Even though this prevalence is low, it demonstrates that non-falciparum 
infections are present among pregnant women in West Africa as its prevalence ranged from 0.28% 
in The Gambia to 4.98% in Mali. The finding of Mali obtaining the highest prevalence of non-
falciparum malaria was significant as that country had the second lowest prevalence of P. 
falciparum infection among the four countries in the trial. This suggests that the relatively high 
prevalence of non-falciparum malaria found in Mali compared to the other countries in the trial 
cannot be explained by differences in the transmission intensity alone and this finding may just 
indicate a greater presence of non-falciparum species in that country. Also, all the non-falciparum 
species tested for in this study were found in Mali, including P.vivax. P. vivax has been detected 
in the northern parts of Mali in a previous study (Bernabeu et al, 2012). However, these P. vivax 
infections in this study were detected in Malian women enrolled in the southern parts of the country 
where vivax infections had not previously been reported. As expected P. vivax infections were not 
detected in any of the other countries in the trial. However, with the exception of Gambia which 
only recorded one case each of mono infections of P. ovale curtisi and P. ovale wallikeri, the other 
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countries in the study all had cases of P. malariae and P. ovale (curtisi and wallikeri) either as 
mono infections or mixed with P. falciparum.  
Significantly, most of the non-falciparum infections detected were mixed infections with P. 
falciparum. A similar finding of mixed malaria infections of falciparum and non-falciparum 
malaria had been found in an earlier study among pregnant women in Ghana (Mockenhaupt et al, 
2000). In Cameroon, Walker-Abbey et al (2005) also found a higher prevalence of mixed malaria 
infections compared to mono infections of non-falciparum malaria. They found that the prevalence 
of P. malariae and P. ovale was 7.6% and 2.5% respectively compared to 9.4% who had mixed 
infections with more than one species.  
The rather low prevalence of non-falciparum infections together with the higher incidence of 
mixed infections has potential implications for species detection by microscopy as the presence of 
P. falciparum parasites particularly when in present in high densities, may mask the presence of 
other species, making it difficult for even expert microscopists to detect them.  This showed quite 
clearly in this study where microscopy only detected very few non-falciparum malaria cases.  
Non-falciparum malaria infections not detected by RDT 
 Intermittent screening and treatment for malaria in pregnancy (IST) depends to a great extent on 
the ability of the RDT that is used to detect  as many of the malaria infections among the pregnant 
women as possible to enable them receive effective treatment with current Artemisinin- 
Combination Therapy. Therefore a test with a high sensitivity is desirable. Even though other 
aspects of this thesis deal with the sensitivity and specificity of the RDT used in the study to screen 
women for malaria, the analysis in this section dwelt on the ability of the RDT to detect non-
falciparum malaria among the women who were screened. The RDT detected only three out of 
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nine mono non-falciparum infections. Given that this RDT is a combo test and should therefore 
detect falciparum and non-falciparum species, this finding fell below expectation. The test 
however appeared to have performed better at detecting the mixed infections, giving positive 
results for all the mixed infections except two cases out of nine cases of P. falciparum mixed with 
P. malariae that were reported negative. Unfortunately, the test results for the RDT did not indicate 
which bands were present at the time of a positive test and therefore it is not possible to 
differentiate a positive test with two bands from a positive test with only one band. When two test 
bands are positive (both HRP2 and pLDH) it may indicate P. falciparum alone or in combination 
with non-falciparum malaria as the P. falciparum parasite has both HRP2 and pLDH proteins. 
Differentiation is only possible when only the pLDH band is positive as this indicates that the 
parasite detected is a non-falciparum species as any P. falciparum present should have resulted in 
a positive HRP2 band as well. Therefore, it is probable that the test was detecting most of the 
mixed infections because P. falciparum was present, as it failed to perform equally well when 
detecting non-falciparum mono infections. 
Risk Factors for non-falciparum malaria 
The country of residence of the woman and the season of enrollment were the only factors which 
had a significant association with having a non-falciparum malaria infection. As discussed in an 
earlier section, women in Mali had a higher prevalence of non-falciparum malaria. However, 
owing to the small numbers of non-falciparum infections the estimates were not very precise, with 
large confidence intervals resulting. Women enrolled in Ghana were also more likely to have non-
falciparum malaria when compared to Gambian women. 
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Season of enrollment is associated with malaria transmission in general. However, we also found 
that it is associated with a greater risk of non-falciparum malaria as women enrolled in the late wet 
season had a greater risk of non-falciparum malaria. 
 
Prevalence of malaria in pregnancy detected at enrolment 
The prevalence of any species of malaria obtained by microscopy among the women in the study 
ranged from 8.4% (95% CI 6.5-10.7) for the women enrolled in the Gambia to 19.6% (95% CI 
16.2-23.5) for the Malian women, to 42.9% (95% CI 38.5-47.4) for the women enrolled in Burkina 
Faso. The highest prevalence of 48.9% (95% CI 45.2-52.7) was obtained among the women 
enrolled at the Ghana site. The prevalence of malaria by PCR was higher than that obtained by 
microscopy in all the four countries in the trial; in the Gambia it was 13.7% (95% CI 11.3-16.4), 
in Mali the prevalence was 31.3% (95% CI 27.2-35.6), in Burkina Faso it was 60.1% (95% CI 
55.6-64.5) and in Ghana the prevalence by PCR was 60.3% (95% CI 56.6-63.9).  
This finding is consistent with findings from other studies where parasitaemia was detected by 
both microscopy and PCR (Mockenhaupt et al. 2000, 2006; Schleiermacher et al. 2001; 
Mankhambo et al. 2002; Walker-Abbey et al. 2005; Malhotra et al. 2005; VanderJagt et al. 2005). 
However, findings by some authors (Mockenhaupt et al. 2000; Adam et al. 2005; Malhotra et al. 
2005; Walker-Abbey et al. 2005;Adegnika et al. 2006) suggesting that PCR-based detection 
methods detect at least twice as many pregnant women infected with malaria compared to 
microscopy was not established in this study in any of the four countries even though PCR always 
detected a higher proportion of infections than microscopy. There is clear evidence that malaria 
prevalence has been decreasing in some African countries in the last decade (Bhattarai et al. 2007; 
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Ceesay et al. 2008, 2010; Bouyou-Akotet et al. 2008; Graves et al. 2008; O’Meara et al. 2008; 
Otten et al. 2009;  Teklehaimanot et al. 2009; Lee et al. 2010; Beiersmann et al. 2011). The decline 
of malaria prevalence in the Gambia for instance, has been documented (Ceesay et al. 2010). These 
declines have been attributed to the scaling up of such interventions as artemisinin-based 
combination therapy (ACT), long lasting insecticide treated bed nets, intermittent preventive 
treatment in pregnancy (IPTp) and lately seasonal malaria chemoprevention (SMC) [WHO, 2012]. 
SMC, which was previously known as Intermittent Preventive Treatment in children (IPTc), is 
defined as:  
“The intermittent administration of full treatment courses of an antimalarial medicine during the 
malaria season to prevent malarial illness with the objective of maintaining drug concentrations 
in the blood throughout the period of greatest malarial risk”.  
SMC is targeted at preventing most of the childhood malaria mortality and morbidity which occurs 
during a short rainy season in the Sahel sub-region. 
This phenomenon of declining malaria prevalence, has not been observed in all the countries 
involved in the trial. In Mali, Coulibaly et al. (2014) followed up a cohort of 400 children aged 0 
to 14 years for four years to document malaria incidence using cross-sectional surveys to measure 
malaria and anaemia prevalence; they concluded that despite the scaling up of malaria 
interventions, malaria incidence did not decrease in their study area. In Burkina Faso, Ramroth et 
al. (2009) also showed that malaria prevalence had not declined. They had found that even though 
all-cause mortality in children had declined over a period, malaria-specific mortality among the 
deaths of children studied had remained fairly stable. 
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This study found that malaria prevalence was higher at first ANC visit than subsequent visits. In 
Ghana and Burkina Faso, the prevalence was very high among these primi- and secundi-gravid 
women whether using microscopy or PCR assays at enrolment. The prevalence was quite moderate 
in Mali and relatively low in the Gambia when compared to Ghana and Burkina Faso. The reasons 
for these differences among these countries is not very obvious. However, the various country 
situations are a reflection of the funding available to the country malaria control programmes and 
how they are being implemented to eliminate malaria. As part of this trial, parasites obtained from 
study women at enrolment were genotyped for markers of SP resistance and the K540E mutation 
which predicts dihydrofolate reductase-dihydropteroase synthetase (dhfr-dhps) quintuple 
haplotype, which indicates a high risk of SP failure (Naidoo and Roper, 2010) was not found in 
Burkina Faso, Ghana and Gambia (Tagbor et al. 2015). In Mali, it was only found at a low 
frequency (<1%) in one of the sites but not at the other site. A parallel study to this trial on the in-
vivo sensitivity of SP which was conducted at two of the study sites (Burkina Faso and Mali) 
showed that SP was still highly efficacious in asymptomatic pregnant women attending ANC 
(Coulibaly et al. 2014). This suggests that SP is still likely to remain efficacious for use in IPTp in 
these countries particularly in Ghana and Burkina Faso where prevalence of malaria among 
pregnant women at enrolment is so high. There is the need to ensure that coverage of IPTp is high 
in such areas. Also frequent dosing may prolong the protective effect of IPTp-SP (White, 2005; 
Kayentao et al. 2013). The World Health Organisation (WHO) Evidence Review Group on IPTp 
with SP has recommended the administration of SP to all pregnant women at each scheduled ANC 
visit starting in the second trimester and given one month apart, with the last dose given in the last 
trimester after 36 weeks (WHO, 2013). A total of five doses is thus envisaged. As the level of 
transmission below which IPTp is no longer useful is not known and consequently countries may 
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be reluctant to stop IPTp in low transmission settings without a non-inferior alternative, 
intermittent screening and treatment of malaria in pregnancy (ISTp) is an alternative which could 
be considered by policy makers and programme managers as this trial determined that it was non-
inferior to IPTp-SP in preventing low birth weight, maternal anaemia and placental malaria 
(Tagbor et al. 2015).   
8.6 Use of Symptoms to Predict Malaria in Pregnancy 
In many malaria endemic areas, the diagnosis of malaria in children and adults has often been 
based on clinical symptoms and signs. However, the usual symptoms and signs that patients 
present with are not specific to malaria as they may also suggest other bacterial, viral or other 
diseases which are often prevalent in areas where malaria tends to be endemic. Clinical diagnosis 
of malaria can therefore be difficult because there is no component of the clinical features which 
is pathognomonic of the infection (WHO, 2000b) as all the features could suggest other tropical 
diseases or even urinary tract infections, which are known to be common in pregnancy. 
The presentation of malaria in pregnancy may depend on such factors as the age of the woman, 
her gravidity, gestational age and her HIV status (WHO, 2004). The clinical manifestation of 
malaria in pregnant women is determined to a large extent by her level of acquired immunity which 
is also determined by the local malaria transmission characteristics. In areas of low unstable 
transmission, women often do not have sufficient acquired immunity and therefore malaria 
infection tends to be symptomatic, affects all parities and is associated with detectable parasitaemia 
(Brabin, 1983, 1985; Shulman et al. 2001; Adam et al. 2005). The main dangers of malaria in non-
immune women include hyperpyrexia, hypoglycaemia, severe haemolytic anaemia, cerebral 
malaria and pulmonary oedema (Shulman and Dorman, 2000). However, in areas of intense stable 
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malaria transmission, malaria in pregnancy may be asymptomatic even though parasites tend to 
sequestrate in the intervillous bed of the placenta leading to maternal anaemia and low birth weight, 
particularly in paucigravidae (Brabin, 1983, 1985; Verhoeff et al. 1999; Shulman et al. 2001; 
Steketee et al. 2001). In a study in Malawi, Mc.Dermott et al. (1988) observed that none of the 19 
women who had parasitaemia at enrolment into the study had a history of fever or symptoms 
suggestive of malaria. Huynh et al. (2011) followed up a prospective cohort of women for two 
years in Benin, an area of stable malaria transmission and analysed the presence of symptoms 
suggestive of malaria infection in 982 women during antenatal clinic visits. The investigators 
concluded that the majority of the women were asymptomatic during their routine visits when 
infected with malaria. They found however, that fever was associated with malaria infection only 
when the women came for unscheduled visits. 
However, Tagbor et al. (2008) concluded after studying pregnant women enrolled in a randomized 
clinical trial to determine the efficacy, safety and tolerability of chloroquine, amodiaquine (AQ), 
sulfadoxine-pyrimethamine (SP) and SP + AQ for the treatment of MiP in a stable transmission 
area in Ghana, that MiP may often be more symptomatic than previously documented and even 
though the symptoms may be mild and non-specific, they can still predict parasitaemia. 
Against this background, the main objective of this analysis was to assess if a symptom score could 
be useful in determining clients at busy antenatal clinics who necessarily have to be tested with an 
RDT for malaria because of symptoms they present with. Ideally in a system where intermittent 
screening and testing has been instituted as a regime for malaria detection and management, all 
women presenting at antenatal clinics need to be tested with an RDT when they attend scheduled 
antenatal clinic visits. However, given constraints in busy clinics in developing countries, there 
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may be instances where owing to lack of some resources, not every woman can be tested at all 
visits. In such situations, symptoms may help to prioritise who has to benefit from limited 
resources. 
In this study, 14.4% of the women reported being sick at their first visit while 13.0% reported 
being sick at the second visit. Only 5.1% and 3.8% of the women reported having a fever at the 
first and second visits respectively. The commonest symptom reported was headache, which was 
complained of by 17.6% of women at first visit and 12.1% at second visit. While it is known that 
many women may be prompted to attend their first antenatal clinic visit for a particular pregnancy 
because they may not be feeling too well, many women may not necessarily be feeling unwell and 
may just have elected to attend clinic on that day. This may account for the rather low proportions 
of women presenting with the symptoms on the checklist. However, of those not presenting with 
particular symptoms, very high proportions tested positive by RDT even though the proportions 
of those having those particular symptoms and testing positive by RDT was always slightly higher. 
It appears therefore that the symptoms were of low sensitivity and specificity to detect women 
with malaria infections.  
Two symptom scores were created with symptoms reported at the first two study visits which were 
significantly associated with positive RDT. The four symptoms which were significant at first visit 
(fever, chills, headache and waist pain) were also significant at the second visit. Other symptoms 
significant at the second visit which were not significant at the first visit were: being currently 
sick, general weakness, dizziness, vomiting and painful urination.  
For score 1, created from the first visit symptoms, there was a linear trend showing increasing 
proportions of RDT positive with increasing number of symptoms in the score. Score 2 also shows 
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a significant association with RDT positivity. However, the trend is not linear. In multivariate 
logistic regression analysis, for score 1, women with 3 or 4 symptoms were 3.87 times (95% CI 
1.07-14.09, P=0.040) more likely to have a positive RDT compared to women who had no 
symptoms. For score 2, women with 3 to 8 symptoms were 3.43 times (95% CI 1.57-7.45, 
P=0.002) more likely to have a positive RDT compared to women without symptoms. These 
findings were obtained after controlling for age group, educational status, gravidity, socio-
economic status and season of enrolment. Arguably, these findings suggest that one or two 
symptoms may not be enough to predict the presence of malaria. However, the presence of three 
or more of these symptoms listed earlier is a fairly strong indication of malaria infection and 
therefore the need for testing to confirm the suspicion. The accuracy of these scores is not sufficient 
indication to start treatment for malaria. However, as a screening tool to decide on testing for 
malaria, it should be of some help to health workers if decisions have to be made about who should 
benefit from limited RDT testing resources.  
The sensitivity of the symptom scores were calculated using two scenarios for each score. The 
scenarios for the first score dichotomised it into “No symptom” versus “any symptom” on one 
hand and “No symptom or one or two symptoms” versus “3 or 4 symptoms” on another hand. The 
first scenario had a sensitivity of 24.7% while the second scenario had a sensitivity of 4.5%. For 
the second score, the first scenario compared “No symptom” versus “Any symptom” on one hand 
and “No symptom or 1 or 2 symptoms” versus “3 to 8 symptoms” on another hand. For the second 
score, the first scenario obtained a sensitivity of 32.3% while the second scenario yielded a 
sensitivity of 15.2%. Therefore, the sensitivities of the various scenarios created ranged from a 
low of 4.4% to 32.5%. This suggests that at best the symptom scores created would be good enough 
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to pick up only a third of pregnant women attending ANC who had a positive RDT. On their own 
therefore, the symptoms do not provide enough precision to predict malaria infection in the 
women. 
A major limitation of this analysis is the sample size. The calculated sample size was 1,281 women. 
However, the women in the IST arm of the study, who were tested intermittently with RDTs were 
653. This therefore reduced the power of this analysis.  
8.7 Research Implications of study 
Even though the First response® Combo RDT had a good profile in in-vitro testing in five rounds 
by the WHO/FIND/CDC and other partners, its failure to detect significant numbers of malaria 
infections gives cause for concern as many countries strive to achieve the WHO recommendation 
of universal testing of all suspected malaria cases. Also with intermittent screening and treatment 
(IST) of malaria in pregnancy increasingly emerging as an alternative to IPTp, particularly in areas 
where malaria prevalence has declined and/or SP resistance has reached levels where the drug is 
no longer useful in malaria prevention, there is the need to ensure that the true malaria cases that 
will go undetected by RDT testing will be reduced to the barest minimum. Accordingly, there is 
the need to develop more sensitive assays which will detect the presence of placental malaria and 
to conduct further research comparing in-vivo performance of sensitive RDTs to determine those 
better suited for screening pregnant women.  
Findings from this study indicate that non-falciparum malaria even though present, are still largely 
uncommon among the population of women that we studied and P. falciparum remains the 
dominant species responsible for a great majority of malaria infections among pregnant women. 
Owing to the low prevalence of non-falciparum malaria among the women in our study, it was not 
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possible to look for their potential association with adverse pregnancy outcomes. Perhaps, a larger 
study may provide an opportunity to examine the effects of non-falciparum malaria on pregnancy 
in view of the fact that there largely is paucity of data in the literature on this subject even though 
there is scanty information on the effects of P. vivax infection on pregnancy.  
Also, given that this study did not find any adverse effects of sub-RDT MiP on pregnancy 
outcomes which agrees with findings from some studies but is at odds with others, there is the 
need for further evaluation of the effects of sub-RDT malaria infections on pregnancy. 
Our symptoms scores were not sensitive enough to predict women who had positive RDT results. 
There may be the need to develop better symptom-based scores which could serve as a useful pre-
screening tool where IST is introduced. 
8.8. Implications for policy and practice 
Even though some malaria infections were undetected by the RDT that was used in the trial, our 
analyses showed that women who had RDT negative/PCR positive (sub-RDT) malaria infections 
were not at an increased risk of adverse pregnancy outcome when compared with women who had 
no malaria. This suggests that even though some malaria infections will be missed by RDTs when 
women are screened and treated at scheduled antenatal clinic visits, women with those infections 
may not suffer any deleterious effects from those infections possibly because those infections are 
of low density parasitaemia and hence are not detected by the RDT. Therefore screening with 
RDTs for malaria at antenatal clinics is a useful test to conduct for the control of malaria in 
pregnancy and should be instituted and maintained as the standard of care. 
RDTs have become cheaper and increasingly available in the last decade or so. However, in many 
developing countries such as Ghana, supply of RDTs is not always guaranteed owing largely to 
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funding issues. Under these circumstances midwives at the antenatal clinics may have to use some 
mechanisms to determine women who necessarily have to be tested for malaria even in situations 
where not every woman can be tested. Our analyses showed that symptoms presented by women 
who may have parasitaemia may not be sensitive enough to indicate the presence of malaria when 
used alone. Although combining a few symptoms into a score gave a higher probability of 
predicting the presence of malaria infection this approach was not sensitive enough to recommend 
not offering IPT to women who test RDT negative. One possibility is a combination of IST with 
IPTp; first screen women using a symptom score to identify who should be tested with RDT. Give 
IPTp-SP to those women who are deemed to be asymptomatic and also to women who are RDT 
negative; and treat with an ACT if the RDT is positive. This approach to using symptoms to suggest 
which women necessarily need to be tested for malaria will also save some cost as well as ease 
pressure on scarce human resource which is often constrained in many developing countries. This 
will require midwives to actively solicit these symptoms from pregnant women attending antenatal 
clinics preferably using a checklist of symptoms most likely to suggest a positive RDT. Midwives 
will have to be trained to look out for these symptoms and ensure that women presenting with 
those get tested with an RDT even if they are receiving IPTp. In spite of these suggestions, it must 
be emphasized that restricting RDT testing to women who may need it based on symptoms which 
are often non-specific, is not ideal. 
This PhD sub-study was also done with the objective of providing further evidence to support IST 
as an alternative to IPTp particularly in situations where SP is failing as a result of high-grade 
resistance. Even though this study provides some of that evidence by the finding that sub-patent 
malaria infections in this study were not associated with adverse outcomes such as low birth weight 
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or anaemia in pregnancy and therefore a few missed infections did not have negative 
consequences, other factors will have to be considered in transferring these results into policy. For 
instance, a cost effectiveness study was conducted for the main trial of IST versus IPTp which 
showed clearly that IST was less cost effective when compared to IPTp in these study countries 
where SP was still efficacious (Fernandes et al. 2016). However, simulations conducted in that 
study also showed that the cost-effectiveness of IST with Artemether Lumefantrine increased as 
the efficacy of SP decreased even though the specific point at which IST becomes cost-effective 
depends on other factors such as bed net use and coverage.  
  
8.9 Conclusions 
We also found that compared to PCR as the gold standard, the sensitivity and specificity of the 
RDT we used in our study was generally quite good.  P. falciparum remains the predominant 
malaria species infecting pregnant women in the four study sites. The risk of malaria in pregnancy 
due to the other malaria species infecting humans (except P. knowlesi, for which we did not test), 
is very low. Even though RDTs will not detect all malaria infections, most probably infections 
with low density parasitaemia, women who may get missed by RDTs are not at great risk of 
developing adverse pregnancy outcomes when compared with women who had no malaria. A 
clinical symptoms based approach to screen women requiring RDT was not sensitive enough to 
be recommended. All pregnant women should be screened with RDT if IST was considered to 
replace IPTp-SP in areas where SP resistance is too high or transmission intensity is very low.   
 
 
 
158  
REFERENCES 
 
Achur, R.N., Valiyaveettil, M., Ockenhouse, C.F., and Gowda, D.C. (2000).Characterisation of 
proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans 
of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected 
erythrocytes to the placenta. Journal of Biological Chemistry; 275:40344-40356. 
 
Adam, I., Khamis, A.H. and Elbashir, M.I. (2005).Prevalence and risk factors for Plasmodium 
falciparum in pregnant women of eastern Sudan. Malaria Journal 4:18. 
 
Adegnika, A.A., Verweji, J.J., Agnandji, S.T., Chai, S.K., Breitling, L.P., Ramharter, M., 
Frolich, M.m Issifou, S., Kremsner, P.G. and Yazdanbakhsh, M. (2006). Microscopic and sub-
microscopic Plasmodium falciparum infection but not inflammation caused by infection is 
associated with low birth weight. American Journal of Tropical Medicine and Hygiene; 75: 798-
803. 
 
Afari, E.A., Nakano, T., Binka, F., Owusu-Agyei, S. and Asigbee, J. (1993). Seasonal 
characteristics of malaria infection in under-five children of a rural community in southern 
Ghana. West African Journal of Medicine, 12:39-42. 
 
Arango, E., Maestre, A., & Carmona-Fonseca, J. (2010). Effect of submicroscopic or polyclonal 
Plasmodium falciparum infection on mother and gestation product: systematic review. Revista 
Brasileira de Epidemiologia, 13(3), 373-386. https://dx.doi.org/10.1590/S1415-
790X2010000300002 
 
Baker, J., McCarthy,J., Gatton, M., Kyle, D.E. Belizario, V., Luchavez, J., Bell, D. and Cheng, 
Q.(2005). Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and its 
effect on the performance ofPfHRP2-based rapid diagnostic tests. Journal of Infectious 
Diseases;192:870–877. 
 
Bardaji, A., Siguaque, B., Bruni, L., Romagosa, C., Sanz, S., Mabunda, S., Mandomando, I., 
Aponte, J., Sevene, E., Alonso, P. and Menendez, C. (2008).Clinical malaria in African pregnant 
women. Malaria Journal. 7: 27-33. 
 
Barker P, and Bingham P. (1992). DNA fingerprinting and contact tracing. British Medical 
Journal. 305(6852):527. 
 
Beeson, J. G., Brown, G. V., Molyneux, M. E., Mhango, C., Dzinjalamala, F., & Rogerson, S. J. 
(1999). Plasmodium falciparum Isolates from Infected Pregnant Women and Children Are 
Associated with Distinct Adhesive and Antigenic Properties. The Journal of Infectious 
Diseases, 180(2), 464–472. http://doi.org/10.1086/314899 
 
 
159  
Beeson J.G., Amin, N., Kanjala, M. and Rogerson, S.J. (2002).Selective accumulation of mature 
asexual stages of Plasmodium falciparum-infected erythrocytes in the placenta. Infection 
Immunity; 70:5412-15. 
 
Beiersmann, C., Bountogo, M., Tiendrébeogo, J., De Allegri, M., Louis, V. R., Coulibaly, B., 
Ye, M. and Mueller, O. (2011). Falciparum malaria in young children of rural Burkina Faso: 
comparison of survey data in 1999 with 2009. Malaria Journal, 10: 296. 
http://doi.org/10.1186/1475-2875-10-296 
 
Bell, D., Wongsrichanalai, C. and Barnwell, J.W. (2006). Ensuring quality and access for malaria 
diagnosis: how can it be achieved? Nature Reviews Microbiology; 9: S7-S20. 
 
Bernabeu, M., Gomez-Perez, G. P., Sissoko, S., Niambélé, M. B., Haibala, A. A., Sanz, A., 
Thera, M.A., Fernandez-Becerra, C., Traore, K., Alonso, P.L., Bassat, Q., del Portillo, H.A. and  
Doumbo, O. (2012). Plasmodium vivax malaria in Mali: a study from three different 
regions. Malaria Journal, 11: 405. http://doi.org/10.1186/1475-2875-11-405 
 
Biritwum, R.B., Welbeck, J. and Barnish, G. (2000).Incidence and management of malaria in 
two communities of different socioeconomic level, in Accra, Ghana. Annals of Tropical 
Medicine and Parasitology; 94: 771-778. 
 
Bharti, P. K., Silawat, N., Singh, P. P., Singh, M. P., Shukla, M., Chand, G., Dash, A.P. and  
Singh, N. (2008). The usefulness of a new rapid diagnostic test, the First Response® Malaria 
Combo (pLDH/HRP2) card test, for malaria diagnosis in the forested belt of central 
India. Malaria Journal, 7, 126. http://doi.org/10.1186/1475-2875-7-126 
 
Bhattarai, A., Ali, A. S., Kachur, S. P., Mårtensson, A., Abbas, A. K., Khatib, R., Al-mafazy, A., 
ramsan, M., Gerstenmaier, J.F., Molteni, F., Abdulla, S., Montgomery, S.M., Kaneko, A. and 
Björkman, A. (2007). Impact of Artemisinin-Based Combination Therapy and Insecticide-
Treated Nets on Malaria Burden in Zanzibar. PLoS Medicine, 4(11), e309. 
http://doi.org/10.1371/journal.pmed.0040309 
 
Bottius E, Guanzirolli A, Trape JF, Rogier C, Konate L, and Druilhe P. (1996). Malaria: even 
more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable 
by the polymerase chain reaction. Transactions of the Royal Society Tropical Medicine and 
Hygiene; 90: 15-9. 
 
Boudin, C., Robert, V., Verhave, J. P., Carnevale, P. and Ambroise-Thomas, P. (1991) 
Plasmodium falciparum and P. malariae epidemiology in a West African village. Bulletin of the 
World Health Organisation, 69(2): 199-205. 
 
Bouvier, P., Breslow, N., Doumbo, O., Rober, C., Picquer, M., Mauris, A., Dolo, A., Dembele, 
H.K., Delley, V. and Rougemont, A. (1997). Seasonality, Malaria and Impact of prophylaxis in a 
160  
West African village II. Effect on birthweight. American Journal of Tropical medicine and 
Hygiene, 56(4): 384-9. 
 
Bouyou-Akotet, M. K., Mawili-Mboumba, D. P., Kendjo, E., Mabika-Mamfoumbi, M., 
Ngoungou, E. B., Dzeing-Ella, A., Pemba-Mihindou, M., Ibinga, E., Efame-Eya, E., MCRU 
team, Planche, T., Kremsner, P. and Kombila, M. (2009). Evidence of decline of malaria in the 
general hospital of Libreville, Gabon from 2000 to 2008. Malaria Journal, 8, 300. 
http://doi.org/10.1186/1475-2875-8-300 
 
Brabin, B.J. (1983). An analysis of malaria in pregnancy in Africa. Bulletin of the World Health 
Organisation. 61:1005-1016 
 
Brabin, B.J. (1985). Epidemiology of infection in pregnancy. Reviews of Infectious Diseases. 7: 
579-603. 
 
Brabin, B.J. and Perrin, L. (1985). Diversity of Plasmodium falciparum antibodies in pregnancy. 
Lancet, 1(8437):1098-9. 
 
Breman, J.G., Alilio, M.S. and Mills, A. (2004). Conquering the intolerable burden of malaria: 
what’s new, what’s needed: a summary. American Journal of Tropical Medicine and Hygiene; 
71 (Suppl 2): 1-15. 
 
Browne, E.N.L., Frimpong, E., Sievertsen, J., Hagen, J., Hamelmann, C., Dietz, K., Horstmann, 
R.D. and Burchard, G.D. (2000). Malariometric update for the rainforest and savanna of Ashanti 
Region, Ghana. Annals of Tropical Medicine and Parasitology, 94(1): 15-22. 
 
Bulmer, J.N., Rasheed, F.N., Francis, N., and Greenwood, B.M. (1993).Placental malaria I. 
Pathological Classification. Histopathology; 22: 211-218. 
 
Carvalho, B., et al. (2010). On the cytoadhesion of Plasmodium vivax-infected erythrocytes. 
Journal of Infectious Diseases; 202(4): 638-647. 
 
Ceesay, S. J., Casals-Pascual, C., Erskine, J., Anya, S. E., Duah, N. O., Fulford, A. J., Sesay, 
S.S.S., Abubakar, I., Dunyo, S., Sey, O., Palmer, A., Fofana, M., Corrah, T., Bojang, K.A., 
Greenwood, B.M. and Conway, D. J. (2008). Changes in malaria indices between 1999 and 2007 
in The Gambia: a retrospective analysis. Lancet, 372(9649), 1545–1554. 
http://doi.org/10.1016/S0140-6736 (08)61654-2 
 
Ceesay, S. J., Casals-Pascual, C., Nwakanma, D. C., Walther, M., Gomez-Escobar, N., Fulford, 
A. J. C., Takem, E.N., Nogaro, S., Bojang, K.A., Corrah, T., Jaye, M.C., Taal, M.A., Sonko, 
A.A.J. and Conway, D. J. (2010). Continued Decline of Malaria in The Gambia with 
Implications for Elimination. PLoS ONE, 5(8): e12242. 
http://doi.org/10.1371/journal.pone.0012242 
161  
 
Cho-Min-Naing, and Gatton, M.L. (2002).Performance appraisal of rapid on-site malaria 
diagnosis (ICT malaria Pf/Pv test) in relation to human resources at village level in Myanmar. 
Acta Tropica Journal; 81: 13-19. 
 
Clerk, C. A., Bruce, J., Affipunguh, P. K., Mensah, N., Hodgson, A., Greenwood, B. and 
Chandramohan, D. (2008). A randomized, controlled trial of intermittent preventive treatment 
with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. 
Journal of Infectious Diseases198(8): 1202-11. 
Clerk, C. A., Bruce, J., Greenwood, B. and Chandramohan, D. (2009). The epidemiology of 
malaria among pregnant women attending antenatal clinics in an area with intense and highly 
seasonal malaria transmission in northern Ghana. Tropical Medicine and International 
Health14(6): 688-95. 
Cohee, L. M., Kalilani-Phiri, L., Boudova, S., Joshi, S., Mukadam, R., Seydel, K. B., Mawindo, 
P., Thesing, P., Kamiza, S., Makwakwa, K., Muehlenbachs, A., Taylor, T.E. and Laufer, M. K. 
(2014). Submicroscopic malaria infection during pregnancy and the impact of intermittent 
preventive treatment. Malaria Journal, 13: 274. http://doi.org/10.1186/1475-2875-13-274 
 
Cottrell, G., Mary, J.Y., Barro, D. and Cot, M. (2005). Is malarial placental infection related to 
peripheral infection at any time of pregnancy? American Journal of Tropical Medicine and 
Hygiene 73: 1112-1118. 
 
Cottrell, G., Moussiliou, A., Luty, A.J.F., Cot, M., Fievet, N., Massougbodji, A., Deloron, P. and 
Ndam, N.T. (2015). Submicroscopic Plasmodium falciparum infections are associated with 
maternal anaemia, premature births and low birth weight. Clinical Infectious Diseases, 
60(10):1481-8. 
 
Coulibaly, D., Travassos, M. A., Kone, A. K., Tolo, Y., Laurens, M. B., Traore, K., Diarra, I., 
Niangaly, A., Daou, M., Dembele, A., Sissoko, M., Guindo, B., Douyon, R., Guindo, A., 
Kouriba, B., Sissoko, M. S., sagara, I., Plowe, C.V., Doumbo, O.K. and Thera, M. A. (2014). 
Stable malaria incidence despite scaling up control strategies in a malaria vaccine-testing site in 
Mali. Malaria Journal, 13:374. http://doi.org/10.1186/1475-2875-13-374 
 
Coulibaly, S. O., Nezien, D., Traore, S., Kone, B. and Magnussen, P. (2006). Therapeutic 
efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated 
malaria in pregnancy in Burkina Faso.Malaria Journal5: 49. 
Coulibaly, S. O., Kayentao, K., Taylor, S., Guirou, E. A., Khairallah, C., Guindo, N.,Djimde, M., 
Bationo, R., Soulama, A., dabira, E., Barry, B., Niangaly, M., Diakite, H., Konate, S., Traore, B., 
Meshnick, S.R., Magnussen, P., Doumbo, O. and ter Kuile, F. O. (2014). Parasite clearance 
following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in 
162  
Burkina-Faso and Mali: 42-day in vivo follow-up study. Malaria Journal, 13: 41. 
http://doi.org/10.1186/1475-2875-13-41 
 
Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO (2010) Quantifying the Number of 
Pregnancies at Risk of Malaria in 2007: A Demographic Study. PLoS Med 7(1): e1000221. 
doi:10.1371/journal.pmed.1000221 
 
Desai, M., ter Kuile, F.O., Nosten, F., McGready, R., Asamoa, K., Brabin, B. and Newman R.D. 
(2007).Epidemiology and burden of malaria in pregnancy. Lancet Infectious Disease; 7: 93-104. 
 
Desowitz, R.S. and Alpers, M.P. (1992). Placental Plasmodium falciparum parasitaemia in East 
Sepik (Papua New Guinea) women of different parity: the apparent absence of acute effects on 
mother and foetus. Annals of Tropical Medicine and Parasitology, 86(2):95-102. 
 
Diagne, N., Rogier, C., Cisse, B. and Trape, J.F. (1997). Incidence of clinical malaria in pregnant 
women exposed to intense perennial transmission. Transactions of the Royal Society of Tropical 
Medicine and Hygiene; 91(2): 166-170. 
 
Dietz, R., Perkins, M., Boulos, M., Luz, F., Reller, B. and Corey, C.R. (1995). The diagnosis of 
Plasmodium using a new antigen detection system. American Journal of Tropical Medicine and 
Hygiene, 52: 45-59. 
 
Dorman, E. and Shulman, C. (2000). Malaria in pregnancy. Current Obstetrics and 
Gynaecology, 10:183-189. 
 
Fernandes, S., Sicuri, E., Diawara, H., Akazili, J., Bojang, K., Chandramohan, D., Coulibaly, S., 
Diawara, S.I., kayentao, K., terKuile, F., Magnussen, P., Tagbor, H., Williams, J., Woukeu, A., 
Cairns, M., Greenwood, B. and Hanson, K. (2016). Cost effectiveness of intermittent screening 
and treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis 
and modelling of results from a non-inferiority trial. Malaria Journal, 15:493  
 
Fried, M. and Duffy, P. (1996). Adherence of Plasmodium falciparum to chondroitin sulfate A in 
the human placenta. Science, 272: 1502-4. 
 
Fried, M., Nosten, F., Brockman, A., Brabin, B.J. and Duffy, P.E. (1998). Maternal antibodies 
block malaria. Nature, 395(6705): 851-2. 
 
Galbraith, R.M., Faulk, W.P., Galbraith, G.M.P., and Holdbrook, T.W. (1980).The human 
materno-fetal relationship in malaria I. Indentification of pigment and parasites in the 
placenta.Transactions of the Royal Society of Tropical Medicine and Hygiene; 74: 52-60. 
 
Gasser, R.A. Jr. (2000). Continuing progress in rapid diagnostic technology for malaria: field 
trial performance of a revised immunochromatographic assay (OptiMAL) detecting 
163  
Plasmodium-specific lactate dehydrogenase. Abstract. Malaria Diagnosis Symposium, XV 
International Congress for Tropical Medicine and Malaria, Cartagena de Indies, Colombia, 20-25 
August, (2000). Abstract Vol. 1 page 179, Santa Fe de Bogota: Corcas Editore Ltda. 
 
Goonewardene, M., Mishkat, S. and Hamad, A. (2012). Anaemia in pregnancy. Best Practice & 
Research Clinical Obstetrics & Gynaecology, 26(1): 3-24. 
 
Graves, P. M., Osgood, D. E., Thomson, M. C., Sereke, K., Araia, A., Zerom, M., Ceccato, P., 
Bell, M., Corral, J. d., Ghebreselassie, S., Brantly, E. P. and Ghebremeskel, T. (2008), 
Effectiveness of malaria control during changing climate conditions in Eritrea, 1998–2003. 
Tropical Medicine & International Health, 13: 218–228. doi:10.1111/j.1365-3156.2007.01993.x 
 
 
Greenwood, B.M., Bradley, A.K., Greenwood, A.M., Byass, P., Jammeh, K., Marsh, K., Tulloch, 
S., Oldfield, F.S.J. and Hayes, R. (1987).Mortality and morbidity from malaria among children 
in a rural area of the Gambia, West Africa. Transactions of the Royal Society of Tropical 
Medicine and Hygiene, 81: 478-486. 
 
Grobusch, M.P., Apelmann, U., Schwenke, S., Jelinek, T. and Warhurst, D.C. (1999). False –
positive rapid tests for malaria in patients with rheumatoid factor. Lancet; 353: 297. 
 
Guthmann, J.P., Ruiz, A., Priotto, G., Kiguli, J., Bonte, L. and Legros, D. (2002). 
Validity,reliability and ease of use in the field of five rapid tests for the diagnosis of Plasmodium 
falciparum malaria in Uganda. Transactions of the Royal Society of Tropical Medicine and 
Hygiene; 96: 254-257. 
 
Han, E.T., Watanabe, R., Sattabongkot, J., Khuntirat, B., Sirichaisinthop, J., Iriko, H., Jin, L., 
Takeo, S. and Tsuboi, T. (2007).Detection of four Plasmodium species by genus- and species-
specific loop-mediated isothermal amplification for clinical diagnosis. Journal of Clinical 
Microbiology; 45: 2521-2528. 
Humar, A., Ohrt, C., Harrington, M. A., Pillai, D. and Kain, K.C. (1997). ParaSight-F test 
compared with the polymerase chain reaction and microscopy for the diagnosis of Plasmodium 
falciparum malaria in travelers. American Journal of Tropical Medicine and Hygiene, 56(1):44-
8. 
 
Huynh, B.-T., Fievet, N., Gbaguidi, G., Borgella, S., Mévo, B. G., Massougbodji, A., Deloron, P. 
and Cot, M. (2011). Malaria associated symptoms in pregnant women followed-up in 
Benin. Malaria Journal, 10:72. http://doi.org/10.1186/1475-2875-10-72 
Iqbal, J., Sher, A. and Rab, A. (2000). Plasmodium falciparum histidine-rich protein-2 based 
immunocapture assay for malaria: cross reactivity with rheumatoid factors. Journal of Clinical 
Microbiology; 38: 1184-1186. 
 
164  
Ismail, M.R., Ordi, J., Menendez, C., Ventura, P.J., Aponte, J.J., Kahigwa, E., Hirt, R., cardesa, 
A. and Alonso, P.L. (2000). Placental pathology in malaria: A histological, immunochemical and 
quantitative study. Human Pathology; 31: 85-93. 
 
Jelinek, T., Grobusch, M.P., Schwenke, S., Steidl, S., von Sonnenburg, F., Northdurft, H.D., 
Klein, E. and Loscher, T. (1999). Sensitivity and specificity of dipstick tests for rapid diagnosis 
of malaria in non-immune travelers. Journal of Clinical Microbiology, 37(3): 721-3. 
 
Karbwang, J., Tasanor, O., Kanda, T., Wattanagoon, Y., Ibrahim, M., Na-Bangchang, K., 
Thanavibul, A. and Rooney, W. (1996). ParaSight-F test for the detection of treatment failure in 
multidrug resistant Plasmodium falciparum malaria. Transactions of the Royal Society of tropical 
Medicine and Hygiene; 90: 513-515. 
 
Kashif, A.H., Adam, G.K., Mohammed, A.A., Elzaki, S.E., Halim, A.M., and Adam, I. (2013). 
Reliability of rapid diagnostic test for diagnosing peripheral and placental malaria in an area of 
unstable malaria transmission in eastern Sudan. Diagnostic Pathology 8: 59. 
 
Kattenberg, J.H., Ochodo, E.A., Boer, K.R. Schallig, H.D.F.H., Mens, P.F. and Leeflang, 
M.M.G. (2011). Systematic review and meta-analysis: rapid diagnostic tests versus placental 
histology, microscopy and PCR for malaria in pregnant women. Malaria Journal, 10:321. 
 
Kawamoto, F., Miyake, H., Kaneko, O., Kimura, M., Nguyen, T.D., Nguyen, T.D., Liu, Q., 
Zhou, M., Le, D.D., Kawai, S., Isomura, S. and Wataya, Y. (1996). Sequence variation in the 
18S rRNA gene, a target for PCR-based malaria diagnosis in Plasmodium ovale from Southern 
Vietnam. Journal of Clinical Microbiology, 34(9):2287-9. 
 
Kayentao, K., Kodio, M., Newman, R.D., Maiga, H., Doumtabe, D., Ongoiba, A., Coulibaly, D., 
Keita, A.S., Maiga, B., Mungai, M.m Parise, M.E. and Doumbo, O. (2005). Comparison of 
intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during 
pregnancy in Mali. Journal of Infectious Diseases; 191(1): 109-116. 
 
Kayentao, K., Garner, P., van Eijk, A. M., Naidoo, I., Roper, C., Mulokozi, A., MacArthur, J.R., 
Luntamo, M., Ashorn, P., Doumbo, O.K. and ter Kuile, F. O. (2013). Intermittent Preventive 
Therapy for Malaria During Pregnancy Using 2 vs 3 or More Doses of Sulfadoxine-
Pyrimethamine and Risk of Low Birth Weight in Africa: Systematic Review and Meta-
analysis. Journal of the American Medical Association, 309(6), 594–604. 
http://doi.org/10.1001/jama.2012.216231 
 
Kilian, A.H.D., Kabagambe, G., Byamukama, W., Langi, P., Weis, P. and von Sonnenburg, F. 
(1999). Application of the ParaSight™ -F dipstick test for malaria diagnosis in a district control 
program. Acta Tropica, 72:281-93. 
 
165  
Kodisinghe, H.M., Perera, K.L., Premawansa, S., Naotunne, T., Wickramasinghe, A.R. and 
Mendis, K.N. (1997). The ParaSight™ -F dispstick test as a routine diagnostic tool for malaria in 
Sri Lanka. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91(4): 398-402. 
 
Kyabayinze, D. J. et al. (2011). Placental Plasmodium falciparum malaria infection: Operational 
accuracy of HRP2 rapid diagnostic test in a malaria endemic setting. Malaria Journal; 10: 306. 
 
Kyabayinze, D.J., Zongo, I., Cunningham, J., Gatton, M., Angutoko, P., Ategeka, J., Compaoré, 
Y.D., Muehlenbachs, A., Mulondo, J., Nakalembe, M., Somé, F.A., Ouattara, A., Rouamba, N., 
Ouédraogo, J.B., Hopkins, H., and Bell, D. (2016). HRP2 and pLDH-Based Rapid Diagnostic 
Tests, Expert Microscopy, and PCR for Detection of Malaria Infection during Pregnancy and at 
Delivery in Areas of Varied Transmission: A Prospective Cohort Study in Burkina Faso and 
Uganda. PLoS One. 2016 Jul 5;11(7):e0156954. doi: 10.1371/journal.pone.0156954. 
 
Kilian, A.H., Kabagambe, G., Byamukama, W., Langi, P., Weis, P. and von Sonnenburg, F. 
(1999).Application of the ParaSight-F dipstick test for malaria diagnosis in a district control 
program. Acta Tropica Journal; 72: 281-293. 
 
Laferi, H., Kandel, K. and Pichler, H. (1997).False positive dipstick test for malaria. New 
England Journal of Medicine; 337: 1635-1636. 
 
Langhi, D.M. and Bordin, J.O. (2006).Duffy blood group and malaria. Hematology; 11(5): 389-
398. 
 
Lauren M. Singer, Robert D. Newman, Amidou Diarra, Allisyn C. Moran, Curtis S. Huber, Gail 
Stennies, Sodiomon B. Sirima, Amadou Konate, Mathias Yameogo, Romial 
Sawadogo, Barnwell JW and Parise ME. (2004).Evaluation of a malaria rapid diagnostic test for 
assessing the burden of malaria during pregnancy. American Journal of Tropical Medicine and 
Hygiene. 70(5): 481–485. 
 
Lee, N., Baker, J., Andrews, K.T., Gatton, M.L., Bell, D., Cheng, Q. and McCarthy, J. (2006). 
Effect of sequence variation in Plasmodium falciparum histidine-rich protein 2 on binding of 
specific monoclonal antibodies: implications for rapid diagnostic tests for malaria. Journal of 
Clinical Microbiology; 44: 2773-2778. 
 
Lee, P.-W., Liu, C.-T., Rampao, H. S., do Rosario, V. E., & Shaio, M.-F. (2010). Pre-elimination 
of malaria on the island of Príncipe. Malaria Journal, 9: 26. http://doi.org/10.1186/1475-2875-9-
26 
 
Leke, R.F.G., Djokam, R.R., Mbu, R., Leke, R.J., Fogako, J., Megnekou, R., Metenou, S., Sama, 
G., Zhou, Y., Cadigan, T., Parra, M. and Taylor, D.W. (1999). Detection of Plasmodium 
falciparum antigen Histidine-Rich Protein 2 in blood of pregnant women: implications for 
diagnosing placental malaria. Journal of Clinical Microbiology, 37(9):2992-6. 
166  
 
Maguire, J.D. and Baird, J.K. (2010). The ‘non-falciparum’ malarias: the roles of epidemiology, 
parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic 
strategies. Annals of Tropical Medicine and Parasitology; 104(4): 283-301. 
 
Malhotra, I., Dent, A., Mungai, P., Muchiri, E., and King C.L. (2005).Real-time quantitative 
PCR for determining the burden of Plasmodium falciparum parasites during pregnancy and 
infancy. Journal of Clinical Microbiology; 43: 3630-3635. 
 
Mankhambo, L., Kanjala, M., Rudman, S., Lema, V.M., Rogerson, S.J. (2002). Evaluation of 
the OptiMAL rapid antigen test and species-specific PCR to detect placental Plasmodium 
falciparum infection at delivery. Journal of Clinical Microbiology 40:155–158 
 
Maubert, B., Guilbert, L. J., & Deloron, P. (1997). Cytoadherence of Plasmodium falciparum to 
intercellular adhesion molecule 1 and chondroitin-4-sulfate expressed by the syncytiotrophoblast 
in the human placenta. Infection and Immunity, 65(4), 1251–1257. 
 
Mayengue, P. I., Rieth, H., Khattab, A., Issifou, S.,Kremsner, P. G., Klinkert, M. Q. & Ntoumi, 
F.(2004). Submicroscopic Plasmodium falciparum infections and multiplicity of infection in 
matched peripheral, placental and umbilical cord blood samples from Gabonese women. 
Tropical Medicine and International Health, 9: 949–958. 
 
Mayor, A. et al. (2009).Submicroscopic infections and long term recrudescence of Plasmodium 
falciparum in Mozambican pregnant women. Malaria Journal; 8: 9. 
 
Mayor, A., Moro, L., Aguilar, R., Bardaji, A., Cistero, P., Serra-Casas, E., Sigauque, B., Alonso, 
P.L., Ordi, J. and Menendez, C. (2012). How hidden can malaria be in pregnant women? 
Diagnosis by microscopy, placental histology, polymerase chain reaction and detection of 
histidine-rich protein 2 in plasma. Clinical Infectious Diseases, 54(11):1561-8. 
 
McDermott, J.M., Heymann, D.L., Wirima, J.J., Macheso, A.P., Wahl, R.D., Steketee, R.W. and 
Campbell, C.C. (1988). Efficacy of chemoprophylaxis in preventing Plasmodium falciparum 
parasitaemia and placental infection in pregnant women in Malawi. Transactions of the Royal 
Society of Tropical medicine and Hygiene, 82:520-523. 
 
McGregor, I.A., Wilson, M.E., and Billewicz, W.Z. (1983).Malaria infection of the placenta in 
the Gambia, West Africa; its incidence and relationship to stillbirth, birth weight and placental 
weight. Transactions of the Royal Society of Tropical Medicine and Hygiene; 77:232-244. 
 
Menard, D. et al. (2010). Plasmodium vivax clinical malaria is commonly observed in Duffy-
negative Malagasy people. Proceedings of the National Academy of Sciences (PNAS); 107(13): 
5967-5971. 
 
167  
Miller, R.S., McDaniel, P. and Wongsrichanalai, C. (2001).Following the course of malaria 
treatment by detecting parasite lactate dehydrogenase enzyme. British Journal of Haematology; 
113: 558-559. 
 
Mishra, B., Samantaray, J.C., Kumar, A. and Mirdha, B.R. (1999).Study of false positivity of 
two rapid antigen detection tests for diagnosis of Plasmodium falciparum malaria. Journal of 
Clinical Microbiology; 37: 1233. 
 
Mockenhaupt, F.P., Bedu-Addo, G., von Gaertner, C., Boye, R., Fricke, K., Hannibal, I., 
Karakaya, F., Schaller, M., Uimen, U., Acquah, P.A., Dietz, E., Eggelte,T.A. and Bienzle, U. 
(2006). Detection and clinical manifestation of placental malaria in southern Ghana. Malaria 
Journal; 5: 119. 
 
Mockenhaupt, F.P., Rong, B., Till, H., Eggelte, T.A., Beck, S., Gyasi-Sarpong, C., Thompson, 
W. N. and Bienzle, U. (2000).Submicroscopic Plasmodium falciparum infections in pregnancy in 
Ghana. Tropical Medicine and International Health; 5: 167-173. 
 
Mohammed, A. H., Salih, M. M., Elhassan, E. M., Mohmmed, A. A., Elzaki, S. E., El-Sayed, B. 
B., & Adam, I. (2013). Submicroscopic Plasmodium falciparum malaria and low birth weight in 
an area of unstable malaria transmission in Central Sudan. Malaria Journal, 12, 172. 
http://doi.org/10.1186/1475-2875-12-172 
 
Moody, A. (2002). Rapid diagnostic tests for malaria parasites. Clinical Microbiology Review; 
15:66-78. 
 
Muehlenbachs, A., Fried, M., McGready, R., Harrington, W., Mutabingwa, T.K., Nosten, F., and 
Duffy, P.E. (2010). A novel histological grading scheme for placental malaria applied in areas of 
high and low malaria transmission. Journal of Infectious Diseases; 202(10): 1608-1616. 
 
Mueller, I., Beteula, I., Ginny, M., Reeder, J.C. and Genton, B. (2007). The sensitivity of the 
OptiMAL  rapid diagnostic test to the presence of Plasmodium falciparum gametocytes 
compromises its ability to monitor treatment outcomes in an area of Papua New Guinea in which 
malaria is endemic. Journal of Clinical Microbiology; 45: 627-630.  
 
Murray, C.K., Gasser Jnr., R.A., Magill, A.J. and Miller, R.S. (2008). Update on rapid diagnostic 
testing for malaria. Clinical Microbiology Reviews; 21(1): 97-110. 
 
Naidoo, I. and Roper, C. (2010). Following the path of most resistance: dhps K540E dispersal in 
African Plasmodium falciparum. Trends in Parasitology, 26(9):447-56. 
 
168  
Nosten, F., McGready, R., Simpson, JA., Thwai, K.L., Balkan, S., Cho, T., Hkirijaroen, L., 
Looareesuwan, S. and White, N.J. (1999). Effects of Plasmodium vivax in pregnancy. Lancet; 
354: 546-549. 
 
Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., and Hase, 
T. (2000).Loop-mediated isothermal amplification of DNA.Nucleic Acids Research; 28: E63. 
 
O’Meara, W. P., Bejon, P., Mwangi, T. W., Okiro, E. A., Peshu, N., Snow, R. W., Newton, C.R. 
and Marsh, K. (2008). Effect of a fall in malaria transmission on morbidity and mortality in 
Kilifi, Kenya. Lancet, 372(9649): 1555–1562. http://doi.org/10.1016/S0140-6736 (08)61655-4 
 
Otten, M., Aregawi, M., Were, W., Karema, C., Medin, A., Bekele, W., Jima, D., Khoti, G., 
Komatsu, R., Korenromp E., Low-Beer, D. and Grabowsky, M. (2009). Initial evidence of 
reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria 
prevention and treatment. Malaria Journal, 8:14. http://doi.org/10.1186/1475-2875-8-14 
 
Pieroni, P., Mills, C.D., Ohrt, C., Harrington, M.A. and Kain, K.C. (1998). Comparison of the 
ParaSight-F test and the KT Malaria Pf test with the polymerase chain reaction for the diagnosis 
of Plasmodium falciparum malaria in travelers. Transactions of the Royal Society of Tropical 
Medicine and Hygiene, 92(2):166-9. 
 
Poon, L.L., Wong, B.W., Ma, E.H., Chan, K.H., Chow, L.M., Abeyewickreme, W., Tangpukdee, 
N., Yuen, K.Y., Guan, Y., Looareesuwan, S. and Peiris, J.S. (2006). Sensitive and inexpensive 
molecular test for falciparum malaria: detecting Plasmodium falciparum DNA directly from 
heat-treated blood by loop-mediated isothermal amplification. Clinical Chemistry; 52: 303-306. 
 
Poschl, B., Waneesorn, J., Thekisoe, O., Chutipongvivate, S. and Panagiotis, K. 
(2010).Comparative diagnosis of malaria infections by microscopy, nested PCR and LAMP in 
northern Thailand. American Journal of Tropical Medicine and Hygiene; 83(1): 56-60. 
 
Premji, Z., Minjas, J.N. and Shiff, C.J. (1994). Laboratory diagnosis of malaria by village health 
workers using the rapid manual ParaSight™-F test. Transactions of the Royal Society of Tropical 
Medicine and Hygiene, 88(4):418. 
 
Ramroth, H., Ndugwa, R. P., Müller, O., Yé, Y., Sié, A., Kouyaté, B., & Becher, H. (2009). 
Decreasing childhood mortality and increasing proportion of malaria deaths in rural Burkina 
Faso. Global Health Action, 2, 10.3402/gha.v2i0.1909. http://doi.org/10.3402/gha.v2i0.1909 
 
Rantala, A-M., Taylor, S.M., Trottman, P.A., Luntamo, M., Mbewe, B., Maleta, K., Kulmala, T., 
Ashorn, P. and Meshnick, S. (2010). Comparison of real-time PCR and microscopy for malaria 
parasite detection in Malawian women. Malaria Journal; 9: 269. 
 
169  
Reeder, J. C., Cowman, A. F., Davern, K. M., Beeson, J. G., Thompson, J. K., Rogerson, S. J., & 
Brown, G. V. (1999). The adhesion of Plasmodium falciparum-infected erythrocytes to 
chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. Proceedings 
of the National Academy of Sciences of the United States of America, 96(9), 5198–5202. 
 
Richter, J., Gobels, K., Muller-Stover, I., Hoppenheit, B. and Haussinger, D. (2004).Co-
reactivity of plasmodial histidine-rich protein 2 and aldolase on a combined immune-
chromatographic malaria dipstick (ICT) as a potential semi-quantitative marker of high 
Plasmodium falciparum parasitaemia. Parasitology Research; 94: 384-385. 
 
Ricke, C.H., Staalsoe, T., Koram, K., Akanmori, B.D., Riley, E.M., Theander, T.G., and Hviid, 
L. (2000). Plasma antibodies from malaria-exposed pregnant women recognise variant surface 
antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and 
block parasite adhesion to chondroitin sulfate A. Journal of Immunology; 165:3309-3316. 
 
Riley, E. M., Hviid, L. and Theander, T. G. (1994). Malaria. In Parasitic Infections and the 
Immune System. F. Kierszenbaum,ed. Academic Press, New York, pp 119-143. 
 
Rogerson, S.J., Pollina, E., Getachew, A., Tadesse, E., Lema, V.M., and Molyneux, M.E. (2003). 
Placental monocyte infiltrates in response to Plasmodium Falciparum malaria infection and their 
association with adverse pregnancy outcomes. American Journal of Tropical Medicine and 
Hygiene; 68: 115-119. 
 
Rogerson, S.J., Mkundika, P. and Kanjala, M.K. (2003). Diagnosis of Plasmodium falciparum 
malaria at delivery: comparison of blood film preparation methods and of blood film with 
histology. Journal of Clinical Microbiology; 41: 1370-1374. 
 
Rogerson, S.J., Hviid, L., Duffy, P.E., Leke, R. F., and Taylor, D.W. (2007). Malaria in 
pregnancy: pathogenesis and immunity. Lancet Infectious Diseases; 7:105-17.  
 
Ruebush,T.K., Kern, M.K., Campbell, C.C., and Oloo, A.J. (1995). Self-treatment of malaria in a 
rural area of western Kenya. Bulletin of the World Health Organisation; 73: 229-236. 
 
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A.T., Sowa, M.P., Arnot, D.E., Hviid, L. and 
Theander, T.G. (2003). Selective upregulation of a single distinctly structured var gene in 
chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated 
malaria; Molecular Microbiology; 49(1): 179-191. 
 
Sanci, M., Toz, E., Ince, O., Ozcan, A., Polanter, K., Inan, A.H., Beyan, E. and Akkaya, E. 
(2017). Reference values for maternal total and differential leukocyte counts in different 
trimesters of pregnancy and the initial postpartum period in western Turkey. Journal of 
Obstetrics and Gynaecology, 37(5): 571-575. 
170  
 
Saute, F., Menendez, C., Mayor, A., Aponte, J., Gomez-Olive, X., Dgedge, M. & Alonso, P. 
(2002).Malaria in pregnancy in rural Mozambique: the role of parity, submicroscopic and 
multiple Plasmodium falciparum infections. Tropical Medicine and International Health; 7: 19-
28. 
 
Schleiermacher, D., Rorier, C., Spiegel, A., Tall, A., Trape, J-F.and Mercereau-Puijalon, O. 
(2001). Increased multiplicity of Plasmodium falciparum infections and skewed distribution of 
individual MSP1 and MSP 2 alleles during pregnancy in Ndiop, a Senegalese village with 
seasonal mesoendemic malaria. American Journal of tropical Medicine and Hygiene; 64: 303-
309. 
 
Schoone, G.J., Oskam, L., Kroon, N.C.M., Schallig, H.D.F.H. and Omar, S.A. (2000).Detection 
and quantification of Plasmodium falciparum in blood samples using quantitative nucleic acid 
sequence-based amplification. Journal of Clinical Microbiology; 38: 4072-4075 
 
Schneider, P., Wolters, L., Schoone, G., Schallig, H., Sillekens, P., Hermsen, R. and Sauerwein, 
R. (2005). Real-time nucleic acid sequence-based amplification is more convenient than real-
time PCR for quantification of Plasmodium falciparum. Journal of Clinical Microbiology; 43: 
402-405. 
 
Seesod, N., Lundberg, J., Hedrum, A., Aslund, L., Holder, A., Thaithong, S. and Uhlen, M. 
(1993). Immunomagnetic purification to facilitate DNA diagnosis of Plasmodium falciparum. 
Journal of Clinical Microbiology, 31(10):2715-9. 
 
Sethabutr, O., Brown, A.E., Panyim, S., Kain, K.C., Webster, H.K. and Echeverria, P. (1992). 
Detection of Plasmodium falciparum by polymerase chain reaction in a field study. Journal of 
Infectious Diseases, 166(1):145-8. 
 
Shulman,C.E, Marshall, T., Dorman, E.K et al. (2001). Malaria in pregnancy: Adverse effects on 
haemoglobin levels and birthweight in primigravidae and multigravidae. Tropical Medicine and 
International Health. 6: 770-778.  
 
Singer, L.M., Newman, R.D., Diarra, A., Moran, A.C., Huber, C.S., Stennies, G., Sirima, S.B., 
Konate, A., Yameogo, M., Sawadogo, R., Barmwell, J.W., and Parise, M.E. (2004). Evaluation 
of a malaria rapid diagnostic test for assessing the burden of malaria during pregnancy. American 
Journal of Tropical Medicine and Hygiene; 70(5): 481-5.  
 
Singh, N., Valecha, N., Nagpal, A.C., Mishra, S.S., Varma, H.S. and Subbarao, S.K. (2003). The 
hospital and field-based performances of the OptiMAL test for malaria diagnosis and treatment 
monitoring in central India. Annals of Tropical Medicine and Parasitology; 97: 5-13. 
 
171  
Singh, N., Shukla, M. M., Shukla, M. K., Mehra, R. K., Sharma, S., Bharti, P.K., Singh, M.P. 
and Gunasekar, A. (2010). Field and laboratory comparative evaluation of rapid malaria 
diagnostic tests versus traditional and molecular techniques in India. Malaria Journal, 9: 191. 
http://doi.org/10.1186/1475-2875-9-191 
 
Singh, N., Bharti, P. K., Singh, M. P., Singh, R., Yeboah-Antwi, K., Desai, M., Udhayakumar, 
V., Muniyandi, M., Hamer, D.H., and Wylie, B. J. (2015). What is the burden of submicroscopic 
malaria in pregnancy in central India? Pathogens and Global Health, 109(1): 30–38. 
http://doi.org/10.1179/2047773215Y.0000000002 
 
Snounou, G., Viriyakosol, S., Jarra.W., Thaithong, S. and Brown, K.N. (1993). Identification of 
the four main human malarial species in field samples by the polymerase chain reaction and 
detection of a high prevalence of mixed infections. Molecular Biochemistry and Parasitology; 
58: 283-292. 
 
Steketee, R.W., Nahlen, B.L., Parise, M.E. and Menendez, C. (2001). The burden of malaria in 
pregnancy in malaria-endemic areas. American Journal of Tropical Medicine and Hygiene; 64 
(1-2 suppl): 28-35. 
 
Steketee, R.W. et al. (1996). The effect of malaria and malaria prevention in pregnancy on 
offspring birthweight, prematurity and intrauterine growth retardation n rural Malawi. American 
Journal of Tropical Medicine and Hygiene; 55(1): 33-41 
 
Swarthout, T.D., Counihan, H., Senga, R.K. and Van den Broek, I. (2007). Paracheck-Pf 
accuracy and recently treated Plasmodium falciparum infections: is there a risk of over-
diagnosis? Malaria Journal; 6: 58. 
 
Tagbor, H., Bruce, J., Browne, E., Greenwood, B., and Chandramohan, D. (2008).Performance 
of the OptiMAL® dipstick in the diagnosis of malaria infection in pregnancy. Therapeutics and 
Clinical Risk Management; 4(3): 631-636. 
 
Tagbor, H., Bruce, J., Browne, E., Greenwood, B. and Chandramohan, D. (2008). Malaria in 
pregnancy in an area of stable and intense transmission: is it asymptomatic? Tropical Medicine 
and International Health. 13: 1016-1021. 
 
Tagbor, H., Cairns, M., Bojang, K., Coulibaly, S. O., Kayentao, K., Williams, J., Abubakar, I., 
Akor, F., Mohammed, K., Dabira, E., Soulama, A., Djimde, M., Guirou, E., Awine, T., Quaye, 
S., Njie, F., Ordi, J., Doumbo, O., Hodgson, A., Oduro, A., Meshnik, S., Taylor, S., Magnussen, 
P., ter Kuile, F., Woukeu, A., Milligan, P., Chandramohan, D. and Greenwood, B. (2015). A 
Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus 
Intermittent Preventive Treatment in the Control of Malaria in Pregnancy. PLoS ONE, 10(8), 
e0132247. http://doi.org/10.1371/journal.pone.0132247 
 
172  
 
Teklehaimanot, H.D., Teklehaimanot, A., Kiszewski, A., Rampao, H.S. and Sachs, J.D. (2009). 
Malaria in São Tomé and Principe: On the Brink of Elimination after Three Years of Effective 
Antimalarial Measures. American Journal of Tropical Medicine and Hygiene, 80(1): 133–140. 
 
Tjitra, E., Suprianto, S., Dyer, M., Currie, B.J. and Anstey, N.M. (1999).Field evaluation of the 
ICT malaria P.f/P.v immunochromatographic test for detection of Plasmodium falciparum and 
Plasmodium vivax in patients with presumptive clinical diagnosis of malaria in eastern 
Indonesia. Journal of Clinical Microbiology; 37: 2412-2417. 
 
Trape, J-F., et al (1994). The Dielmo Project: A longitudinal study of natural malaria infection 
and the mechanisms of protective immunity in a community living in a holoendemic area of 
Senegal. American Journal of Tropical Medicine and Hygiene 51(2): 123-137. 
 
Umbers, A.J., Aitken, E.H. and Rogerson, S.J. (2011). Malaria in pregnancy: small babies, big 
problem. Trends in Parasitology; 27(4): 168-175. 
 
Uneke, C.J. (2008). Diagnosis of Plasmodium falciparum malaria in pregnancy in sub-Saharan 
Africa: the challenges and public health implications. Parasitology Research; 102: 333-342. 
 
UNICEF (2016). Malaria rapid diagnostic tests market and supply update. UNICEF Supply 
Division, New York. 
 
VanderJagt, T. A., Ikeh, E. I., Ujah, I. O. A., Belmonte, J., Glew, R. H. and VanderJagt, D. J. 
(2005), Short communication: Comparison of the OptiMAL rapid test and microscopy for 
detection of malaria in pregnant women in Nigeria. Tropical Medicine & International Health, 
10: 39–41. doi:10.1111/j.1365-3156.2004.01349.x 
 
Verhoeff, F.H., Brabin, B.J., Chimsuku, L., Kazembe, P. and Broadhead, R.L. (1999). Malaria in 
pregnancy and its consequences for the infant in rural Malawi. Annals of Tropical Medicine and 
Parasitology, 93 Suppl 1:S25-33. 
 
Wagner, G., Korman, K., McGuinness, D., Bennett,S., Nkrumah, F. and Riley, E. (1998). High 
incidence of symptomatic malaria infections in a birth cohort of children less than one year of 
age in Ghana detected by multiplicity gene polymerase chain reaction. American Journal of 
Tropical Medicine and Hygiene;59: 115–123. 
 
Walker-Abbey, A., Djokam, R.R., Eno, A., Leke, R.F., Fogako, J., Sama, G., Thuita, L.H., 
Beardslee, E., snounou, G., Zhou, A. and Taylor, D.W. (2005). Malaria in Cameroonian women: 
the effect of age and gravidity on sub-microscopic and mixed-species infections and multiple 
parasite genotypes. American Journal of Tropical Medicine and Hygiene; 72(3): 229-35. 
 
173  
Walter, P.R., Garin, Y. and Blot, P.(1982). Placental pathological changes in malaria: a 
histological and ultrastructural study. American Journal of Pathology; 109:330-42. 
 
Warhurst, D.C. and Williams, J.E. (1996).Laboratory diagnosis of malaria. Journal of Clinical 
Pathology; 49: 533-538. 
 
Wataya, Y., Kubochi, F., Mizukoshi, C., Ohya, Y., Watanabe, K., Arai, M., Ishii, A., Nakagami, 
S. and Yamane, A. (1991). DNA diagnosis of falciparum malaria. Nucleic Acid Symposium 
Series, 25:155-6. 
 
Wataya, Y., Arai, M., Kubochi, F., Mizukoshi, C., Kakutani, T., Ohta, N. and Ishii, A. (1993). 
DNA diagnosis of falciparum malaria using a double PCR technique: a field trial in the Solomon 
Islands. Molecular Biochemistry and Parasitology, 58(1): 165-7. 
 
White, N. J. (2005). Intermittent Presumptive Treatment for Malaria. PLoS Medicine, 2(1), e3. 
http://doi.org/10.1371/journal.pmed.0020003 
 
Williams, J.E., Cairns, M., Quaye, S.L., Awine, T., Oduro, A., Tagbor, H., Bojang, K., 
Magnussen, P., Ter Kuile, F., Wokeu, A., Milligan, P., Chandramohan, D., and Greenwood, B. 
(2015). The performance of a rapid diagnostic test in detecting malaria infection in pregnant 
women and the impact of missed infections. Journal of Clinical Infectious Diseases, doi: 
10.1093/cid/civ1198. 
 
Wongsrichanalai, C., Barcus, M.J., Muth, S., Sutamihardja, A. and Wernsdorfer, W.H. (2007). A 
review of malaria diagnostic tools: Microscopy and rapid diagnostic test (RDT). American 
Journal of Tropical Medicine and Hygiene; 77 (Suppl 6): 119-127. 
 
World Health Organisation. (2000). Expert Committee on Malaria. WHO technical report series 
892, i-v. World Health Organisation, Geneva. 
 
World Health Organisation. (2000b). Malaria Diagnosis New Perspectives, Report of a Joint 
WHO/USAID Informal Consultation October 25-27, 2000. World Health Organisation, Geneva. 
 
World Health Organisation. (2004) A Strategic Framework for Malaria Prevention and Control 
During Pregnancy in the African Region. WHO Regional Office for Africa, Brazzaville. 
 
World Health Organisation. (2011). Malaria rapid diagnostic test performance: results of WHO 
product testing of malaria RDTs: round 3 (2010-2011). World Health Organisation, Geneva. 
 
World Health Organization. (2012). WHO Policy Recommendation: Seasonal Malaria 
Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal 
transmission areas of the Sahel sub-region in Africa. World Health Organization. 
 
174  
World Health Organization. (2013) WHO policy brief for the implementation of intermittent 
preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). 
Geneva, Switzerland: WHO 
 
World Health Organization. (2015). Malaria rapid diagnostic test performance: summary results 
of WHO product testing of malaria RDTs: rounds 1-6 (2008-2015). World Health Organization, 
Geneva. 
 
World Health Organisation. World Malaria Report (2016). Geneva: World Health Organisation, 
2016. 
 
Yamada, M., Steketee, R., Abramowsky, C., Kida, M., Wirima, J., Heymann, D., Rabbege, J., 
Breman, J. and Aikawa, M. (1989). Plasmodium falciparum associated placental pathology: A 
light and electron microscopic and immunohistologic study. American Journal of Tropical 
Medicine and Hygiene; 41: 161-167. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175  
APPENDIX 1 
Data Collection Forms 
 
10.1 Screening Form 
 
176  
10.2 Demography Form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
177  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
178  
10.3 Medical and Obstetric Assessment Form 
 
 
 
 
 
 
179  
10.4 Obstetric Assessment Form 
 
  
 
180  
10.5 Physical Exam Form 
 
 
 
 
181  
10.6 Treatment Form 
 
 
182  
10.7 Intervention Period Follow-Up Form 
 
 
 
183  
10.8 Illness Complaint Form 
 
  
 
184  
10.9 Birth Assessment Form 
 
185  
 
186  
 
187  
 
188  
10.10 Placental History Form 
 
 
  
189  
 
 
 
 
190  
10.11 Parasitology Form 
 
 
 
191  
10.12 PCR – Molecular Analysis Form 
 
 
192  
APPENDIX 2 
Ethics Approvals and Laboratory SOPs 
 
193  
 
194  
 
195  
 
 
 
 
 
196  
 
197  
 
198  
 
199  
 
200  
 
201  
 
202  
 
203  
 
204  
 
205  
 
 
206  
 
Standard Operating Procedure (SOP) for detection of Plasmodium 
infection using Nested PCR Assay. 
 
 
Scope 
Date: June, 2010 
Version: 1.02 
This SOP describes the procedure for routine diagnostic PCR to detect infection by Plasmodium 
species at the Malaria Diagnostics Unit, MRC (UK) The Gambia. 
 
Background 
PCR Diagnosis of Malaria is based on amplifying malaria parasite-specific DNA sequences usually in a 
nested PCR format involving two rounds of amplification reaction. The target DNA sequence is the 18S 
rRNA gene which is multi-copy and contains genus and specie-specific variations that are exploited to 
design discriminatory assays (Snounou et al. 1993, Mol Biochem Parasitol 61: 315-20; Rougemont et al., 2004, J. Clin. 
Microbiol 42: 5636–5643). 
 
Safety considerations 
Laboratory coats and gloves should be worn at all times; gloves should be changed at regular intervals. 
Ethidium bromide is a mutagen, handle and dispose of with extreme care. 
Face and eyes should be protected with a screen or visor when using UV light. 
 
Anti-contamination considerations 
DNA extraction, PCR set-up and post-PCR procedures should be carried out in separate, designated 
areas of the lab. Use of aerosol resistant tips, dedicated pipettes and the frequent changing of gloves 
also help to prevent cross contamination of samples. 
 
Preparation and storage of reagents 
PCR stock reagents (eg primers at 100mM) and enzymes should be stored at -20ºC. 
Working dilutions of PCR reagents (10X buffer, dNTPs, MgCl2, primers at 10uM) can be stored in the 
fridge if in frequent use but at -20ºC for longer term storage (ie over one week). 
Similarly, working aliquots of sample and control DNA and Nest 1 products can be kept in the fridge if 
in daily use but must be kept at -20ºC for longer term storage. 
 
Summary of Procedure 
• Starting with already extracted DNA* carry out diagnostic PCR as below: 
• Nest-1 PCR with primers rPLU5 + rPLU6; include positive controls for each species 
(falciparum, ovale, malariae & vivax) and negative control of PCR mix without DNA. 
• Run Nest-2 PCR reaction to determine presence of Plasmodium infection using the genus-
specific primers, Plasmo-1 + Plasmo-2. 
*See DNA extraction SOP. 
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• Determine the specific Plasmodium species by running four (4) parallel Nest-2 PCR assays (for 
only positive samples!). Use the primers indicated below to set up separate reaction master 
mixes to amplify species-specific sequences: 
• P. falciparum use rFAL 1 + rFAL 2. 
• P. malariae use rMAL 1 + rMAL 2. 
• P. ovale use rOVA 1 + rOVA 2. 
• P. vivax use rVIV 1 + rVIV 2. 
• Load 5-10μl of Nest-2 product on a 2% agarose gel containing Ethidium bromide and carry 
out electrophoresis for 30-45mins at 100v. Photograph the completed gel under UV light using 
the gel documentation system. 
• Score results as presence or absence of bands by comparing with control bands. Two 
individuals should independently score each gel. Discordant scores should be reviewed by a 
supervisor and repeated if unresolved. 
 
PCR Protocol 
1. Include positive and negative controls into final sample number ensuring that all the species 
controls are included at the Nest1 stage. A 96-well plate will accommodate 88 samples with 
one column left for controls. 
2. Calculate volume of PCR Master Mix enough for samples +8 to account for pippetting loss and 
dead volume that will be left in the reaction trough– eg. if total number of samples is 80, 
make enough Master Mix for 88. 
3. Make plate plan with detailed notes in the lab book – date, experiment, list of samples to be 
amplified, target gene for amplification, whether Nest-1 or Nest-2, PCR Master Mix recipe etc. 
4. Thaw, vortex briefly and spin down all PCR reagents, except Taq polymerase enzyme. 
5. Add PCR reagents together in a clean trough in the order listed in the master mix 
preparation table below. This should be done in a clean, DNA-free environment – 
preferably a clean, sterile hood with laminar air flow or a designated area. Use dedicated 
pre-PCR pipettes. 
6. Keep Taq polymerase enzyme in an ice box or in the freezer until all other reagents have 
been added. 
7. Mix by pipetting up and down several times with a wide bore pipette tip (P1000) while tilting 
the trough slightly with the pipette tip fully immersed to avoid foaming. 
8. Label clean, sterile PCR plates with sample/N1 or N2/gene/date/operator etc as 
necessary (you can never include too much information!) 
9. Dispense Master Mix into the labelled clean, sterile PCR plates according to plate plan (13µl 
for Nest-1 reactions, 19-29µl for Nest-2 reactions as appropriate). 
10. . Spin down DNA or Nest 1 product briefly before opening (quick spin at max speed). 
11. . Add DNA (2µl) or Nest-1 product (1µl) to relevant sample according to the plate plan. Seal 
plate carefully, do a quick spin down and place on PCR machine and start the appropriate 
cycling programme (see PCR cycling condition below). 
12. . After PCR has finished, spin plate briefly. Store in fridge or at -20°C for further use or 
proceed to gel electrophoresis for Nest-2 reaction product . 
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Preparation of PCR Master Mix 
 
Outer PCR (Nest I) 15µL 
 Stock 
conc. 
Final 
conc. 
1X 
(µL) 
105X 
(µL) 
  
PCR H2O   10.12 1062.6   
Buffer 
(Thermopol) 
10X 1X 1.5 157.5   
rPLU5 10 µM 0.4 µM 0.6 63   
rPLU6 10 µM 0.4 µM 0.6 63   
dNTPs 50 mM 0.2 mM 
ea 
0.06 6.3   
Taq 5 U/µL 0.6 U 0.12 12.6   
DNA   2.0    
 
 
Inner PCR (Nest-2) 15µL 
 Stock 
conc. 
Final conc. 1X 
(µL) 
105X 
(µL) 
  
PCR H2O   11.42 1199.1   
Buffer 
(Thermopol) 
10X 1X 1.5 157.5   
Primer 1 10 µM 0.3 µM 0.45 47.25   
Primer 2 10 µM 0.3 µM 0.45 47.25   
dNTPs 50 mM 0.2 mM ea 0.06 6.3   
Taq 5 U/µL 0.6 U 0.12 12.6   
PCR product   1.0    
 
*Buffer from New England Biolabs; contain MgCl2 at 1.5mM conc 
Changes in total volume requirements: as a guide, the volume of Taq and primers remains the same. 
The volume of dNTPs (2.5mM each) and 10x reaction buffer is always 10% of the total volume. 
Adjust water accordingly. This assumes total volume to a maximum of 50µl per sample. 
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Sequences of 18s rDNA primers for Plasmodium diagnostic PCR 
Gene Primers Sequence Product 
size 
18SrRNA Nest-1 forward 
rPLU5 
5'-CCTGTTGTTGCCTTAAACTTC-3' 1,200 bp 
 Nest-1 reverse 
rPLU6 
5'-TTAAAATTGTTGCAGTTAAAACG-3'  
 Nest-2 forward 
Plasmo 1 
5'-GTTAAGGGAGTGAAGACGATCAGA-3' 157-165 bp 
 Nest-2 reverse 
Plasmo 2 
5'-AACCCAAAGACTTTGATTTCTCATAA-3'  
 Nest-2 forward 
rFAL 1 
5'-TTAAACTGGTTTGGGAAAACCAAATATATT-3' 205 bp 
 Nest-2 reverse 
rFAL 2 
5'-ACACAATGAACTCAATCATGACTACCCGTC-3'  
 Nest-2 forward 
rMAL 1 
5'-ATAACATAGTTGTACGTTAAGAATAACCGC-3' 144 bp 
 Nest-2 reverse 
rMAL 2 
5'-AAAATTCCCATGCATAAAAAATTATACAAA-3'  
 Nest-2 forward 
rOVA 1 
5'-ATCTCTTTTGCTATTTTTTAGTATTGGAGA-3' 800 bp 
 Nest-2 reverse 
rOVA 2 
5'-GGAAAAGGACACATTAATTGTATCCTAGTG-3'  
 Nest-2 forward 
rVIV 1 
5'-CGCTTCTAGCTTAATCCACATAACTGATAC-3' 120 bp 
 Nest-2 reverse 
rVIV 2 
5'-ACTTCCAAGCCGAAGCAAAGAAAGTCCTTA-3'  
 
 
 
Nest1: 
rPLU5 + rPLU6 
PCR Cycling Conditions: 
- 94°C3min / (94°C30secs – 58°C30secs – 72°C60secs x24) / 72°C5min/End. 
 
Nest2: 
Plasmo1 + Plasmo2 
- 94°C3min / (94°C30secs – 58°C30secs – 72°C45secs x29) / 72°C5min/End. 
 
Nest2: 
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rFAL1 + rFAL2; rMAL1 + rMAL2; rOVA1 + rOVA2; rVIV1 + rVIV2 
- 94°C3min / (94°C30secs – 60°C30secs – 72°C45secs x29) / 72°C5min/End. 
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Agarose Gel Electrophoresis 
 
1. Prepare 10X TBE stock buffer as below: 
For 1 litre, weigh out: 
Tris base 108g 
Boric acid 55g 
EDTA (di-sodium salt) 9.3g 
 
Add 900mL deionized water, mix on a magnetic stirrer until dissolved. Make up to 1litre 
in a measuring cylinder. 
 
2. TBE buffer is used at 0.5X concentration for making agarose gels and for use as running 
buffer. Dilute stock TBE 1:20 (1 part TBE stock + 19 parts de-ionized water) to obtain working 
concentration of 0.5X 
 
3. Add 0.5X TBE and agarose to a conical flask, mix for a few minutes to hydrate agarose, and 
melt agarose in microwave. 
To make 150ml of 2% agarose gel 
0.5X TBE 150ml 
Agarose 3g 
(Smaller DNA fragments will require higher concentration gels eg 2.5%) 
 
4. Allow to cool until warm to touch while stirring to avoid gelling, add Ethidium bromide 
(10mg/ml stock solution) to a final concentration of 0.5µg/ml and mix well. Try not to 
introduce bubbles. 
Example; for a 100ml gel, add 5µl Ethidium bromide stock 
 
5. While the agarose is cooling, place gel casting tray on a level surface and seal ends with 
paper tape or silicone casting gates 
 
6. Insert comb(s) and carefully pour agarose solution into tray. 
 
7. Leave to set for 30mins or longer and then remove ends and combs from gel tray, place in 
tank and cover gel with 0.5X TBE buffer to a depth of 2-5mm. 
 
9. Mix 2µl of 6X loading buffer with 5-10µl Nest 2 product and load into the well. 
 
10. Load 6µl molecular weight marker (100bp ladder) on every first well followed by the 
controls and then samples. Follow a particular order for loading samples for each project and 
note this in the lab book. 
 
11. Connect the electrophoresis plate and run at approx 3-5volts/cm (100v for a 20cm gel) for 
30 mins-1hour (depending on degree of separation required) 
 
12. Visualise bands by placing gel on UV transilluminator. Capture gel photo using the geldoc 
system, save and print a copy of gel picture for scoring. 
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Nested PoTRA protocol for distinguishing between P.o. curtisi and wallikeri 
NEST 1 
Reagent Final Concentration Volume 
Nuclease-free H2O  8.0µl 
10X NH4 Buffer 1X 2.0 
50mM MgCl2 2mM 0.8 
10mM dNTPs 1.0mM 2.0 
10µM PoTRA fwd 3 0.5µM 1.0 
10µMPoTRA rev 3  0.5µM 1.0 
5U BioTaq 1U 0.2 
DNA  5.0 
Total volume  20.0 
 
NEST 2 
Reagent Final Concentration Volume 
Nuclease-free H2O  12.0 
10X NH4 Buffer  2.0 
50mM MgCl2  0.8 
10mM dNTPs  2.0 
10µM PoTRA fwd 5  1.0 
10µM PoTRA rev 5  1.0 
5U BioTaq  0.2 
1° Amplicon  1.0 
Total volume  20.0 
 
Primer sequence 
Cycling conditions 
PCR Primer sequences and reaction conditions used in PoTRA and PoRBP2 amplification 
reactions 
Gene Primer 
name 
Primer sequence PCR 
product 
size(bp) 
PCR cycling conditions 
PoTRA PoTRA fwd3 
 
PoTRA rev3 
5’-GCACAAAAATGGTGCTAACC-3’ 
 
5’-ATCCATTTACCTTCCATTGC-3’ 
      787 95°C for 2min ; (95°C for 30s ; 58°C for 45s ; 
72°C for 1min) x 35cycles ; 72°C for 5min 
 PoTRA fwd5 
 
PoTRA rev5 
5’-ACGGCAAACCCGATAAACAC-3’ 
 
5’-GTGTTTGTAGTATTTACAGG-3’ 
299bp 95°C for 2min ; (95°C for 30s ; 52°C for 45s ; 
68°C for 1min) x 29cycles ; 68°C for 5min 
 
PCR product size: Poc 299bp; Pow 245bp.  
Note: There is another Poc with 6 extra repeats about 319bp.  
Run on 1.5% agarose gel stained with ethidium bromide and run at 120V 
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APPENDIX 3 
Participant Information Sheet and Consent form 
Title: Intermittent preventive treatment with sulphadoxine-pyrimethamine versus intermittent 
screening and treatment of malaria in pregnancy 
Investigators: Local Investigators  
The following will be translated into appropriate local languages. 
Malaria in pregnancy is life threatening to both the mother and the baby she is carrying. It can 
result in the destruction of the mother’s blood and in babies born weighing less than normal, 
making them less healthy in their first years of life. Over the years, effective measures have 
been taken to control the harmful effects of malaria in pregnancy and this has resulted in less 
pregnant women suffering from malaria than previously in our country, as in many parts of 
Africa. Scientists now think it is time to find out whether one of these measures called 
intermittent preventive treatment (IPTp), which requires that pregnant women are given a 
malaria drug called SP on several occasions during pregnancy, is still useful particularly in 
areas like ours where pregnant women are at risk for only a short period of the year.   
We in Burkina Faso, Ghana, Mali, and the Gambia wish to test this idea in two groups 
of pregnant women. One group will have a blood test for malaria and treatment of 
anyone who is positive at scheduled antenatal clinic visits; the second group of 
pregnant women will be given the drugs two or more times as is currently done. When 
women in the two groups deliver we will compare the strength of their blood and the 
weight of their babies and take a sample of the placenta to see if this has been infected 
with malaria. This will help us to know which strategy is more effective in protecting 
pregnant women from having low birth weight babies and anaemia due to malaria 
infection.  We would like you to help us do this by participating in the study. If you 
agree to participate in this study, you will be one of 5000 women in Ghana, Burkina 
Faso, The Gambia and Mali also participating in the study. The findings will help the 
Ministry of Health to better control malaria in pregnancy. 
If you agree to participate in this study, this is what this will involve. 
1. We will ask you some questions about yourself including your general health, your 
education level and living conditions. 
2. We will take a little blood by a prick of your fingertip to test for malaria and thinning 
of blood to help us know your health status at the beginning of the study. The blood 
samples will not be used for any other purpose without your permission. 
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3. You will be allocated to one of the two options by lottery. You will receive a long-
lasting insecticide treated bed net and will be expected to use it throughout your 
pregnancy. We will visit your home at random to find out whether you are using it. 
4. If we find malaria parasites in your blood you will be given treatment. You will be 
required to return to the clinic on dates we give you.  
5. If you are included in the group that requires us to test you for malaria and treat if this 
is found on the blood test, we will do this on the dates we give you. If you are 
allocated to the group to receive treatment as is currently practiced you will be given 
the next dose of SP. 
6. We will ask you to deliver at hospital so that we can examine and weigh your baby, 
check the thinning of your blood and obtain a sample of your placenta. However, if 
you are unable to deliver at hospital please notify us through a member of your 
community health committee so that we can visit you at home and do the necessary 
tests on you and your baby as soon as possible after it is born. 
7. When your baby is 40 days old we will visit you to find out how you and the baby are 
doing and take blood by finger prick to test for malaria parasite and thinning of blood. 
This visit marks the completion of your participation in this study. 
From today until the time you deliver you will not be required to pay for any treatment you 
receive as part of this study. This includes other visits you may make for other illnesses on 
days other than those we gave you.  Every medicine including those for treating malaria and 
strengthening your blood will be free. There will be someone at the clinic to attend to you 
anytime you come in between scheduled visits.    
Any information we have about you will not be disclosed to anyone by us. Participation in 
this study is voluntary. If you do not wish to participate in the study, it will not affect the 
regular attention you have been receiving from this hospital/health centre now or in the future. 
You may withdraw from the study at any time without this affecting the care that you receive 
at the antenatal clinic. 
We are happy to answer any questions you may have that will help you decide whether or not 
you want to take part in the study, or to explain further what taking part in this study will 
mean for you and your baby. 
 
 
CONSENT: 
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I have been adequately informed of (I have read and understood) the purpose, procedures, 
potential risks and benefits of this study. I have had the opportunity to ask questions about the 
study. Any questions that I have asked have been answered to my satisfaction. I know that I 
can refuse to participate in this study without any loss of benefit to which I would have 
otherwise been entitled. I understand that if I agree to participate, I can withdraw my consent 
at any time without losing any benefits or services to which I am entitled. I understand that any 
information collected will be treated confidentially. I understand that agreeing to participate 
and signing this form does not necessarily mean I will be able to participate in the study because 
I will be assessed for eligibility before enrolment. 
I freely agree to participate in the study. After signing below, I will receive a copy each of the 
information sheet and the consent form. 
 
Name of participant: 
………………………………………………………………………………. 
 
Signature or Right Thumb Print: ………………… 
 
Date:  -----/-----/----- 
 
 
Name of witness: 
………………………………………………………………………………….. 
 
Signature or Right Thumb Print: ………………….. 
 
Date: -----/-----/----- 
 
I have adequately informed the participant of the purpose, procedures, potential risks and 
benefits of this study. I have answered all questions to the best of my ability. 
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Name of study personnel: …………………………………………….. 
 
Signature: …………………………………… 
 
Date:  -------/------/------ 
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ASSENT FORM FOR PREGNANT WOMEN UNDER LEGAL AGE 
(To be completed by the woman and their parent/guardian) 
 
Under age woman (or if unable, parent on their behalf) /young person to circle all they agree with: 
 
Have you read (or had read to you) about this project?     Yes/No 
Has somebody else explained this project to you?  Yes/No 
Do you understand what this project is about?               Yes/No 
Have you asked all the questions you want?      Yes/No 
Have you had your questions answered in a way you understand? Yes/No 
Do you understand it’s OK to stop taking part at any time? Yes/No 
Are you happy to take part?  Yes/No 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name! 
 
If you do want to take part, please write your name and today’s date  
 
Your name      ___________________________  Age_______ 
 
Date             ___________________________ 
 
 
Your parent or guardian must write their name here too if they are happy for you to do the project 
 
Print Name ___________________________ 
 
Sign               __________________________ 
 
Date              ___________________________ 
 
218  
 
The doctor who explained this project to you needs to sign too: 
 
Print Name    ___________________________ 
 
Sign               ___________________________ 
 
Date              ___________________________ 
 
Thank you for your help. 
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INFORMED CONSENT FORM FOR PARTICIPANTS UNABLE TO GIVE CONSENT 
THEMSELVES 
Please initial box 
1. I confirm that I have read and understand the subject information sheet dated (please insert 
date) for the above study.  I have had the opportunity to consider the information, ask 
questions and have had these answered fully. 
 
2. I understand that my child/spouse/partner’s participation is voluntary and she is free to 
withdraw at any time, without giving any reason, without their medical care or legal rights 
being affected. 
 
3. I understand that sections of any of their medical notes and data collected during the study, 
may be looked at by responsible individuals from (please insert centre name), from 
regulatory authorities and sponsors to this study, where it is relevant to my taking part in 
this research.  I give permission for these individuals to access my records. 
 
5. I agree for my child/spouse/partner to take part in this study.  
 
 
________________________ ________________ ________________ 
Name of Participant Signature (if able) Date 
  
_______________________ ________________ ________________ 
Name of parent/guardian/legal Signature Date 
representative  
 
________________________ ________________ ________________ 
Name of Person taking consent Signature Date 
(if different from Principal Investigator) 
 
_________________________ ________________ ________________ 
Investigator Signature Date  
 
1 copy for subject and to be kept with participant’s CRFs 
 
 
